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Introduction 1
INTRODUCTION 
Current Drug Discovery
Reducing time, resources and serendipity has been the major aim for the development  of 
modern, rational drug discovery strategies. 
Historically, most drugs have been discovered mainly by two of the following methods. The 
first is to modify a know starting molecule like a natural ligand, co-factor or simply an already 
existing drug. The first drug to market is rarely the best.  COX-2 inhibitors,  HIV protease 
inhibitors or the “patent-busting” around PDE5 inhibitors serve as quite productive examples 
for this approach [Wermuth,  2004, 2006a, 2006b].  For diseases where neither a  drug nor 
natural  template  structure  exists,  the  second  route  is  applied,  random  screening.  Being 
venerable this approach requires a certain serendipity to succeed. Cyclosporine and paclitaxel 
are prominent examples for drugs identified by screening corporate compound selections. The 
invention of combinatorial chemistry increased the size of the chemical collections and assay 
automation  reduced time and resources  necessary to  screen  large  libraries.  Still  a  certain 
degree of serendipity is required. Therefore, more rational routes for drug discovery have 
been sought [Lundqvist, 2005], [Klebe, 2000], [Oprea, 2004].
Today, the whole drug discovery process from development to registration for the market is 
an impressively long, expensive, and risky challenge. On average, only one out of 10,000 
originally  synthesized  or  isolated  compounds  will  clear  all  the  hurdles  on  the  way  to 
becoming a commercially available drug [Gad, 2005]. The process from first discovery to full 
development takes ~15 years to complete and costs approximately 800 million dollars. 
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Figure 1.1 Scheme of the pharmaceutical company’s drug design and development strategy. 
The process starts with finding the right molecular target to address a certain disease, i.e., a 
single gene or protein [Kubinyi, 2003]. Interestingly,  current drug therapy is based on less 
than  500  targets.  Molecular  biology  efforts  help  understanding  disease  processes  at  the 
genetic level and to determine optimal targets [Drews, 2000]. The completion of the human 
genome together with new technologies like bioinformatics, genomics and proteomics allow 
to  characterize  more  genetic  and  molecular  processes  in  humans  and  other  species,  thus 
providing thousands of possible enzymes, receptors and ion channels as potential new drug 
targets [Austin, 2004]. Unfortunately, having more targets does not necessarily lead to more 
drugs on the market. Contrarily, the number of new molecular entities (NMEs) approved by 
the Food and Drug Administration (FDA) decreased in recent years (Figure 1.2). 
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Figure 1.2 Survey of recent submissions and approvals of new molecular entities to the food and 
drug administration by fiscal year. (http://www.fda.gov)
Once a target is validated, different screening strategies are applied to identify the so called 
lead,  a  prototypical  structure  that  demonstrates  an  adequate  activity. Considering  a 
representative target portfolio, high-throughput screening (HTS) is presently the most widely 
applicable  technology  delivering  chemistry  entry  points  for  drug  discovery  programmes 
[Baxter, 2000]. Identified lead compounds are subsequently “optimized,” i.e., altered in ways 
that  both  increase  their  potential  efficacy  as  well  as  minimize  any  potential  side  effects 
[Keseru, 2006]. The tools of modern chemistry (parallel and automated synthesis) and modern 
biology merge in these stages to give the best candidates for the drugs of the future. 
To  ensure  the  safety  of  administering  a  new drug  candidate  to  healthy  volunteers  and 
patients, extensive toxicological and safety pharmacological profiles are done in both, in vitro 
tests and animals studies. Once the initial safety profile is established, the drug candidate is 
given to a small group of patients or healthy volunteers to verify tolerance and possible effects 
to the human disease (first-man-first-visit). Subsequently, Phase I trials are undertaken to gain 
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information about tolerable dose ranges and the metabolism of the drug candidate. Phase II 
clinical trials involving up to a few hundred patients establish the range of efficacious doses. 
Phase III trials (up to 10,000 patients) provide final information about the drug’s effectiveness 
and provide comparison to standard treatments. For the registration of the new drug, quality, 
efficacy and safety of the drug need to be demonstrated to the FDA (USA) or EMEA (EU). At 
times, additional Phase IV studies are undertaken after registration to add new indications or 
improve existing formulations of the drug.
Future  challenges  are  to  reduce  development  time  and  control  costs  effectively  without 
compromising safety and quality. Therefore, the pharmaceutical industry tries to constantly 
integrate new research and development techniques. At drug discovery state (Figure 1.1), this 
means to consider “compound quality” as early as possible.  Compound quality comprises 
drug-likeness  of  a  molecule  with  respect  to  administration,  distribution,  metabolism  and 
excretion (ADME).
Another requirement is high affinity of the drug to its target to keep the necessary dosage as 
low as possible.  This facilitates  formulation and decreases the risk to experience possible 
side-effects. It is well recognized that even when compounds are identified from HTS they are 
not  always  suitable  to  embark  on  further  chemistry  exploration  [Keseru,  2006].  One 
promising  and  now  frequently  applied  approach  is  to  integrate  computational  models  to 
predict the desired property at each step of the discovery process. In the last 20 years, those 
models and computational approaches to assist drug discovery have gained in importance and 
proven to  be  a  resource-saving  techniques  to  identify  and optimize  novel  chemotypes  in 
biologically active molecules. 
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Computational drug design
Computer-aided drug design is an essential part of the modern medicinal chemistry, and has 
led to the acceleration of many projects, and even to drugs on the market [Coupez, 2006]. Its 
application  ranges  from early  target  validation  to  toxicity  models  at  late  discovery/early 
development transition state. 
Assessing the druggability of a target is supported by the analysis of theoretical signaling 
pathway networks [Coupez, 2006], comparing the putative binding pocket to existing ones 
[Nettles,  2006],  [Weber,  2004],  or  generating  homology  models  [Evers,  2004],  [Hillisch, 
2004],  [Kairys,  2006],  [Rong,  2002]  if  neither  crystal  nor  NMR structures  are  available. 
Computational strategies for the target validation process have been reviewed by Wiemann, 
Blundell,  Hajduk,  and  Keller  [Blundell,  2006],  [Hajduk,  2005a],  [Hajduk,  2005b], 
[Wieman, 2004]. 
Most  extensively,  computer-aided  strategies  are  applied  in  the  lead  discovery  and  lead 
optimization stage. In addition to high throughput screening (HTS), the main lead discovery 
technology employed by most pharmaceutical companies today is virtual screening [Walters, 
1998], [Klebe, 2006]. It involves the rapid assessment of large libraries of chemical structures 
and can be categorized as being either ligand-based or receptor-based. The compounds are 
compared to previously as active identified molecules (similarity searches) or matched to a 
pharmacophore  derived  from  the  target  binding  site  (pharmacophore  search).  When  the 
structure  of  the  target  protein  is  known,  receptor-based  docking  can  be  employed.  This 
approach  aims  to  predict  correctly  the  structure  of  the  intermolecular  complex  formed 
between  the  target  receptor  and  the  ligand.  To  correctly  dock  a  molecule,  two  technical 
challenges imply, (1) the pose generation (docking) of the ligand in the active site and (2) the 
evaluation of the different poses (scoring). Scoring requires estimation of the binding energy 
between protein and ligand and produces a relative rank-ordering between different ligand, 
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docked to the same target. Examples of virtual screening have been published as referenced in 
the appendix. Different screening protocols and their successful application are reviewed by 
Jalaie, Pirard, Hou, Green, Langer and Schneider [Green, 2003], [Hou, 2004], [Jalaie, 2006], 
[Langer, 2003], [Pirard, 2005], [Schneider, 2002]. An alternative to screen for compounds is 
designing molecules with desired properties from scratch. Integration of so called de-novo 
design to drug discovery is reviewed by Schneider and Honma [Honma, 2003], [Schneider, 
2005]. At lead optimization state, docking is applied to assess the modifications of the lead 
compound.  As  a  series  of  molecules  with  known  activity  arises,  three  dimensional 
quantitative structure-activity relationships (3D QSAR) methods gain in importance. Using 
3D  QSAR  statistical  correlations  are  established  between  the  potencies  of  a  series  of 
structurally related compounds and one or more quantitative structural parameters, such as 
lipophilicity, polarity, and molecular size, by using multi linear regression analysis [Gohlke, 
2003], [Kuo, 2004]. 
For lead compound series with convincing activities computational methods are also applied 
to estimate pharmacokinetic  properties.  Again docking, homology modeling and statistical 
correlations  methodologies  are  used  in  order  to  evaluate  potential  Cyp450  inhibition 
[Cruciani, 2005], [Zamora, 2003], plasma protein binding [Gleeson, 2007], HERG channel 
blockage  [Farid,  2006],  [Pearlstein,  2003],  bioavailability  and  toxicity  [Egan,  2002], 
[Lipinski, 2001]. 
Computer-aided drug design techniques are nowadays established and have emerged as key 
strategy  to  help  assessing  compounds  [Good,  2000].  Predicting  chemical  and  biological 
properties with computational models identifies compounds that are likely to fail in primary, 
secondary  and  further  downstream  screen  at  significantly  lower  costs.  Integration  of 
computational approaches into the drug discovery process is nicely reviewed by Chin and 
Oprea [Chin, 2004], [Oprea, 2004]. 
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Scope of the thesis
The present  thesis  describes  two aspects  of  modern  drug discovery in  detail.  Firstly,  the 
challenges of lead optimization are addressed considering two antimalarial drug targets. As 
mentioned  above,  one  important  aspect  of  lead  optimization  is  increasing  the  target-drug 
affinity as much as required. This is especially important for antimicrobial drugs. To prevent 
secondary resistance development during the drug therapy they are usually administered at 
high dosages. 
Using computer-aided drug design techniques, target-drug binding affinities are analyzed 
for the two enzymes,  DOXP-reductoisomerase (DXR) and farnesyltransferase (ftase). Both 
targets  have  recently  been  validated  as  potential  antimalarial  drug  targets  [Jomaa, 1999], 
[Chakrabarti, 1998].  As  a  potential  drug  has  to  inhibit  the  enzymatic  activity  the  terms 
'inhibitor' or 'ligand' are used for the drug candidate as well as the term 'protein' to represent 
the target. 
DOXP-Reductoisomerase: Structure-activity relationships for 43 inhibitors are established, 
derived  from  protein-based  docking,  ligand-based  3D QSAR  and  a  combination  of  both 
approaches as realized by AFMoC (Adaptation of fields of molecular comparison). DXR is a 
key enzyme of the non-mevalonate pathway for isoprenoid building blocks. As part of an 
effort to optimize the properties of the established inhibitor Fosmidomycin, analogues have 
been synthesized and tested to gain further insights into the primary determinants of structural 
affinity.  Herein,  these  molecules  have  been  used  to  create  a  predictive  model  for  DXR 
inhibition  applying  data  taken  from  several  DXR  X-ray  structures.  Unfortunately,  these 
structures still leave the active Fosmidomycin conformation and detailed reaction mechanism 
undetermined. This fact, together with the small inhibitor data set provides a major challenge 
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for presently available docking programs and 3D QSAR tools. Using the recently developed 
protein tailored scoring protocol AFMoC precise prediction of binding affinities for related 
ligands as well as the capability to estimate the affinities of structurally distinct inhibitors has 
been achieved.
Farnesyltransferase: Farnesyltransferase  is  a  zinc-metallo  enzyme  that  catalyzes  the 
posttranslational  modification  of  numerous  proteins  involved  in  intracellular  signal 
transduction. The development of farnesyltransferase inhibitors is directed towards the so-
called non-thiol inhibitors because of adverse drug effects connected to free thiols. A first step 
on the way to non-thiol  farnesyltransferase  inhibitors  was the development  of an CAAX-
benzophenone peptidomimetic  based on a  pharmacophore  model.  On its  basis  bisubstrate 
analogues were developed as one class of non-thiol farnesyltransferase inhibitors. In further 
studies two aryl binding and two distinct specificity sites were postulated. Flexible docking of 
model compounds was applied to investigate the sub-pockets and design highly active non-
thiol farnesyltransferase inhibitor. In addition to affinity, special attention was paid towards in 
vivo activity and species specificity. 
The  second  part  of  this  thesis  describes  a  possible  strategy  for  computer-aided  lead 
discovery. Assembling a complex ligand from simple fragments has recently been introduced 
as an alternative to traditional HTS [Carr, 2002]. While frequently applied experimentally, 
only  a  few  examples  are  known  for  computational  fragment-based  approaches.  Mostly, 
computational tools are applied to compile the libraries and to finally assess the assembled 
ligands. Using the metalloproteinase thermolysin (TLN) as a model target, a computational 
fragment-based  screening protocol  has  been established  (Fig  1.3).  As  a  prerequisite,  it  is 
assumed that (1) the three-dimensional structure of the target is available and (2) experimental 
validation assays for both, affinity and structure are established. 
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Starting with a data set of commercially available chemical compounds, a fragment library 
has been compiled considering (1) fragment likeness and (2) similarity to known drugs (Step 
1a). The library is screened for target specificity (Step 1b). After analyzing the performance 
of multiple docking programs and scoring functions for fragments in general (Step 2a), the 
fragments  derived from the  screening  are  docked and the  most  promising  candidates  are 
selected  for  further  analysis  (2b).  After  purchasing  both,  already  validated  reference 
fragments  and  the  selected  candidates,  co-crystallization  and  soaking  experiments  were 
performed on the reference fragment to derive a general applicable crystallization protocol 
(Step 3a) for TLN. Subsequently, crystallization experiments are done to derive new protein-
fragment  complex  structures.  Additionally,  the  affinity  is  validated  using  the  formerly 
established inhibition assay [Silber, 2001] (Step 4a,b). 
Some  additional  studies  based  on  the  screening  results  include  (1)  a  retrospective 
performance  analysis  of  the  applied  scoring  functions  and  (2)  some  modification  on  the 
screening hit.  Having discovered unexpected binding properties  of  a  new fragment,  some 
slightly deviating molecules were synthesized, computationally and experimentally analyzed 
and compared to the screening result molecule. 
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Figure 1.3 Schematic overview over the development and application of a fragment-based lead 
discovery approach. Left panel: General approaches applied to literature-derived test sets. 
Right panel: Design performed to find new fragments binding to thermolysin. 
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AFMOC ENHANCES PREDICTIVITY OF 3D QSAR: 
A CASE STUDY WITH DOXP-REDUCTOISOMERASE 
Introduction 
In recent years, virtual screening of large compound libraries has been established as a fast 
and  rather  inexpensive  alternative  to  experimental  high-throughput  screening  in  the  lead 
discovery process. It has been successfully applied to suggest new inhibitors of, e.g. carbonic 
anhydrase,  tRNA-guanine  transglycosylase  [Brenk,  2003]  and  DNA  gyrase  in  the 
submicromolar range [Doman, 2002], [Gane, 2000], [Shoichet, 2002]. 
Of utmost importance in a virtual screening assay is the reliable filtering of putative hits in 
terms of their predicted binding affinity (scoring problem) which is based on the  in silico-
generated near native protein-ligand configurations (docking problem). Over the last years, a 
broad  spectrum  of  first  principle-,  regression-  or  knowledge-based  scoring  functions  for 
protein–ligand complexes has emerged. Although these scoring functions achieve increasing 
reliability  in  affinity  prediction  for  some  biological  targets,  for  many  others,  predictions 
remain rather unsatisfactory [Bissantz,  2000],  [Ferrara,  2004], [Wang, 2003].  In any case, 
scoring based on one single function remains a crucial and often limiting step. Alternatively, 
very pragmatic approaches have been suggested such as intersection-based consensus scoring 
[Ferrara, 2004], [Clark, 2002], [Charifson, 1999], [Wang, 2001a] or multivariate analysis of 
scoring results based on different functions [Jacobsson, 2003] to improve the reliability in 
ranking putative screening hits and predicting their binding affinities. A promising approach, 
in particular in the incipient phase of a drug-development program, where multiple aspects of 
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the protein-ligand binding determinants are still to be unraveled, is the weighting and tailoring 
of a general purpose scoring function, using information collected for some first leads known 
to bind to the target under consideration. These leads could correspond to known endogenous 
ligands or result from early hits discovered by high throughput screening (HTS). Trimming of 
methods by additional information has already been introduced into docking tools. The option 
to specify positions in the binding site to be favorably accommodated by certain atom types 
was  first  implemented  in the  program Targeted-DOCK [DesJarlais,  1994],  [Good,  2003], 
[Shoichet, 1993] as an extension to DOCK [Ewing, 1997], [Kuntz, 1982], [Shoichet, 1992]. 
Later, a “similarity-driven approach to flexible ligand docking” described the possibility to 
include  a  similarity  term  to  a  given  reference  ligand  or  pharmacophore  during  docking 
[Fradera, 2000]. The program FlexX [Claussen, 2001], [Rarey, 1996], [Rarey, 1997], [Rarey, 
1999] allows one to define starting fragments or pharmacophore restraints [Hindle, 2002] to 
guide the ligand placement during its construction phase. However, the subsequent affinity 
ranking of the generated docking solution(s) is purely based on a general scoring function. No 
additional information about the binding mode of already characterized ligands is considered 
at this stage. 
To incorporate knowledge about characterized ligands, Grüneberg et al. [Gruneberg, 2001], 
[Gruneberg, 2002], analyzed the library to be docked by computing mutual superimpositions 
of the candidate molecules with known high affinity ligands. Only candidates showing some 
degree  of  similarity  in  terms  of  spatial  physicochemical  properties  with  the  reference 
structures  were  further  considered  for  docking.  This  strategy  retrieved  subnanomolar 
inhibitors for human carbonic anhydrase II. Furthermore, tailor-made scoring functions have 
been derived by either correlating force-field contributions with experimental affinity data of 
a  known  training  set  [Holloway,  1885]  or  by  factorizing  the  total  binding  energy  into 
individual components of van der Waals, Coulomb, and desolvation contributions per residue. 
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In the COMBINE (COMparative BINding Energy)  [Ortiz,  1995],  [Wang, 2001b],  [Wang, 
2002] approach these contributions are correlating with experimentally determined binding 
free  energies  to  derive  a  3D QSAR  model.  COMBINE  factorizes  the  protein-ligand 
interactions on a per residue basis into individual contributions. This can be protein residues 
as well  as parts  of a ligand. Both ligand and protein design is  facilitated by the spatially 
resolved selection of important protein-ligand interactions. However, with respect to ligand 
design  this  more  generic  information  of  contributions  to  protein-ligand  interactions  is 
somewhat difficult to translate into actual design concepts of how to optimize a ligand by 
chemical means. 
In case of missing structural information about the receptor, binding affinity predictions are 
usually  attempted  by  “three-dimensional  quantitative-structure-activity-relationship” 
(3D QSAR) methods such as “Comparative Molecular Field Analysis” (CoMFA) [Cramer, 
1988], [Cramer, 1989], [Cramer, 1993] or Comparative Molecular Similarity Indices Analysis 
(CoMSIA) [Klebe, 1994]. Surprisingly high predictive power can be achieved. However, their 
success strongly depends on the composition and mutual alignment of the training set ligands. 
If knowledge about the protein structure is incorporated into the latter approaches, it is only 
used to generate a meaningful alignment of the ligands [Cruciani,  1994], [Medina-Franco, 
2004], [Pastor, 1997], [Sippl, 2002]. 
Surprisingly enough, in the affinity prediction step, information about the surrounding protein 
environment is virtually neglected. This rather imprudent fact prompted Gohlke and Klebe 
[Gohlke,  2002a]  to  develop  a  tailor-made  scoring  function  (which  can  also  be  termed  a 
protein-based CoMFA). In this method, the general purpose knowledge-based pair-potentials 
of DrugScore [Gohlke, 2000a] are specifically adapted with respect to a given protein. The 
AFMoC (Adaptation of Fields of Molecular Comparison) approach [Gohlke, 2000a] allows to 
gradually move from generally applicable to specifically adapted affinity scoring considering 
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an  increasing  amount  of  information  about  the  training  set  inhibitors.  Important  enough, 
already a small set of several known inhibitors can enhance the predictive power and makes 
AFMoC a suitable tool to support the drug development process in its early phase. 
In the present contribution, AFMoC´s potential to improve the predictive power in affinity 
prediction will be demonstrated using the first leads from a drug development program for 1-
deoxyxylulose-5-phosphate (DOXP)-reductoisomerase inhibitors as potent antimalarials. The 
sole application of standard 3D QSAR methods did not achieve any prospectively predictive 
models  in  the present  case study, although significant  correlations  among the training set 
compounds could be derived. This observation can be regarded as a caveat that comparative 
molecular field analyses easily achieve descriptive potential, however rarely accomplish the 
desired predictive power required for ligand design. 
The AFMoC Approach
Distance-dependent  pair-potentials  of  atomic  protein-ligand  contacts  retrieved  from 
experimentally determined protein-ligand complexes have been widely used to score protein-
ligand interactions. As such, they have been successfully applied to rank docking solutions 
[DeWitte,  1996],  [DeWitte,  1997],  [Gohlke,  2000a],  [Gohlke,  2001],  [Muegge,  1999a], 
[Muegge,  1999]  in  de  novo  design  or  served  as  objective  function  in  ligand  placement 
[Sotriffer,  2002a].  However,  as  these  potentials  only provide  an  average description of  a 
general type of interactions, special situations in biological systems that deviate significantly 
from this “average“ cannot be described adequately. For example, an ionic hydrogen bond 
formed at the rim of a binding pocket, partly exposed to the solvent, contributes significantly 
less to affinity than a comparable contact deeply buried in a hydrophobic environment. Per se, 
both are not distinguished using “averaged” potentials. If additional structural and energetic 
knowledge about a system under investigation is considered, such “averaged” potentials can 
be  tailored  to  the  specific  situation.  In  this  respect,  AFMoC allows to  specifically  adapt 
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DrugScore pair-potentials to one particular protein. AFMoC requires a protein structure with a 
predefined binding pocket and several bound ligands. If such data are available, the mutual 
ligand  superpositioning  can  be  achieved  based  on  the  crystallographically  characterized 
protein-ligand complexes; if no such complex structures are available, solutions from docking 
runs might serve equally well, though with the clear caveat that the considered geometries are 
computed and not experimentally confirmed. 
The AFMoC approach proceeds in three steps. First, a regularly spaced grid is embedded 
into  the  protein  binding  pocket.  Similar  to  the  “hot  spots”  analysis  [Gohlke,  2000b],  the 
interaction  between  a  probe  atom  of  a  given  type  (as  parameterized  for  the  original 
DrugScore) and the surrounding protein atoms is calculated at every grid point. To account 
for missing experimental contact data at close distances, an artificial repulsion term is added 
to the original pair-potentials in this region. In a second step, structural information about the 
bound ligands is considered. By placing a Gaussian function onto a particular atom position, a 
distance-dependent contribution of ligand atoms of a given type with respect to each grid 
point is established. For each atom type and at each grid point, this contribution is multiplied 
with the original DrugScore value (potential field), yielding “interaction fields” (Figure 2.1). 
In a third step, the interaction fields are correlated with experimental binding affinities using 
Partial least-square (PLS) analysis. 
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Figure 2.1 Concept of the AFMoC approach. As an example DrugScore “potential fields” for the 
ligand  atom  type  “hydroxyl  oxygen”  are  calculated  (left).  The  ligand  is  described  by 
assigning Gaussian functions to the positions of the individual atoms and loading them by 
the atom types under consideration. Subsequently, the potential field values at the different 
grid positions are multiplied by the values of the adjacent Gaussian functions attributed to 
the atoms of the accommodated  ligand.  Finally,  the obtained product values are mapped 
back  onto  the  binding  site  grid  points.  This  figure  is  adapted  from Gohlke  and  Klebe 
[Gohlke, 2002a]. 
In  contrast  to  the  “generic”  fields  in  CoMFA  or  CoMSIA  (i.e.  electrostatic,  steric,  …), 
AFMoC- “interactions fields” are based on individual ligand-atom types. Depending on the 
size and composition of the training set,  some atom types  might  occur  only rarely.  As a 
consequence, the corresponding fields will hardly achieve the required statistical significance. 
Using  the  original  pair  potentials  in  DrugScore,  experimentally  determined  pIC50 can  be 
factorized into contributions originating from all  considered atom types.  Only those atom 
types  which explain affinity  differences are subsequently considered in PLS (pIC50PLS).  In 
consequence, the contribution of atom types, not explicitly considered in the PLS (pIC50tot- 
pIC50PLS),  must  be  regarded  in  terms  of  their  original  DrugScore  potential  contributions. 
Therefore, statistical  results are always described by two correlation coefficients.  First the 
coefficient considering only the contribution to affinity corresponding to atom types used for 
the PLS and second, considering the total affinity and using PLS results for the corresponding 
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atom types and general DrugScore for the remaining ones. By use of a linear combination of 
the “original” DrugScore potential  fields and the AFMoC-adapted ones,  the approach can 
gradually shift  between generally applicable and specifically adapted fields for prediction. 
Accordingly, an optional mixing coefficient θ is used to switch from pure DrugScore (θ=0) to 
pure  AFMoC  fields  (θ=1).  As  in  CoMFA,  the  results  of  an  AFMoC  analysis  can  be 
interpreted in graphical terms consulting contribution maps, and binding affinities of novel 
ligands are predicted by evaluating the established 3D QSAR equation. Therefore, compounds 
to be predicted must  be placed into  the binding pocket  by the same docking protocol  as 
applied to the training set ligands. As major advantage of AFMoC, ligands to be predicted can 
structurally exceed beyond the scope of the training set compounds or comprise deviating 
functionalities, simply because properties not included in PLS will be scored purely based on 
the original DrugScore potentials. 
Target Protein
Malaria is  world wide one of the most  severe infectious diseases killing more than three 
million people each year [WHO, 2005]. The most fatal infections are caused by the protozoa 
plasmodium falciparum, the pathogen for malaria tropica. Due to large scale administration a 
widespread resistance has developed and quinine-type antimalarials have meanwhile become 
less  effective  in  therapy.  Moreover,  some  strains  of  plasmodium  falciparum in  Africa, 
Thailand, and South America have mutated in a way to produce multi-drug resistance. Thus, 
antimalarial research desperately seeks new targets, involving novel therapeutic principles. In 
this context valuable information is expected to result from the complete sequencing of the 
plasmodium genome [Gardner,  2002a],  [Gardner,  2002b].  As a  consequence,  several  new 
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pathways, unique to pathogenic microbes, have already been identified that could culminate 
in the development of innovative antimalarial chemotypes. 
In  recent  years,  the  biosynthesis  of  isoprenoids  being involved in a  plethora  of  natural 
products, has attracted considerable attention since an alternative biosynthetic route has been 
discovered  to  the  classical  mevalonate  pathway  [Eisenreich,  1998],  [Eisenreich,  2004], 
[Lichtenthaler,  1999],  [Rohdich,  2001a],  [Rohdich,  2001b],  [Rohdich,  2002],  [Schwender, 
1996],  [Seto,  1997].  Most  isoprenoids  are  assembled  from  two  universal  precursors, 
dimethylallyl  diphosphate  (DMAPP)  and  isopentenyl  diphosphate  (IPP).  These  are  either 
synthesized  via  the  classical  mevalonate  pathway  or  along  the  newly  discovered  non-
mevalonate or DOXP-pathway. As plasmodium falciparum relies exclusively on this second 
DOXP route,  all  enzymes  involved  in  this  pathway (Figure 2.2)  could  serve  as  potential 
targets for antimalarial therapy. The first intermediate, 1-deoxy-D-xylulose-5-phosphate, is a 
precursor  not  only  of  isoprenoids  but  also  of  the  cofactors  thiamine  pyrophosphate  and 
pyridoxal  phosphate.  Consequently,  the  subsequent  enzyme  DOXP-reductoisomerase 
(IspC/DXR)  [Kuzuyama,  2000],  [Kuzuyama,  2002],  [Mueller,  2000],  [Takahashi,  1998], 
operating on this substrate through an isomerization and reduction step, has been the first 
target selected for a drug development program. Recently, successful inhibitor design has also 
been  reported  for  the  downstream  enzyme  2C-Methyl-D-erythritol  2,4-cyclodiphosphate 
synthase [Crane, 2006]. Other enzymes of the pathways are also investigated regarding target 
suitability. 
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Figure  2.2  Biosynthesis  of  isoprenoids  precursors  IPP  and  DMAPP  via  the  non-mevalonate 
pathway.  The  framed  step  shows  the  reaction  catalyzed  by  DOXP-reductoisomerase 
(IspC/DXR). 
DOXP-reductoisomerase is inhibited by fosmidomycin (Table 2.1-1) [Jomaa, 1999], a drug 
which is already in clinical trials and shows promising antimalarial activity [Borrmann, 2004], 
[Lell,  2003],  [Missinou,  2002],  [Wiesner,  2003a].  Despite  of  its  good inhibitory potency, 
fosmidomycin shows unfavorable properties such as complexation of essential bivalent metal 
cations. Therefore, a consortium of several groups began a synthesis program described in 
other contributions to discover improved lead structures [Reichenberg, 2001]. To support this 
development by rational ligand design concepts, computer methods were applied to provide 
some insight into the structural determinants for DXR-inhibitor binding. Although previous 
studies  provide  new insights  into  the  binding  mechanism [Proteau,  1999]  and  DXR has 
reached enormous attention [Proteau, 2004], [White, 2003] an inhibitor with higher affinity to 
DXR  has  not  yet  been  discovered.  Chemical  modification  of  fosmidomycin  include 
cyclization of the alkylchain to rigidify molecule [Devreux, 2006]. New substrate analogs and 
fosmidomycin analogs have been published [Phaosiri, 2004], [Woo, 2006] as well as prodrugs 
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to enhance fosmidomycin efficiency [Ortmann, 2003], [Ortmann 2005]. The lack of success 
to  develop  a  non-fosmidomycin  like  inhibitor  has  motivated  other  experimental  and 
computational  studies  to  gain  insights  into  target  specificity  [Fernandes,  2005],  [Merkle, 
2005], [Singh, 2006]. 
Crystal structure analyses have shown that the protein can adopt various different states. 
The apo structure (pdb ID: 1K5H) [Reuter,  2002] lacks the bound catalytic  metal  ion, the 
cofactor  and a  bound substrate  or  ligand molecule.  This  fact  handicaps its  direct  use  for 
structure-based  drug  design.  Although  an  alternative  structurally  deviating  entry 
(pdb ID: 1JVS) [Yajima, 2002] accommodates NADPH and a sulfate ion in the active site, 
only little information can be extracted with respect to putative protein-ligand interactions. 
This is mainly due to the fact that an extended loop folds down on the catalytic site, forming 
interactions  to  the bound ligand.  In  the  apo structure  three different  loop conformers  are 
observed, among them, two exhibiting rather distinct loop conformations. Steinbacher et. al. 
[Steinbacher,  2003]  published  the  first  DXR-ligand  complex  structure  (pdb ID: 1ONP) 
[Berman, 2000] which shows fosmidomycin together with one Mn2+ ion bound to the active 
site. Unfortunately, this structure lacks the cofactor. The covering loop region is only poorly 
defined in the electron density. 
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Figure 2.3 Superimposition of the apo (pdb ID: 1K5H, violet), holo (1JVS, green) comprising the 
cofactor NADPH and the fosmidomycin- and Mn2+ (magenta) bound protein (1ONP, blue). 
For  all  three  structures,  only the  chain  A is  shown and  the  part  of  the  flexible  loop  is 
highlighted. 
Nevertheless,  it  clearly  shows  differences  compared  to  the  previously  determined  protein 
structures. A superimposition of all three structures (only chain A for 1K5H, 1JVS, 1ONP) is 
shown  in  Figure 2.3.  Recently,  nine  new DXR structures  were  published.  Ricagno  et  al. 
solved the apo (pdb ID: 1R0K) and DXR-NADPH complex (pdb ID: 1R0L) structure from 
Zymomonas  mobilis  [Ricagno,  2004].  Besides  small  differences  in  the  recognition  of  the 
cofactor,  the enzymes  of both organisms share high similarity in  structure and active site 
architecture.  Very close to the  Plasmodium falciparum protein-inhibitor-complex structure 
(pdb ID: 1ONP) is the apo structure of Mycobacterium tuberculosis [Henriksson, 2006] (pdb 
ID: 2C82). Although the overall RMS is 12.6  Å,  the binding sites are quite similar. It has 
neither metal ion nor NADPH bound, yet the flexible loop is very close. Two biphosphonate 
inhibitors (pdb Ids: 1T1R and 1T1S) bound to DXR were published by Yajima et al. [Yajima, 
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2004]. Neither NADPH nor a metal ion are present but a buffer sulfate ion is observed which 
fits  to  the  substrate  phosphate  pocket  similarly  to  the  pdb ID:  1JVS.  Compared  to  the 
fosmidomycin-metal-DXR complex, these inhibitors adopt totally different binding modes. 
Their biphosphonate moieties replace the metal ion and their hydrophobic substituents orient 
towards the solvent which enforces an overall 90° rotation of both inhibitors compared to 
fosmidomycin.  Additionally,  parts  of  the  flexible  loop  occupy  a  region  formerly 
accommodated by the propylene chain of fosmidomycin. Further crystal structures show the 
ternary  complexes  of  DXR-NADPH-fosmidomycin,  selenomethionine-labelled  DXR-
NADPH-fosmidomycin  and  the  DXR-NADPH-substrate  binding  [Mac  Sweeney,  2005] 
(pdb IDs: 1Q0L, 1Q0H, and 1Q0Q). Considering the assumption of a two step binding mode 
of  fosmidomycin  [Koppisch,  2002],  the  ternary  structure  1Q0L indicates  a  12.5°  domain 
rotation, likely to occur upon cofactor binding, thus forming the “tight-binding conformation 
of the DXR-fosmidomycin  complex”.  Additionally,  the loop interacts  with the ligand,  not 
observed  in  the  former  complex structures.  Unfortunately,  the  protein  was  crystallized  at 
pH=5.  As  reported,  DXR  is  not  catalytically  active  under  these  acidic  conditions  [Mac 
Sweeney, 2005] and binding of the metal ion is very weak. Additionally, the carboxylic acids 
which normally complex the metal ion are most likely protonated and therefore have different 
interactions. Superimposing the metal-fosmidomycin (1ONP) and the NADPH-fosmidomycin 
(1Q0L) structures (Cα-fit) the N-hydroxyl oxygen in the latter complex replaces the metal ion 
in the former one. In total fosmidomycin is moved by 1.5 Å towards the cofactor binding site 
(rmsd of both ligands: 1.84Å). Although these new complex structures give very important 
information  about  the  domain  and  loop  movements,  we  believe  that  due  to  the  low and 
unlikely relevant pH conditions, the protein-ligand interactions exhibited are supposedly quite 
different compared to the in vivo situation. The complex structural properties along with the 
presence of a strong substrate- or inhibitor-metal interaction and the observed adaptability of a 
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large flexible loop make this enzyme a real challenge for any currently available computer 
tool in structure-based drug design.  The protein data bank had currently seven new DXR 
crystal  structures  on  hold  which  will  be  released  spring  2007.  They  all  are  from 
Mycobacterium tuberculosis DXR, including mutant apo structures as well as inhibitor-metal-
complex structures. They will reveal very interesting details in the interaction mechanism and 
the dependencies between loop conformation and ligand and/or metal ion presence (pdb ID: 
2JCV, 2JCX, 2JCY, 2JCZ, 2JD0, 2JD1, 2JD2). 
Methods
All  molecular  modeling  and  comparative  molecular  field  analyses  were  performed  using 
SYBYL 6.9 [TRIPOS, 2002] and DrugScore 1.2 [Gohlke, 2002a]. 
Data Set and Alignment
All ligands considered in this analysis  were tested under the same conditions in the same 
laboratory.  For  affinity  measurements  as  well  as  for  crystallization  and  docking  the 
Escherichia coli enzyme was used, which shows 74 % sequence identity to the putative active 
site  of  the  parasitic  enzyme.  To  obtain  a  diverse  training  set,  we  selected  representative 
ligands from all compound classes complemented by additional examples to achieve an equal 
distribution of affinity data. This training set of in total 27 inhibitors was used for all CoMFA, 
CoMSIA, and AFMoC analyses (Table 2.1). The binding affinities covered a range of 3.6 
logarithmic units. 
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Table 2.1 DOXP-reductoisomerase inhibitors used as training set ligands. 
No. Namea) Structure pIC50
1 Fosmidomycin PN
O O
O
O
O 7.70
2 BC183 PN
O
O
O
O
OOH
4.30
3 FR900098 PN
O
O
O
O
O
7.55
4 KL562 PN
O
O
O
O
O
7.19
5 LD_1_1 N
H
O
O
P
O
O
O
6.59
6 LD_1_4 PN
H
N
H
O O
O O
O
4.79
7 LD_1_5 PNN
H
O O
O O
O
4.50
8 LD_2_6 PN
O
O O
O
O
6.19
9 LD_2_7
PN
O
O O
O
O
5.19
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No. Namea) Structure pIC50
10 LD_2_8 PN
O
O O
O
O
7.00
11 LIHP_83 PN
O
O
O
O
O
N
H
O
4.70
12 LIHP_84 PN
O
O
O
O
O
N
H
ON
H
4.77
13 LIHP_87
PN
O
O
O
O
O
N
H
O
O
O
4.85
14 LIHP_88 PN
O
O
O
O
O
N
H
O
O
F
F
F 5.29
15 LTB59 PN
O
O
O
O
O
4.62
16 LTB65 PN
O
O
O
O
O
Cl
Cl
6.75
17 LTB66 PN
O
O
O
O
O
5.77
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No. Namea) Structure pIC50
18 LTB95 PN
O
O
O
O
O
NH3
+ 4.59
19 LTB97 PN
O
O
O
O
O
NH3
+ 4.39
20 TK54 P
O
O
O
N
O
O
5.63
21 TK85 PN
H
O O
O O
O
NH3
+
5.01
22 UK153 P
O
O
O
N
O
OOH
4.30
23 UK213 PN
O
O
O
O
OOH
5.74
24 UK243 PN
O
O
O
O
O
OO
4.00
25 UK513 PN
O
O
O
O
O
7.27
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No. Namea) Structure pIC50
26 UK613
PN
O
O
O
O
O 6.55
27 UK721 PN
O
O
O
O
O
5.75
mean (standard deviation) 5.55 (1.0)
a) Name column names refer to compound codes as worked with during the project
Whereas the binding-site geometry of fosmidomycin(1) was taken as observed in the crystal 
structure with bound Mn2+ (pdb ID: 1ONP),  the training set ligands were docked into the 
binding pocket  using AutoDock 3.0 [Goodsell,  1996],  [Morris,  1996],  [Morris,  1998].  All 
ligands exhibit a hydroxamate function to mimic the α-ketohydroxyl moiety of the substrate. 
Both oxygen atoms in the hydroxamate function show nearly the same distance to the metal 
(N-hydroxyl:  2.1 Å and carbonyl:  2.4 Å). Based on these structural findings along with an 
expected  pKa shift  due  to  the  neighborhood  of  a  metal  ion,  the  hydroxamate  function  is 
assumed as planar and deprotonated. The atom types of both oxygen atoms were assigned to 
be  O.3.  Additionally,  most  ligands  exhibit  a  phosphonate  moiety  that  is  also  considered 
deprotonated. Assuming these protonation states, most ligands were formally assigned a total 
charge of minus three. The partitioning of the total charge into individual atomic contributions 
was performed using the AM1 Hamiltonian [Dewar, 1985] within the semiempirical package 
MOPAC 6.0 [Limited, 1993], [Stewart, 1990].
From the reference crystal structure (pdb ID: 1ONP), ligand and solvent molecules were 
removed and Mn2+ was converted to Mg2+.  The latter exchange was performed as Mg2+ is 
better parameterized for all techniques applied in this study. Chemical experience has been 
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collected that both ions resemble closely in their coordination properties (as Mn2+ or Mg2+) 
and can mutually replace each other in active DXR. 
To suggest a reasonable cofactor binding mode NADPH coordinates were transferred from 
pdb ID: 1JVS after both protein structures were superimposed, based on Cα coordinates. A 
subsequent  minimization  of  the  transferred  cofactor  with  the  MAB  force  field,  as 
implemented in MOLOC [Gerber, 1995], revealed no significant movements. 
AutoDock 3.0  requires  polar  hydrogens  for  docking.  They  were  added  with  the 
PROTONATE utility in AMBER [Case, 2005] and the generated hydrogen bonding network 
was visually inspected for internal consistency. AMBER united-atom charges were assigned 
as defined in the AMBER force field [Weiner, 1984], and solvation parameters were added 
using the ADDSOL utility from AutoDock3.0. All bonds except the one in the C(=O)–NO-
fragment, were kept rotatable. Docking runs were performed using the Lamarckian genetic 
algorithm as implemented in AutoDock 3.0, using an initial population of 50 randomly placed 
individuals, a maximum number of 1.5 x 106 energy evaluations, a mutation rate of 0.02, a 
crossover rate of 0.80 and an elitism value of 1. Generated ligand docking solutions, mutually 
differing by rmsd ≤ 1 Å were clustered together and the lowest docking energy found for one 
entry of  a  cluster  was  used as representative.  For each ligand,  in  total  10 solutions  were 
generated. Out of these, one configuration was selected for the ligand alignment (Figure 2.4) 
by  visual  inspection,  examining  the  obtained  metal  coordination  and  placement  of  the 
phosphonate group. This protocol was initially validated by docking fosmidomycin back into 
its original protein crystal structure (1ONP). Furthermore, docking into the model including 
the bound cofactor was attempted. Results are summarized in Table 2.2. 
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Table 2.2 Validation of the docking protocol. 
Results of Docking Fosmidomycin with AutoDock
DXR incl. NADPH DXR excl. NADPH
Rank No. of molecules per clustera) RMSD
b) Energy Rank No. of molecules per clustera) RMSD
b) Energy
1 4 0.96 -8.47 1 2 0.86 -8.63
2 4 1.31 -8.25 2 3 0.81 -8.52
3 1 1.23 -8.21 3 1 1.62 -8.46
4 1 1.12 -7.86 4 1 1.20 -8.40
5 1 1.34 -8.40
6 1 5.04 -8.25
7 1 5.02 -8.20
a) rmsd-threshold = 1.0 Å. b) In Å compared to fosmidomycin as observed in pdb-entry 
1ONP. 
Additional docking with 100 runs was performed to approve significance of the previously 
applied parameters. Results are given in Table 2.9 (Supporting Information). As alternative, 
the docking program FlexX was tested to generate the required protein-ligand complexes. 
Default  parameters were applied as well as including restraints as implemented in FlexX-
Pharm. Therefore, the phosphorous-atom position was constrained as observed in 1ONP with 
a 1Å threshold. Results are discussed below. 
CoMFA and CoMSIA Analyses
An identically oriented lattice of 1 Å grid spacing was chosen for the comparative molecular 
field  analyses  as  already  defined  for  docking  with  AutoDock,  possessing  a  size  of 
22x25x22 Å thus guaranteeing sufficient embedding of all ligands with a margin of at least 
4 Å. Steric and electrostatic CoMFA fields were calculated as implemented in SYBYL using 
Lennard-Jones  and  Coulomb  potentials,  respectively.  All  CoMFA  calculations  were 
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performed with SYBYL standard parameters (TRIPOS standard field, dielectric constant 1/r, 
cutoff 30 kcal/mol) using a sp3 carbon probe atom with a charge of +1.0. For CoMSIA, five 
physicochemical properties (steric, electrostatic, hydrophobic and hydrogen-bond donor and 
acceptor)  were  evaluated  using  a  common  probe  atom  of  1Å  radius,  charge  +1,  and 
hydrophobicity and hydrogen bond property values of +1. The attenuation factor α used in the 
Gaussian functions was set to 0.3. PLS analyses and “leave-one-out” (LOO) cross-validations 
were  performed  using  the  SAMPLS  [Bush,  1993],  [Wold,  1984],  [Wold,  1993]  as 
implemented in SYBYL. The optimal number of components was determined by taken the 
following rules into account. As suggested by Thibaut et al.  [Thibaut, 1993], the number of 
components has been checked to be lower than the amount of training set ligands divided by 
5. The sPRESS values achieved a minimum and any further component was only added if the q2 
increased by at least 5%. The latter rule follows the “parsimony-principle” by selecting the 
smallest number of significant components. In our case, both rules suggested the same results. 
Accordingly, the model with the smallest number of components was subsequently used to 
establish the final QSAR. For CoMFA-PLS, the “minimum σ” standard deviation (“column 
filtering” in SYBYL) was set to a threshold of 2 kcal/mol, resulting in approximately 16% of 
the columns considered in the PLS analysis. For CoMSIA, we compared the PLS results by 
selecting the same percentage of considered columns and the same σ-value. As both criteria 
produce similar results, we finally selected a σ-value of 2 also for CoMSIA. The q2, sPRESS, r2, 
S and  contribution values  were computed  as  described by Cramer  et  al.  [Cramer,  1988], 
[Cramer, 1989], [Cramer, 1993]. They are summarized in Tables 2.3 and 2.4.
Receptor-based predictions
To compare the predictive power of the applied 3D QSAR techniques with those of protein-
based  scoring  functions,  the  ligand  orientations  considered  for  the  alignment  were  also 
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evaluated by three  different  scoring  functions.  As  force-field  based function,  scores  from 
AutoDock 3.0 were used. Additionally, the regression-based Boehm-scoring function [Bohm, 
1994a] and DrugScore were applied. For DrugScore, affinities considering and neglecting the 
solvent-accessible-surface area dependent contributions were calculated (Table 2.7). 
AFMoC analysis
Interaction fields for the superimposed DOXP-reductoisomerase inhibitors were calculated 
using the protein atom coordinates given in 1ONP as reference. The box size applied was 
identical to the prior studies. A value of 10 for the height of the added Gaussian repulsion 
function  at  short  atom-atom  distances  was  taken  as  suggested  by  Gohlke  and  Klebe. 
Subsequent to the calculation of DrugScore pair-potentials for the training set ligands, atom-
type  based  Gaussian  functions  located  at  the  spatial  positions  of  each  ligand  atom were 
mapped onto the neighboring grid points and multiplied with the potential values to convert 
them  into  interactions  fields.  This  step  is  only  performed  for  those  atom  types  that  are 
frequently populated in the training set ligands and/or that show a variance in space to avoid 
false correlations when deriving the model (pIC50PLS). For example, all phosphorous atoms in 
the training data are closely aligned in space. Therefore, phosphorous fields are not expected 
to provide significant information to the model and, hence, are not considered. PLS analysis 
extracts the contribution of each considered atom-type specific interaction field as given in 
Table 2.4. The correlation of interaction fields with the binding affinities of the training set 
ligands  was  calculated  using  the  (SAM)PLS  algorithm as  implemented  in  AFMoC.  The 
statistical  significance of the obtained model  was assessed by performing “leave-one-out” 
cross-validation runs. The optimal number of components was determined by selecting the 
smallest sPRESS value and the same number of components was subsequently used to derive the 
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final AFMoC models. Statistical results for all 3D QSAR and AFMoC are summarized in 
Table 2.3 and 2.4. 
Table 2.3 Statistical results for PLS obtained for a leave-one-out analyses.
CoMFA CoMSIA AFMoC
spacinga) 1.0 1.0 1.0
column filtering 2.0 2.0
σ 0.85
No. components 5 4 4
q2 b,c) 0.58 0.39 0.46 (0.36)
spressd,e) 0.80 0.97 0.97 (0.97)
r2 b,f) 0.98 0.92 0.88 (0.86)
Sd,g) 0.20 0.35 0.46 (0.46)
Fb,h) 164.90 63.5 40.0 (32.8)
a) In Å. b) Values are given considering only the part of binding affinity (pKiPLS) used in 
PLS  analysis  or  considering  the  total  binding  affinity  (values  in  parentheses).  c) 
q2 = 1-PRESS/SSD as obtained by “leave-one-out” cross-validation. PRESS equals to the 
sum of  squared  differences  between predicted  and experimentally  determined binding 
affinities, SSD is the sum of the squared differences between experimentally determined 
binding affinities and the mean of the training set binding affinities. d) In logarithmic 
units. e) )1( −−= hnPRESSsPRESS  as obtained by “leave-one-out” cross-validation. n 
equals to the number of data points, h is the number of components. f) squared correlation 
coefficient. g) )1( −−= hnRSSS . RSS corresponds to the sum of squared differences 
between fitted and experimentally determined binding affinities. h) Fisher’s F-value. 
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Table 2.4 Field contributions to the models. 
CoMFA CoMSIA AFMoCb)
no. comp. 5 4 4
fraction
steric 0.62 0.16 C.3 0.45
electrostatic 0.38 0.12 C.ar 0.25
hydrophobic 0.31 C.2 0.15
donor 0.28 O.3 0.06
acceptor 0.14 O.co2 0.05
N.ara) 0.04
a)  For  AFMoC, N.2 is  converted to  N.ar.  b)  The denotation of  the  combination of 
interaction fields follows the atom type convention of SYBYL, further details are given in 
the original paper describing DrugScore. 
Plots of predicted versus experimentally determined pIC50 values are shown in Figure 2.5. 
Ten  runs  of  a  “leave-five-out”  procedure  were  also  performed.  For  this  rather  rigorous 
statistical  test  with  respect  to  the  amount  of  training  set  ligands,  five  arbitrarily  selected 
compounds  were  discarded  from  the  training  set  and  subsequently  used  for  prediction. 
Statistical results are shown in Table 2.10 (Supporting Information).
Additionally, the biological data were randomly scrambled and the model derivation was 
repeated, which allows the detection of possible chance correlations. Only negative q2 values 
in the PLS analyses were observed after randomizing the data by several protocols. Results 
are given in Table 2.11 (Supporting Information). Besides statistical analyses, AFMoC results 
can  also  be interpreted  graphically.  Therefore,  the  least  squares  coefficients  and standard 
deviations (STDEV*COEFF) assigned to each grid intersection were contoured within the 
binding pocket (Figure 2.10-12). 
In order to validate the predictive power of the derived models, a test set of 16 additional 
DOXP-reductoisomerase inhibitors was selected (Table 2.5). To obtain a reasonable ligand 
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conformation,  the  same  ligand  placement  protocol  as  described  for  the  training  set  was 
applied.  In contrast  to any of the training set  ligands,  the test  set  includes a  sulfonamide 
moiety to coordinate the Mg2+ ion as well  as ligands that protrude beyond the commonly 
occupied volume accommodated by the training set ligands. The scaling factor  csPair which 
adjusts  DrugScore values to  the  pIC50 range was originally  derived based on four  targets 
covering a broad range of inhibitors. For the present study, it converged to a slightly different 
value (-1.97x10-5 compared to -1.25x10-5) possibly because the affinity data within the DXR 
data  set  differs  in  range  and  order  of  magnitude.  AFMoC  predictions  were  performed 
adjusting the mixing factor θ in 10 steps of 0.1 from 0 to 1. To compare the performance of 
AFMoC with  respect  to  the  other  approaches,  pIC50 values  for  the  test  set  ligands  were 
predicted  solely  using  protein-based  scoring  and  comparative  molecular  field  analyses 
(CoMFA, CoMSIA; see Table 2.8).
Results and Discussion
Molecular alignment 
In the present  study,  we considered the crystal  structure of DXR with fosmidomycin  and 
merged the cofactor NADPH into the complex with a geometry as found in a related structure. 
For a training (27 compounds) and test set (16 compounds) of inhibitors with known binding 
affinity reasonable binding modes were generated by docking the ligands into the active site 
of DXR. The reliability of the applied protocol using AutoDock was validated by docking 
fosmidomycin successfully (rmsd = 0.86 Å) back into its crystal structure. Considering the 
modeled complex with NADPH, a very similar geometry is generated (rmsd with respect to 
the original orientation in the crystal structure = 0.96 Å). Taking the frequency how often a 
Rationalizing inhibitor potency with AFMoC 35
particular solution is found within one cluster by AutoDock as an additional figure-of-merit, 
the relevant binding modes are repeatedly detected, obviously even more frequently if the 
cofactor is bound. Therefore, we included NADPH in our docking simulations. Apparently, 
the  cofactor  restraints  the  binding  pocket  in  space  and,  as  a  consequence,  more  relevant 
binding  modes  are  produced.  A  repetition  with  100  docking  runs  to  increase  statistical 
significance revealed similar results (see Table 2.9, Supporting Information). 
As a matter of fact, FlexX did not generate ligand poses of comparable quality,  neither 
based on its original scoring function nor on the implemented DrugScore. To our opinion, this 
deficiency can be traced back to an inadequate reproduction of the geometry between the 
hydroxamate moiety of fosmidomycin and the Mg2+ ion. Even by restraining the placement of 
the  phosphorous  atom  using  FlexX-Pharm,  the  metal  hydroxamate  interaction  was  not 
correctly generated. The better performance of AutoDock 3.0 in this respect might be due to 
its explicit consideration of electrostatic interactions which are apparently of overwhelming 
importance in the present example. 
The protocol developed for fosmidomycin was similarly applied to all ligands. A suitable 
placement of the phosphonate and a correct coordination of hydroxamate moiety to the Mg2+ 
ion served as criteria to select the most appropriate docking solutions. For 16 (55%) out of 31 
training set ligands, the top-ranked docking solutions were selected to generate the alignment. 
In  four  cases,  no  acceptable  docking  solutions  could  be  obtained.  Accordingly,  those 
structures were excluded from further analyses, resulting in a training set of 27 ligands. A 
similar procedure was followed to construct the binding modes of the 16 test set ligands. 
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Table 2.5 DOXP-reductoisomerase inhibitors used as test set ligands. 
No. Name Structure pIC50
28 LD_1_6
PN
N
H
O O
O O
O
5.74
29 LIHP_86 PN
O
O
O
O
O
N
H
O
O 6.00
30 LIHP_89 PN
O
O
O
O
O
N
H
O
5.15
31 LTB104 PN
O
O
O
O
O
F
F
F
4.85
32 LTB60 PN
O
O
O
O
O
4.44
33 LTB71 PN
O
O
O
O
O
4.30
34 LTB75 PN
O
O
O
O
O
4.96
35 LTB77 PN
O
O
O
O
S
OO
4.42
36 LTB96 PN
O
O
O
O
O
NH3
+
4.80
Rationalizing inhibitor potency with AFMoC 37
No. Name Structure pIC50
37 UK163 P
O
O
O
N
O
O
O
O
4.80
38 UK2203
PN
O
O
O
O
O
5.62
39 UK2213 PN
O
O
O
O
O
6.64
40 UK711 PN
O
O
O
O
O
6.15
41 UK811
PN
O
O
O
O
O
5.18
42 UK821
PN
O
O
O
O
O
5.09
43 UK921 PN
O
O
O
O
O
5.18
mean (standard deviation) 5.2 (0.65)
a) Name column names refer to compound codes as worked with during the project
The finally achieved molecular alignment is shown in Figure 2.4. This alignment has been 
used in all comparative molecular field analyses and in protein-based affinity scoring.
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Figure  2.4 Docking  solutions  of  DOXP-inhibitors,  superimposed  in  the  binding  pocket  of 
pdb ID: 1ONP. Amino acids Gly185-Ile218 which compose the flexible loop are shown as 
cartoon to allow a better view into the active site; a) 27 inhibitors of the training data set; b) 
16 inhibitors of the test data set. 
CoMFA/CoMSIA analyses
For CoMFA, a satisfactory training set model could be established whereas for CoMSIA a 
model  at  the  borderline  to  significance  has  been  obtained  (Tables 2.4, 2.5, 2.9  and 
Figure 2.5a).  The  correlation  coefficients  for  the  leave-one-out  analyses  are  q2=0.58  and 
q2=0.39 respectively, indicating “good” models. For CoMFA, steric interactions dominate, as 
their fraction contributes with 62% (Table 2.4). 
Both 3D QSAR models lack any predictive power to correctly estimate the binding data of 
the 16 test set ligands (Table 2.7, 2.9). CoMFA as well as CoMSIA are known to be only 
valid for interpolation. Accordingly no satisfactory prediction is achieved for test set ligands 
comprising functional  groups  not  present  in  any of  the  training set  ligands.  Additionally, 
a) b)
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prediction fails for test set ligands that extend in space into areas never experienced by any of 
the training set ligands. 
However,  surprisingly  enough,  predictions  also  fail  for  ligands  exhibiting  only  minor 
structural  differences to  the training set  references.  For  example,  training set  inhibitor  15 
(pIC50=4.62) and test set entry 32 (pIC50=4.44) differ only slightly in affinity. This parallels 
with  minor  structural  differences;  15 has  an  isopropyl-group,  whereas  32 exhibits  a 
cyclopropyl moiety. Nevertheless, CoMFA predicts 32 by two orders of magnitude too strong 
in binding (pIC50=6.48). Remarkably, the smallest inhibitors of the training set exhibit the best 
affinity, whereas any increase in size parallels with a loss in affinity. Any spatial extension 
beyond  the  hydroxamate  is  detrimental  to  affinity.  Nevertheless,  if  a  test  set  ligand’s 
placement  of  the  phosphonate  and  hydroxamate  functions  matches  exactly  with  those  of 
fosmidomycin, this ligand is predicted as high in affinity. Test set inhibitor  32 (pIC50=4.44) 
serves again as an illustrative example. In Figure 2.6b it is shown together with the strong 
binding training set ligand 10 (pIC50=7.00). The phenyl moiety of the latter contributes to a 
favorable hydrophobic field which suggests the incorrect affinity prediction of 32 in CoMSIA. 
Compared to 15 or 10, the hydrophobic portion of inhibitor  32 does not accommodate an 
area  indicated  as  unfavorable  for  steric  occupancy  but  points  to  the  field  contributions 
favorable for hydrophobic properties. In consequence, CoMSIA (pIC50=6.58) overestimates 
32 even  more  than  CoMFA.  Possibly  a  limited  training  set  of  27  ligands  captures 
insufficiently  the  molecular  diversity  supposedly  allowed  for  ligands  accommodating  the 
binding site of DXR. We believe that this limited view of CoMFA and CoMSIA mainly arises 
from the fact that such field-based methods solely exploit ligand information and completely 
ignore the properties of the surrounding binding pocket. This detrimental disregard of any 
influences caused by the local binding site becomes increasingly evident once CoMFA or 
COMSIA are trained by rather small or uniformly distributed data sets. 
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Figure 2.5 a)  Experimentally  determined binding  affinities  versus  fitted  predictions  using  the 
derived CoMFA model for the training set. Results are shown applying the optimal number 
components  which  is  5  for  CoMFA  ()  and  4  for  CoMSIA  (∆),  respectively. 
b) Experimentally determined binding affinities versus fitted AFMoC predictions for the 27 
training set DOXP-reductoisomerase inhibitors. Both, experimental and calculated values are 
shown considering only the part of binding affinity (pIC50PLS) used in PLS analysis (◊) or 
considering the total binding affinity (▲). In addition to the line of ideal correlation, dashed 
lines are depicted to indicate deviations of one logarithmic unit from ideal prediction.
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Figure 2.6 a)  Stdev*coeff contour plots elucidating the steric  features as obtained by CoMFA 
analysis. Yellow contours (contour level 0.006 kcal/mol) highlight areas that should remain 
in their vicinity unoccupied, otherwise affinity will decrease. Despite its structural similarity 
to training set inhibitor 15 (white), test set ligand 32 (orange) is overestimated by CoMFA, 
because it does not penetrate into the unfavourable steric field region (yellow contour). b) 
Stdev*coeff  contour  plots  elucidating  hydrophobic  and  steric  features  as  obtained  by 
CoMSIA analysis. Magenta contours (contour level -0.021) encompass regions favourable to 
be occupied by hydrophobic groups. Yellow contours (contour level -0.0083) highlight areas 
unfavourable for any steric occupancy of a ligand. Additional to a), also the strong binding 
training set ligand 10 (pink) is shown. It contributes in the training model to the favourable 
hydrophobic field which on the opposite is responsible for the overestimation of 32. 
This observation motivated us to use AFMoC, since it considers simultaneously ligand and 
protein  structural  information.  This  enhancement  should  equip  AFMoC  with  improved 
predictive power to correctly handle also test set ligands strongly deviating from their training 
set references. 
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Generating the AFMoC model
Results  for  the  PLS analyses  are  given in  Table 2.3.  The LOO-analysis  suggests  optimal 
statistical results when considering four components in the model. With respect to the limited 
number of 27 training set ligands, a model based on a small number of components appears 
most reasonable. The correlation of predicted and experimentally determined affinity data of 
the training set is shown in Figure 2.5b), resulting in an r2 of 0.86. The final AFMoC model 
reveals a q2=0.46 considering only the atom-type contributions to affinity (pKiPLS) used in PLS 
analysis, or  q2=0.36 considering all contributions to binding affinity (Table 2.3, Figure 2.5). 
Ten  runs  of  “leave-five-out”  (LFO)-analyses  resulted  in  q2 values  between  0.41-0.61  for 
pKiPLS and  0.31-0.54  for  the  total  binding  affinity  with  optimal  numbers  of  components 
varying between 3 and 5. This variance indicates the inappropriate size of the training set. 
Leaving  out  five  rarely  represented  functionalities  reveals  models  of  only  minor  quality. 
Random assignment  of the affinity data to the ligands of the training set  resulted in only 
negative  q2 (see Table 2.11, Supporting Information). These results indicate that the models 
derived with the properly assigned affinity data are statistically significant. As apparent from 
PLS, contributions of C.2, C.3, and C.ar fields dominate the correlation. In all cases the Mg2+ 
ion is coordinated by a hydroxamate group through the O.3 and N.2 atom. For convenience, 
the N.2 atom type has been converted into N.ar in our analysis. As the field contributions for 
both  atom  types  correspond  to  6%  or  4%,  resp.,  the  correct  placement  of  the  group 
coordinating  Mg2+ is  important  for  affinity  correlation  in  our  model.  Similarly  the  5% 
contribution attributed  to the O.co2 field experiences  differences  in  the orientation of the 
phosphate groups across the data set.  To some degree also the placement  of these groups 
correlates with the affinity data. 
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Application of the derived AFMoC model to predict binding affinities
To assess the predictive power of the AFMoC model in particular in comparison to CoMFA 
and  CoMSIA,  binding  affinities  of  16  inhibitors  not  included  in  the  training  set  were 
predicted. As mentioned, the linear combination of DrugScore and PLS contributions fields 
allows  AFMoC to  gradually  move  between  generally  applicable  and  specifically  adapted 
interaction  fields  (Figure 2.7  and  Figure 2.8).  Accordingly,  the  mixing  factor  θ  was 
augmented in steps of 0.1 from 0 to 1. The best result was obtained for θ=0.5, with a squared 
correlation coefficient r2=0.47. 
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Figure 2.7 Dependence of squared correlation coefficient (r2) for AFMoC models on the mixing-
coefficient θ between original DrugScore potentials (θ=0) and specifically adapted AFMoC 
fields (PLS-model, θ=1).
44 Rationalizing inhibitor potency with AFMoC
Figure 2.8 a) Experimentally determined binding affinities versus fitted predictions for the test set 
molecules not considered in the training set.  Correlations are shown for varying mixing-
factor  θ.  θ=0  (a, ∆),  θ=0.5  (b, ),  θ=1.0  (c, ○).  Best  regression  is  obtained  for  θ=0.5, 
indicated by the slope of the regression line. d) Experimentally determined binding affinities 
versus predictions for the test set using the following additional methods, based on the same 
binding modes as used for the comparative molecular field analyses.  The diagram shows 
scoring using the Boehm function (×), AutoDock (∆), and DrugScore considering only pair-
potentials  ()  (including  the  solvent  accessible  surface  term  results  only  in  minor 
deviations, data not shown).
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Table 2.6 Affinity predictions for the test set ligands, using AFMoC and the mixing factor θ. 
Mixing factor θ
pure DrugScore pure AFMoC
ligand pIC50 0.00 0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90 1.00
28 5.74 6.86 6.76 6.66 6.55 6.45 6.35 6.38 6.15 6.04 5.94 5.84
29 6.00 8.65 8.42 8.20 7.97 7.75 7.52 7.28 7.07 6.85 6.62 6.40
30 5.15 6.71 6.65 6.59 6.53 6.47 6.41 6.34 6.29 6.23 6.18 6.12
31 4.85 5.20 5.36 5.52 5.68 5.84 6.00 6.18 6.33 6.49 6.65 6.81
32 4.44 5.47 5.51 5.55 5.59 5.63 5.67 5.70 5.75 5.79 5.83 5.88
33 4.30 7.00 6.75 6.50 6.25 5.99 5.74 5.51 5.24 4.99 4.74 4.49
34 4.96 5.39 5.44 5.49 5.54 5.59 5.64 5.77 5.73 5.78 5.83 5.88
35 4.42 4.41 4.59 4.77 4.95 5.13 5.31 5.53 5.67 5.85 6.03 6.21
36 4.80 4.49 4.78 5.07 5.36 5.65 5.95 6.23 6.53 6.82 7.11 7.40
37 4.80 5.60 5.44 5.29 5.14 4.99 4.83 4.71 4.53 4.38 4.23 4.07
38 5.62 7.55 7.25 6.94 6.64 6.34 6.04 5.74 5.44 5.14 4.84 4.54
39 6.64 7.01 6.93 6.85 6.78 6.70 6.62 6.51 6.47 6.39 6.31 6.24
40 6.15 5.05 5.28 5.51 5.74 5.97 6.19 6.43 6.65 6.88 7.11 7.34
41 5.18 5.77 5.89 6.00 6.12 6.24 6.35 6.46 6.59 6.70 6.82 6.93
42 5.09 5.54 5.63 5.73 5.83 5.92 6.02 6.15 6.21 6.31 6.41 6.50
43 5.18 5.52 5.57 5.62 5.67 5.72 5.77 5.82 5.87 5.92 5.98 6.03
r2 0.25 0.29 0.34 0.40 0.46 0.47 0.41 0.29 0.18 0.11 0.06
The minor  performance  of  pure  DrugScore  ranking (Figure 2.8d)  clearly  underlines  the 
need  to  include  specific  target  information  to  create  more  predictive  models.  Since 
detrimental  entropic  contributions  due  to  conformational  immobilization  of  both  binding 
partners are only rudimentarily taken into account by DrugScore, larger molecules usually 
receive a better scoring than smaller ones. However, in the present DXR example some of the 
smaller  ligands  exhibit  high  affinities.  Possibly  they  mimic  the  substrate  more  closely 
allowing  the  flexible  loop  region  to  properly  fold  upon  the  substrate  binding  site 
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(Figure 2.9a). It might well be that in particular the substrate-like inhibitors gain in affinity 
due to the fact that the protein can adopt a fully relaxed conformation corresponding to its 
natural  stage  along  the  catalytic  path.  For  larger  molecules  adequate  loop  closure  is 
supposedly  prevented.  Possibly  this  explains  why  some  of  the  larger  DXR  inhibitors 
frequently exhibit  reduced binding affinities,  even though they should be capable to form 
more favorable interactions compared to the smaller substrate analogs (Figure 2.9b). 
Figure 2.9 a) Different conformations of the flexible loop closing-up the active site of DOXP-
reductoisomerase.  In  red  the  loop  conformation  is  shown  as  determined  for  the 
fosmidomycin-Mn2+ complex  (pdb ID: 1ONP).  Superimposed  are  the  loop  conformations 
adopted either in the apo structure (pdb ID: 1K5H, blue) and in the cofactor-bound complex 
(pdb ID: 1JVS, green). b) Superimposition of the proposed binding mode of the rather bulky 
inhibitor 29 onto fosmidomycin. Obviously, in addition to the shape of the binding pocket 
(not  shown),  the  estimated  conformation  from  docking  strongly  depends  on  the  loop 
conformation (shown in wheat) selected for the docking studies. 
In such a situation, the tailored AFMoC model is capable of dealing with this difference as 
the contribution of the various moieties in the ligands are weighted dissimilarly. For example, 
enhancing contributions next to the putative loop position adopted along the catalytic pathway 
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are reduced. Affinity predictions of the test set inhibitors  33,  37, and  38 is exaggerated by 
DrugScore  (Table 2.6).  Most  likely,  their  large  hydrophobic  portions  interfere  with  the 
putative  loop conformation  adopted in  the  fully  closed  state.  In  the  AFMoC model,  this 
repulsive impact is penalized with increasing θ (Figure 2.10a+b). One might speculate that the 
pure  AFMoC  (θ=1.0)  would  reveal  the  best  predictions.  However,  this  is  not  the  case. 
Possibly,  the  slightly  shifted  phosphonate  groups  of  these  inhibitors  compared  to  the 
phosphonate positions in the training set are penalized (Figure 2.10c). 
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Figure 2.10 Test set inhibitors  33,  37, and  38 as predicted based on AFMoC using DrugScore 
potentials only. The binding modes of  33 (a) and  37 (b) are shown together with AFMoC 
STDEV*COEFF contour plots where the presence of ligand atom type C.2 (violet),  C.ar 
(blue), and C.3 (cyan) will reduce binding affinity. Contour levels are 0.005, 0.015 and 0.04, 
respectively. c) In comparison to fosmidomycin (white),  38 and 37 obviously do not adopt 
an  ideal  interaction  geometry  with  respect  to  the  phosphonate  group  in  our  model.  In 
addition AFMoC STDEV*COEFF contour plots are displayed that elucidate regions in the 
binding pocket where the presence of O.co2 will enhance (pink) or reduce (blue) affinity. 
Contour levels are –0.007 and 0.002, respectively. The upper left image is a blow-up of the 
phosphonate binding modes. The corresponding phosphorous atoms are indicated as sphere 
shown  in  the  same  color  as  the  corresponding  ligand  carbon  atoms.  The  flexible  loop 
capping the active site (is clipped off in the figure for reasons of clarity. 
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In a pure AFMoC model such a deviating placement  is handled very strictly.  In contrast, 
mixing  with  information  from  the  original  DrugScore  potentials  allows  one  to  score 
appropriately this deviating placement of the phosphonate groups. 
The key binding interaction of DXR inhibitors is the interaction with the Mg2+ ion. Upon 
visual  inspection  of  original  DrugScore  versus  adapted  AFMoC  contribution  maps,  it 
becomes  obvious  that  the  O.3,  N.ar,  and  C.2  fields  get  increasingly  restricted  in  space. 
Inhibitors 5 (pIC50=6.59) and 1 (pIC50=7.70), both included in the training set, differ only in 
their stereochemistry at the hydroxamate moiety because the sequence of hydroxylamino and 
carbonyl  functions  is  reversed.  This  reversal  parallels  a  loss  in  affinity  by  one  order  of 
magnitude compared to fosmidomycin (Figure 2.11a) possibly due to a different desolvation 
energy. 
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Figure  2.11  AFMoC  STDEV*COEFF  contour  plots  for  ligand  atom  types  N.ar  (blue),  C.2 
(white),  O.co2  (pink)  and  O.3  (red)  representing  regions  where  the  presence  of  the 
corresponding atom type will enhance binding. Contour levels are –0.02, –0.005, –0.008 and –
0.008,  respectively.  The  position  of  the  Mg2+ ion  is  indicated  by  the  magenta  sphere. 
a) Fosmidomycin  (white)  and  training  data  set  inhibitor  5 (cyan)  which  only  differ  by  the 
reversal of their hydroxamate functions are distinguished by one order of magnitude in affinity. 
b) Test data set inhibitor  28 which exhibits a similar reversal hydroxamate superimposes well 
with  the  training  set  inhibitor  5.  AFMoC  based  on  pure  DrugScore  potentials  (θ=0.0), 
overestimates  binding affinity for  28.  However,  with  increasing mixing of  adapted  AFMoC 
fields (θ>0…1), the presence of the reversed hydroxamate moiety is sufficiently penalized and a 
more accurate prediction is achieved. 
Obviously this reversal does not affect the position of the terminal O.3 atoms that interacts 
with the Mg2+ ion. Adapted AFMoC fields for N.ar and C.2 next to the Mg2+ site are sharply 
contoured in a narrow spatial area (Figure 2.11). The N.2 and C.2 atoms of 5 coincide exactly 
with the encompassed regions. This fact of very localized field contributions using AFMoC is 
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convincingly demonstrated by the test set ligand 28 (pIC50=5.74; Figure 2.11b). This inhibitor 
shows  the  same  reversed  hydroxamate  geometry  as  5 and  the  accuracy  of  its  affinity 
prediction improves with increasing contribution of the adapted AFMoC fields to the total 
score, to achieve an optimum (predicted pIC50=5.84) at θ=1.0 (Table 2.6). 
Based on a  sufficiently  diverse training set  covering a broad affinity  range,  one would 
expect  that  the  adapted  fields  (θ=1.0)  reveal  the  highest  predictive  power,  because  they 
include  the  largest  amount  of  knowledge  about  the  actually  contributing  target-ligand 
interactions. However, such an ideal spread of training set data is never given. Accordingly, a 
mix between AFMoC adapted fields and original DrugScore fields helps to overcome model 
restriction  or  over-fitting  in  particular  in  case  of  a  small  and  restricted  training  set.  For 
example,  binding  affinities  of  31 and  36 are  best  predicted  applying  pure  DrugScore 
potentials  only  (Table 2.6).  As  shown  in  Figure  2.12(a-c),  they  perfectly  align  with 
fosmidomycin and their N.2 and C.2 atoms coincide exactly with the corresponding AFMoC 
contribution maps. The same holds for the O.co2 atoms of the phosphonate group, in total 
these features results in a high affinity prediction of both compounds.
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Figure 2.12 Comparison of the binding mode of fosmidomycin (a, ligand shown with atom type 
coding), with two inhibitors 31 (b, ligand carbon atoms in yellow) and 36 (c, ligand carbon 
atoms in  green).  The  latter  two  examples  from the  test  set  are  overpredicted  using  the 
AFMoC-adapted  fields  (θ=1)  because they firstly satisfy very similar  interactions  as  the 
potent  inhibitor  fosmidomycin.  Secondly,  due  to  their  additional  substituent  at  the 
hydroxamate  group,  they  can  experience  additional  interactions  with  the  protein.  For 
analysis  purposes  the  AFMoC  STDEV*COEFF  contour  plots  are  shown  that  highlight 
favorable regions for occupancy by a C.2 (white), N.ar (blue), O.3 (red) and O.co2 (pink) 
type ligand atom. Contour levels are –0.02, –0.005, –0.008 and –0.008, respectively. The 
additional decorations of  31 and  36 are detrimental to affinity, however since none of the 
training set ligands reflect such information, the adapted AFMoC model cannot predict the 
properties  of  these  additional  substituents  correctly.  In  the  present  case,  the  original 
DrugScore potentials perform somewhat better. 
Nevertheless,  both  ligands  comprise  a  side  chain,  e.g.  a  trifluormethylene  (31)  and  an 
aminopropyl group (36). These decorations are detrimental to affinity, however since none of 
the examples in the training set indicates such behavior, the AFMoC model cannot reflect this 
information. As a consequence, AFMoC fields fail to predict  31 and  36 correctly, both are 
highly overestimated in affinity. Considering purely the fields based on original DrugScore 
reveals much better predictions. For 36, a slight mixing with adapted AFMoC fields (θ=0.1) 
achieves the best predictive power. 
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Prediction using other scoring schemes 
The predictive power of AFMoC (Table 2.8) has to be faced to prediction rates achieved by 
applying either the CoMFA or CoMSIA model or other scoring functions.  A summary is 
given in Table 2.7, detailed information on scoring the test set ligand is given in Table 2.8. 
Table 2.7. Statistical parameters for the prediction of binding affinities of the test set ligands applying 
docking, AFMoC and 3D QSAR. 
DrugScorea) AutoDock Boehm-fct AFMoCd)
(θ=0.5)
CoMFAd) CoMSIAd)
r2 b) 0.28 (0.30) 0.33 0.0002e) 0.47 “0.33”e) “0.03”e)
SDc) 0.75 (0.74) 0.60 0.99
a) Values are given considering only the pair potentials for the prediction or considering 
also the solvent-accessible surface term (values in parentheses). b) Squared correlation 
coefficient.  c)  In  logarithmic  units.  d)  Values  are  given  for  the  optimal  number  of 
components, which are 4 for AFMoC, 5 for CoMFA, and 4 for CoMSIA. e) Values in 
italics denote lacking correlation. 
Table  2.8: Affinity  predictions  for  the  test  set  ligands,  using  CoMFA,  CoMSIA,  DrugScore. 
AutoDock and the Boehm function. 
ligand pIC50 CoMFA CoMSIA DrugScore
DrugScore 
incl. SAS
Auto
Dock
Boehm-
function
28 5.74 5.08 5.70 6.11 6.20 6.05 6.06
29 6.00 4.95 4.37 7.08 7.06 6.18 5.57
30 5.15 5.38 4.99 5.60 5.55 5.27 10.18
31 4.85 6.38 7.39 4.63 4.57 4.57 8.06
32 4.44 6.48 6.58 4.70 4.76 4.68 7.56
33 4.30 5.58 6.23 5.72 5.65 5.75 9.26
34 4.96 6.59 6.75 4.85 4.84 4.32 6.57
35 4.42 7.01 6.04 3.98 3.91 4.40 8.12
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ligand pIC50 CoMFA CoMSIA DrugScore
DrugScore 
incl. SAS
Auto
Dock
Boehm-
function
36 4.80 6.01 5.26 3.95 3.99 5.16 5.1
37 4.80 4.94 4.14 4.52 4.52 4.89 2.22
38 5.62 5.15 6.00 6.02 6.09 6.25 9.12
39 6.64 5.36 6.42 5.78 5.83 6.01 9.04
40 6.15 6.62 6.90 4.50 4.50 4.93 5.85
41 5.18 6.96 7.04 5.16 5.09 5.20 6.55
42 5.09 6.47 7.03 4.97 4.97 5.01 6.61
43 5.18 6.34 6.60 4.82 4.78 4.71 5.06
r2 “0.33“a) “0.03“a) 0.28 0.30 0.34 0.00
a) Values in italics denote lacking correlation. 
As mentioned above, both 3D QSAR methods do not reveal any predictive power for the 
test  set  (r2CoMFA=“0.33”,  r2CoMSIA=“0.03”).  The  AutoDock  scoring  function  correlates  the 
experimental  data  to  docking  results  with  an  r2=0.33  (Table 2.7,  Figure 2.8b).  Major 
deviations can be attributed to a score-to-size dependency. E.g. compared to the actually more 
potent methyl derivative 40 (pIC50=6.15), the ethyl analog 41 (pIC50=5.18) obtains a slightly 
higher  score,  although  40 matches  better  with  the  fosmidomycin  binding  mode. 
Unfortunately, the Boehm scoring function is of no predictive power across the test data set. 
Considering  the  examples  in  detail  shows  that  the  Boehm  function  performed  poor  in 
particular  for  inhibitors  with  large  hydrophobic  moieties  (32,  39).  Obviously,  a  general 
purpose scoring function as the Boehm function does not perform sufficiently well in the 
present case, since special features in the correlation cannot be regarded properly. DrugScore 
shows a weak correlation at the borderline to significance (r2=0.25). In summary it can be 
concluded that AFMoC with a mixing factor θ=0.5 achieves the highest predictivity across the 
different methods applied in this study. 
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Conclusions
Comparative  molecular  field  analyses  were  applied  to  correlate  binding  data  of  DOXP-
reductoisomerase (IspC/DXR) inhibitors.  The target  enzyme provides some challenges for 
structure-based drug design: it (1) contains a metal-ligand coordination, (2) requires cofactor 
binding and (3) possesses a large flexible loop, that folds upon the active site. Although X-ray 
structures  of  the  apo  enzyme  (pdb ID:  1K5H),  the  holo  enzyme  with  bound  cofactor 
(pdb ID: JVS), and a protein-inhibitor complex (pdb ID: 1ONP) lacking the bound cofactor 
have been solved, they do not provide enough information about the protein conformation 
adopted during the critical hydride transfer reaction step. This is mainly due to the fact that 
none  of  the  crystal  structures  shows the  flexible  loop in  a  conformation relevant  for  the 
situation when metal ion, cofactor and substrate are simultaneously bound. It is assumed that 
in this situation ligands experience tightest binding. This assumption appears justified for the 
following reasons. First  of all,  the hydride transfer step has to avoid any access of water 
molecules  from  the  surrounding  solvent  environment.  Second,  the  close-up  of  the  loop 
regions on top of the catalytic center will enhance the strength of the electrostatic interactions 
to the Mg2+ ion as a result of the shift in the dielectric conditions. 
To establish a relevant structure activity relationship, in particular to predict affinity data for 
new  inhibitors,  we  applied  comparative  molecular  field  analyses.  Whereas  CoMFA  and 
CoMSIA  succeed  to  produce  reasonable  models  based  on  a  training  set  of  27  aligned 
inhibitors, they do not exhibit any predictive power with respect to 16 ligands not included in 
the training set. To enhance comparative molecular field analysis, AFMoC can be considered 
as a knowledge-based scoring function tailored to a specific protein using additional inhibitor 
data. Similar to the other two 3D QSAR methods, the training set of 27 ligands produces a 
statistically significant model. In addition, AFMoC performs well on the 16 test set inhibitors, 
which comprise functional groups, not contained in the training data or address areas of the 
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binding pocket not experienced by any of the training set ligands. In contrast to CoMFA and 
CoMSIA,  AFMoC provides  reasonable  affinity  estimates.  Best  results  are  obtained  if  the 
original DrugScore fields are equally mixed with the PLS-derived AFMoC fields. Compared 
to pure DrugScore scoring, the tailored AFMoC fields also allow to better handle the affinity 
prediction of some stronger binding ligands of reduced size. 
Especially at the beginning of a structure-based drug design project, when only one or two 
protein-ligand complexes are available and binding data of a small set of inhibitors has been 
characterized, AFMoC offers the opportunity to include a maximum of knowledge about the 
studied target protein into a computer model. With an increasing amount of additional data, 
the training set can be extended and in consequence the affinity prediction will improve the 
adopted model (i.e. θ can be chosen larger). Furthermore, the AFMoC model can be applied 
as a tailored scoring function in virtual screening. Finally, by contouring the atom-type based 
contribution maps, AFMoC provides in a very similar fashion as usual CoMFA or CoMSIA 
the opportunity to create new ideas for drug design. However, as major improvement to the 
classical comparative molecular field analyses, AFMoC incorporates information about the 
interaction properties of the surrounding protein. 
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Supporting Information 
Table 2.9 Approval of statistical significance of the docking protocol
Results of 100 docking runs for Fosmidomycin with AutoDock
DXR incl. NADPH DXR excl. NADPH
Rank No. of molecules per clustera) RMSD
b) Energyc) Rank No. of molecules per clustera) RMSD
b) Energyc)
1 80 0.83 -8.77 1 66 0.86 -8.99/
2 3 1.38 -8.59 2 4 1.34 -8.87
3 4 5.63 -8.43 3 11 5.54 -8.68
4 1 1.98 -8.41 4 2 5.44 -8.67
5 1 5.12 -8.37 5 3 1.47 -8.74
6 3 5.40 -8.30 6 3 5.07 -8.58
7 2 5.10 -8.21 7 3 5.49 -8.60
8 2 5.31 -8.11 8 2 5.52 -8.47
9 4 5.23 -8.06 9 1 4.94 -8.48
10 2 5.26 -8.41
11 1 5.37 -8.41
12 1 5.17 -8.33
13 1 1.80 -8.29
a)  rmsd-threshold  =  1.0  Å.  b)  In  Å  compared  to  fosmidomycin  as  observed  in 
pdb ID: 1ONP. c) In kcal/mol.
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Table 2.10 Statistical results for 10 runs of „leave-five-out“ cross-validation, averaged over (no. of 
training set compounds/5)+1 runs. 
Leave-five-out
 no. of run q2 a) Spress b) components
1 0.47 (0.36) 0.97 5
2 0.60 (0.53) 0.84 5
3 0.54 (0.45) 0.89 4
4 0.47 (0.37) 0.98 5
5 0.61 (0.54) 0.82 4
6 0.43 (0.32) 0.99 4
7 0.41 (0.31) 1.00 4
8 0.51 (0.42) 0.93 5
9 0.44 (0.35) 0.90 4
10 0.46 (0.36) 0.94 3
LOOc) 0.46 (0.36) 0.96 4
a) Values are given considering only the part of binding affinity (pKiPLS) used in PLS 
analysis or considering the total binding affinity (values in parentheses). b) In logarithmic 
units. c) For comparison, results of the “leave-one-out” cross-validation are shown.
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Table 2.11 q2 values for AFMoC models obtained with randomly scrambled affinity data. 
no. of 
components
q2 a)
1 -0.44 (-0.70)
2 -0.19 (-0.42)
3 -0.30 (-0.54)
4 -0.19 (-0.41)
5 -0.18 (-0.40)
6 -0.29 (-0.53)
7 -0.38 (-0.64)
8 -0.45 (-0.72)
9 -0.60 (-0.90)
10 -0.66 (-0.97)
a) Values are given considering only the part of binding affinity (pKiPLS) used in PLS 
analysis or considering the total binding affinity (values in parentheses).
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METHODS IN 
RECEPTOR-BASED DRUG DESIGN
As outlined in the introduction, the present work comprises examples for computer-aided lead 
optimization.  These  challenges  are  mostly  addressed  via  protein-based  docking  [Kitchen, 
2004],  [Sotriffer,  2002b].  This  chapter  gives  a  brief  summary  of  currently  available 
approaches and applications. Programs applied for the present work are discussed in detail. 
Protein-based docking 
Protein-based docking is defined as to computationally predict structures of protein-ligand 
complexes. The orientation that maximizes the interaction reveals the most accurate structure 
of the complex. Docking a data set of ligands comprises two problems; (1) generation of the 
ligand-binding  mode  that  corresponds  best  to  the  experimentally  given  situation,  and  (2) 
reasonable estimate of the expected binding affinity and thus, ranking a series of different 
compounds for one target. 
Early docking approaches were done orienting a ligand inside a three-dimensional structure 
of the protein and simply reducing steric clashes. Both, protein and ligand were treated as 
rigid bodies and only six degrees of translational and rotational freedom were sampled. With 
increasing computational  power  it  is  now possible  to  consider  conformational  degrees  of 
freedom. Solving the configuration generation problem, three categories of search algorithms 
are used. 
1. The ligand is  divided into multiple  fragments.  The core fragment is  docked into the 
binding  site  and additional  fragments  added  in  an  incremental  way.  Examples  are  the 
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programs DOCK4.0 [Ewing, 2001], FlexX [Rarey, 1996], LUDI [Bohm, 1992a], [Bohm, 
1994b], [Bohm, 2002] and HammerHead [Welch, 1996]. Being very fast, the pitfall of the 
approach is the high number of docking geometries possible for multiple core fragments. 
Unfortunately  favorable  protein-core  fragment  interactions  might  prevent  the  correct 
placement of the whole ligand. 
2. Random changes are applied to a population of ligand geometries,  mostly via Monte 
Carlo  search  or  genetic  algorithms.  Examples  are  the  programs  GOLD [Jones,  1997], 
AutoDock [Goodsell, 1996], [Morris, 1996], [Morris, 1998] and ICM [Totrov, 1997]. Key 
issue here is the number of iterations necessary to correctly sample the binding site. 
3. Full  simulation  of  both,  ligand  and  receptor  using  force  fields.  Examples  are  the 
programs  AMBER  [Case,  2005],  CHARMM  [Brooks  B.  R.  Bruccoleri,  1983]  and 
GROMOS  [Osterberg,  2002].  Caveats  here  are  the  long  computation  times  and  the 
possibility of getting trapped in local minima. 
One docking algorithm which combines the protocols is GLIDE [Friesner, 2004]. In a first 
step, active site properties are mapped on a grid, a set of ligand conformation is placed using a 
Monte Carlo approach and minimized. In the second step only a selected number (3-6) of 
conformations  is  considered  for  the  subsequent  Monte  Carlo  simulation.  Comprehensive 
reviews  on  docking  algorithms  and  their  implementations  have  been  given  by  Taylor, 
Halperin,  Leach and others [Brooijmans,  2003], [Chen, 2006], [Coupez, 2006],  [Halperin, 
2002], [Leach, 2006a], [Sousa, 2006], [Taylor, 2002]. 
Protein-based scoring
Using structural information from both the protein target and the docked ligand geometry 
protein-based scoring  functions  are  applied  to  achieve  two goals.  For  a  calculated  set  of 
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different docking solutions for one ligand to one target, the scoring function has to recognize 
the  binding  mode  that  corresponds  best  to  the  experimentally  derived  complex  structure 
(structure  prediction  problem),  thus,  discriminating  between correct  and incorrect  binding 
modes with reasonable accuracy and speed [Abagyan, 2001], [Kramer, 1999]. Based on the 
selected complex geometry, an ideal scoring function should be able to estimate as accurately 
as possible binding free energies. This way, different ligands can be ranked with respect to 
their  affinity  to  one  target  (affinity  prediction  problem)  [Stahl,  2001],  [Wang,  2003]. 
Unfortunately,  current scoring functions are a trade-off between fast evaluation of protein-
ligand interaction needed for database screening and the accuracy. The limited accuracy is 
due to an incomplete understanding of complex interactions, to an incomplete training set for 
parameterization,  and  to  a  highly  simplified  approximation  (or  omission)  of  important 
variables in binding such as solvation and entropy [Chin, 2004]. There are three main classes 
of scoring functions. 
1. Molecular mechanics functions are the closest to first principles that are used in docking. 
Examples are those implemented into the programs AMBER [Cornell, 1995], CHARMM 
[MacKarell,  1998],  AutoDock  [Morris,  1998],  DOCK4.0  [Ewing,  2001]  and  GOLD 
[Jones, 1997]. These functions are based on additive atomic parameters (van der Waals, 
electrostatics,  bonds,  angles  and  torsions)  usually  derived  from  quantum  mechanical 
calculations, which are assumed to be transferable between molecules containing similar 
atom types. Molecular mechanics scoring functions have a number of limitations. They 
model  gas-phase  contributions  and  neglect  solvation  and  significant  contributions  to 
entropy. To account for speed, cut-off distances are applied which prevent the accurate 
treatment of long range effects. 
2. Empirical or regression-based scoring functions are calibrated to associate numbers of 
atomic  or  molecular  features  (e.g.  rotatable  bonds,  hydrogen-bonding  parameters, 
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lipophilic interactions, solvation and entropic effects) with a training set of ligands with 
known affinity to their targets. Coefficients are determined via multiple linear regression, 
partial-least square or neural-network analysis. Examples are the Boehm scoring function 
applied in FlexX [Bohm, 1994a], [Bohm, 1998], [Bohm, 1999], X-Score/X-CScore [Wang, 
2003]  and  ChemScore  [Eldridge,  1997].  Often  successfully  applied  it  remains 
questionable,  whether  it  is  possible  to  predict  binding  affinities  for  ligands  that  are 
structurally different from those used in the training set. 
3. Knowledge-based  scoring  functions  apply  a  Boltzmann  weighting  to  distributions  of 
atom-atom  distances  observed  in  crystal  structures.  They  are  originally  developed  to 
reproduce binding geometries  rather  than binding energies.  Binding effects,  difficult  to 
describe explicitly are somewhat captured implicitly in the derivation of interaction pair 
potentials.  Examples  for  knowledge-based  scoring  function  are  DrugScore  [Gohlke, 
2000a],  [Gohlke,  2001]  and  PMF [Muegge,  1999b],  [Muegge,  1999],  [Muegge,  2006] 
SmoG [Ishchenko, 2002] and BLEEP [Mitchell, 1999]. Their advantage is speed, better 
independence  from  a  training  set  than  empirical  functions  and  a  certain  amount  of 
robustness towards small changes in the protein target structure compared to molecular 
mechanics scoring functions. However, their capabilities are restricted to the information 
implicitly contained in the training set which can lead to a limited differentiation of atom 
types and rare distribution effects. Using the CSD instead of the PDB, this restriction has 
been  overcome  by  deriving  DrugScoreCSD [Velec,  2005].  The  better  resolved  small 
molecule structures provide more contact data and produce potentials of superior statistical 
significance and more detailed shape. 
A common pitfall for most scoring functions is the size dependency: the larger the ligand, the 
better the score [Kirtay, 2005]. Correction methods to account for stickiness of a molecule 
have been proposed [Vigers, 2004]. Protein-based scoring function have been reviewed by 
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Gohlke,  Tame,  and others  [Gohlke,  2002b],  [Kirtay,  2005],  [Stahl,  2001],  [Tame,  1999], 
[Tame, 2005]. 
Applied docking programs and Scoring functions
The three most popular [Sousa, 2006] docking programs have been applied in the present 
work:  FlexX,  GOLD and AutoDock.  With  respect  to  scoring,  we additionally  considered 
Chemscore as implemented in GOLD, DrugScore and SFC-Score. 
FlexX
In  FlexX  [Kramer,  1999],  [Rarey,  1996],  [Rarey,  1997]  protein-ligand  interactions  are 
describes  by  certain  interaction  types  and  their  corresponding  geometry  [Bohm,  1992b], 
[Klebe, 1994]. Interaction groups and their compatibilities are assigned to the ligands to be 
docked. For each interaction pair, a special geometry and a surface at a certain threshold is 
defined. An actual  protein-ligand interaction is  considered if  the interaction center  of one 
group contacts the surface of the counter group. The ligand placement is performed in three 
steps. The first step is the selection of the base fragment. The second step is the base fragment 
placement into the binding site. Conformers are created using the MIMUMBA torsion angle 
database [Klebe, 1999], [Sadowski, 2006]. The energy cutoff allowing divers conformers can 
be manually controlled as well as the number of possible base fragment poses. Subsequently, 
the remaining fragments are added in following a tree-search technique and a number of best 
partial  solution  based  on  assessment  of  the  scoring  function  are  kept  until  the  ligand  is 
completely assembled. The weakness of FlexX is docking very flexible and large molecules. 
A potentially reasonable base fragment placement might prohibit any further of the remaining 
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ligand to the binding site. This can be overcome in two different ways. For a series of similar 
compounds it might be useful to apply the mapref option. It allows to manually place the base 
fragment and therefore increases the probability of producing a reasonable binding mode. A 
second option is to apply user-defined constraints via the FlexX-Pharm option [Hindle, 2002]. 
This way, either a certain interaction type or a certain atom type at a specific position can be 
defined as essential or partial constraint. Checking the possibility to obey these constraints 
upon ligand construction, falsely placed fragments are discarded early and more reasonable 
geometries  are  further  considered.  The  FlexX  scoring  function  belongs  to  the  class  of 
empirical  scoring  functions.  It  comprises  terms  for  hydrogen  bonding,  ionic  interactions, 
lipophilic interactions as well as penalties for unfavorable angles. Coefficients were derived 
adapting the function to a data set of originally 45 protein-ligand complexes SCORE1 [Bohm, 
1994a] and later updated to 84 complexes SCORE2 [Bohm, 1998], [Rarey, 1995]. 
AutoDock
An example of the implementation of a genetic algorithm into protein-ligand docking is the 
program AutoDock  [Goodsell,  1996],  [Morris,  1996],  [Morris,  1998].  To  model  putative 
interactions to be formed by the protein an user defined affinity grid is calculated for the 
binding site. For each atom type present in the ligand data set one grid is calculated with 
expected  protein-ligand  affinities  attributed  to  each  grid  point.  Additionally,  one  grid  is 
calculated  for  the  electrostatic  potential.  A  population  of  ligand  conformers  is  placed 
randomly  onto  the  grid.  Using  either  a  Lamarckian  genetic  algorithm,  a  Monte  Carlo 
simulated annealing or a traditional genetic algorithm ligand conformations are generated, 
evaluated using the affinity grids and kept or discarded. Stop criterion is  either a defined 
number of energy evaluations or reaching a energy minimum with a further improvement 
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within a given energy threshold. Evaluating the three different algorithms, a combination of 
the  Lamarckian  genetic  algorithm with  a  traditional  genetic  algorithm to perform a local 
energy minimization had been reported to perform best [Morris, 1996]. Scoring implemented 
in AutoDock is a force field-based function comprising five terms based on the AMBER force 
field [Case, 2005]. It comprises a Lennard-Jones 12-6 dispersion term, a directional 12-10 
hydrogen bonding term and an intermolecular pairwise desolvation term. The scaling factor 
for each of these five terms is  empirically calibrated from a set  of 30 structurally known 
protein-ligand complexes. 
GOLD
Also  GOLD  uses  a  genetic  search  algorithm  and  allows  for  full  ligand  flexibility. 
Furthermore,  it  considers  multiple  orientations  of  protein polar  hydrogens  [Kairys,  2006]. 
Each possible protein-ligand interaction is defined as a chromosome. Starting from an initial 
randomly  generated  population  of  chromosomes  the  fitness  is  evaluated  by  the  scoring 
function and the least fittest members is replaced. Ligands are placed into the binding site 
based on fitting points. Then, the program adds fitting points to hydrogen-bonding groups on 
protein and ligand, and maps acceptor points in the ligand on donor points in the protein and 
vice versa. Additionally GOLD generates hydrophobic fitting points in the protein cavity onto 
which ligand CH groups are mapped. The generic algorithm uses a least-square routine to 
attempt to form as many hydrogen bonds as possible.  Therefore, rotatable ligand dihedral 
angles, ligand ring geometries and protein OH and NH3+ groups are optimized. Many new 
options in GOLD now allow to keep specified scaffolds rigid, allowing to introduce user-
specific interaction (e.g. metal interactions) [Verdonk, 2003]. The GOLD scoring function is 
force-field based and includes four terms,  a hydrogen bonding term, a 4-8 intermolecular 
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dispersion potential, and a 6-12 intramolecular potential for the internal energy of the ligand 
and an intramolecular hydrogen bonding term which is mostly switched off in applications. 
Integrated into GOLD is the scoring function Chemscore [Verdonk, 2003]. It is a regression-
based  function  considering  scores  for  hydrogen-bonding,  acceptor-metal,  and  lipophilic 
interactions, and the loss of conformational entropy. The coefficients were derived from a 82 
protein-ligand complexes [Eldridge, 1997]. 
DrugScore
DrugScore [Gohlke, 2000a], [Gohlke, 2001] is one of the most widely used knowledge-based 
scoring function. The basis is the comparison of the observed number of contacts between 
certain atom types to the number of contacts one would expect if there were no interaction 
between the atoms. For the development of DrugScore ~1400 protein-ligand complexes have 
been used. Due to missing information about non-binding events, the derived potentials are 
adapted using a reference state, representing an “average interaction”. For 17 atom types, the 
number of contacts between protein atom of type i and ligand atom of type j in the database 
(ReliBase+ http://relibase.ccdc.cam.ac.uk/) are tabulated as a function of their distance. To 
consider only direct protein-ligand contacts, the upper sample radius has been set to 6 Å. In 
addition  to  the  statistical  atom-atom  pair  potentials,  DrugScore  also  contains  a  solvent-
accessible surface (SAS)-dependent term. Non-polar surfaces on both protein and ligand in 
both complexed and uncomplexed state are calculated. They express the probability of protein 
and ligand atoms to get buried upon formation of the complex. The term rewards burial of 
certain atom types and penalizes the burial of others. Additionally to scoring final docking 
geometries, DrugScore potentials were also applied directly as energy function upon docking 
[Sotriffer, 2002a], [Radestock, 2005]. 
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An extension to DrugScore was reported which uses the CSD instead of the PDB as database. 
The new pair-potentials (DrugScoreCSD) are based on a larger number of crystal structures. 
Especially for ligand atom types rarely found in the PDB (like S, P, Cl) this led to a better 
recognition of “relevant” binding geometries and affinity prediction [Velec, 2005]. Formulas 
for all described scoring functions are given in the supporting information. 
SFC-Score
In order to derive the empirical scoring function SFC score data was collected from both, 
public  and  industrial  contributions.  Over  60  descriptors  were  applied  and  evaluated  for 
affinity prediction. Via correlation and regression analysis the most suitable descriptors were 
selected to calibrate the empirical function. Using selected training datasets, general functions 
as well as target class biased (serine proteases) or ligand feature biased (fragment-like sized) 
functions  were  derived  [Sotriffer,  2007].  Applying  the  functions  to  several  test  data  set 
superior performance of the SFCscore functions was observed in many cases, but the results 
also illustrate the need for further improvements. 
Addressing challenges for docking 
This work addresses a protein target showing flexibility in the active site and the docking of 
fragment-sized ligands. Therefore, two additional aspects of docking should be discussed. The 
first is how to consider protein flexibility during the docking process and the second is how to 
incorporate  water  molecules  in  the  case  the  ligand  occupies  only  parts  of  the  pocket  or 
protein-ligand interactions are transmitted via water contacts. 
Most commonly used docking methods treat the ligand as flexible and the protein as rigid. 
However,  in  most  cases  it  is  not  justified  to  neglect  protein  flexibility.  McGovern  and 
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Shoichet docked a data set against the holo (ligand bound), apo (empty) and protein binding 
sites derived via homology modelling [McGovern, 2003a] for several targets. Achieving best 
docking performances upon using the holo structures clearly demonstrates the importance of 
the  particular  representation  of  the  target  used  in  the  screen.  However,  using  only  one 
particular protein structure will clearly bias virtual screening. Same conclusions can be drawn 
from so-called “cross-docking” experiments. For a single target and a set of experimentally 
determined protein-ligand complexes each ligand is docked into its own holo structure as well 
as into the other available protein structures. The lowest energy configuration for a ligand 
should be found when docking it back to the protein structure it was originally complexed 
with [Sotriffer, 2005], [Zentgraf, 2006]. 
To  meet  the  need  for  a  docking  algorithm  which  considers  certain  degrees  of  protein 
flexibility while keeping computational complexity at a reasonable level, several approaches 
have been introduced recently.  There are reviewed by Carlson [Carlson, 2000a], [Carlson, 
2002]. Examples for programs which consider target flexibility are Glide, FlexE, Slide. The 
methodological foundation is (1) sampling binding site conformational space via molecular 
dynamic simulations [Sivanesan, 2005], (2) using rotamer libraries for binding site side chains 
[Alberts,  2005], (3) docking into an ensemble representation of the binding site [Carlson, 
2000b] or (4) permitting some steric clashes with the protein [Ferrari, 2004]. However, it has 
also been reported that  considering multiple  protein structures  for  a  virtual  screening can 
result in reduced hit rates [Barril, 2005]. Successful virtual screening for a flexible binding 
site has also been reported by pragmatically only targeting one specific representation of the 
binding site [Kraemer, 2004]. 
Another aspect currently discussed with respect to docking of especially small ligands is the 
contribution made by water molecules. Water can form hydrogen bonds between the ligand 
and the protein and thus contributing to the affinity  or  it  can be displaced by the ligand 
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[Ladbury, 1996]. Recently implemented into GOLD, water molecules can now be switched on 
and off [Verdonk, 2005]. The authors claim to be able to correctly predict water mediation/ or 
displacement in 93% of the tests. 
Improving scoring function performance [Verdonk, 2004] has led to several new concepts. A 
pragmatic  strategy  to  enhance  the  reliability  of  predicted  binding  affinities  results  from 
simultaneously  considering  multiple  scoring  functions  [Clark,  2002].  Theoretically,  this 
should be more robust and accurate than only applying a single method [Charifson, 1999], 
[Clark,  2002],  [Wang,  2001b].  Proven successful  in  several  applications  [Bissantz,  2000], 
[Oda, 2006], [Wang, 2003],  consensus scoring has been implemented in the FlexX-docking 
suite.  A  subsequent  procedure,  introduced  by  Terp  [Terp,  2001],  is  to  correlate  several 
predicted  affinities  to  experimental  data  via  PLS  to  determine  the  best  scoring  function 
combination  [Jacobsson,  2003].  Alternatively  to  consensus  scoring,  less  relevant  docking 
poses can be filtered out to avoid artificial scores [Springer, 2005]. More sophisticated, but 
much more time consuming is the application of MM/PBSA to protein-ligand docking. First 
studies  [Kuhn,  2005],  [Michel,  2006]  have  been  reported  as  successful.  However,  an 
extensive  analysis  of  comparing  detailed  kinetic  data  retrieved  from  isothermal  titration 
calorimetry  to  MM/PBSA  energy  terms  revealed  certain  shortcomings  of  the  method 
[Zentgraf, 2006]. 
Many groups have addressed the task of comparing the performance of docking programs and 
scoring functions. Providing useful information there are certain caveats to consider [Cole, 
2005]. Test sets must be large and appropriate. Numerical quality measurements need careful 
statistical interpretation. For affinity prediction, compatibility of the experimental data must 
be given. Systematic studies comparing docking engines and scoring functions are given by 
Ferrara,  Perola,  Kellenberger,  Warren  and  others  [Cummings,  2005],  [Ferrara,  2004], 
[Kellenberger, 2004], [Perola, 2004], [Warren, 2006]. 
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OPTIMIZING BINDING AFFINITIES FOR 
BENZOPHENONE-BASED PROTEIN 
FARNESYLTRANSFERASE INHIBITORS 
Introduction 
During  lead  optimization,  properties  of  a  compound  such  as  potency,  selectivity, 
bioavailability, absorption and metabolism must be assessed and optimized. Although some 
strategies towards parallel optimization of these properties have been developed in the last ten 
years,  enhancement  of  the  potency (resp.  activity)  is  most  essential.  Given  a  data  set  of 
ligands  with  experimentally  determined  activities  computational  models  for  quantitative 
structure-activities  relationships  are  derived.  These  models  are  subsequently  applied  to 
prioritize compounds suggested for synthesis. Two key technologies aimed at achieving this 
goal are protein-based docking and ligand-based 3D QSAR. 
Target Protein
Over the last several years protein prenylation has been the subject of intense study and has 
been found to be critical  for  the function of  key proteins involved in signal  transduction 
[Marshall, 1993]. Prenylation is a form of lipid modification in which either a C15 farnesyl or 
C20 geranylgeranyl group is covalently attached via a thioether linkage to the cysteine residue 
of proteins near the carboxy terminus. Proteins in mammalian cells that are prenylated fall 
into  four  classes,  depending  on  their  size  [Reese,  1991].  The  best  characterized 
isoprenyltransferases  is  protein  farnesyltransferase  (ftase).  Ftase  transfers  a  C15 farnesyl 
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residue to a cysteine carbon atom, which is the fourth amino acid from the carboxy terminus 
of the CA1A2X tetrapeptide sequence. The residues A1 and A2 are generally aliphatic amino 
acids  and  X  may  be  methionine  or  serine.  In  similar  fashion  protein  geranylgeranyl 
transferase transfers C20 and the selectivity is given by the identity of the X amino acid. Ftase 
was  discovered  following  the  incorporation  of  mevalonic  acid  to  polypeptides.  It  is  a 
heterodimer  with  a  molecular  weight  of  48 kDa  (α-subunit)  and  46 kDa  (β-subunit) 
respectively [Reiss, 1990]. Ftase is a metalloenzyme requiring a single zinc ion for activity 
[Moomaw, 1992]. The zinc ion is located in the  β-subunit, near the subunit interface [Park, 
1997]  and is  coordinated  by residues  Asp297,  Cys299,  and His362.  The precise  reaction 
mechanism needs yet to be fully explored. 
Figure 4.1 Representation of protein ftase as observed in pdb ID: 1FT1. Left gives the overall 
structure,  showing  the  α-subunit  in  orange,  the  β-subunit  in  blue.  Right  gives  the  zinc 
coordination in the active site, showing Asp287, His362, and Cys299. 
Combining  biochemical  assays,  X-ray  crystallography  and  computational  approaches  the 
following  mechanisms  have  been  proposed  [Long,  2002]:  Comparable  to  common  zinc 
metalloproteinase,  a  water  molecule  is  bound  to  the  zinc  ion.  The  water  molecule  gets 
replaced  by  the  peptide  substrate  during  the  reaction.  In  due  course  of  the  chemical 
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transformation  this  water  molecule  returns  to  its  coordination  site  to  be  available  for  a 
proceeding reaction turnover. The other hypothesis suggests that residue Asp297 is in fact an 
almost symmetrical bidentate ligand. Upon peptide binding, one oxygen atom is displaced by 
the peptide cysteine thiol. These structural alteration could facilitate the nucleophilic addition 
during the prenylation reaction [Tobin, 2003]. 
Figure 4.2 Coordination of active site components of protein ftase as observed in pdb ID: 1QBQ. 
Left,  given a surface representation,  identifiying the active site  at  the interface of the  α-
subunit (orange) and β-subunit (blue). Right, a close-up of the binding site is shown. Shown 
with yellow carbon atoms is the farnesylpyrophosphote  and with green carbon atom, the 
tetrapeptide, Selenomethionine- Isoleucine-Valine-Cysteine. The zinc atom is represented by 
the pink sphere. 
Ftase was investigated as a potential target for oncology therapy. Special ftase activity was 
recognized in tumor cells and more than 70% of cancer cell lines have shown sensitivity to 
treatment  with  ftase  inhibitors  [Haluska,  2002].  Medicinal  chemistry  efforts  to  find  ftase 
inhibitors have already led to several potential anticancer agents currently in clinical trials 
[Dinsmore, 2003]. Recently it has been shown, that clinically relevant red blood cell (RBC) 
stages of Plasmodium falciparum contain high ftase activity [Ohkanda, 2001]. The application 
of  ftase  inhibitors  to  cells  infected  by  Plasmodium  falciparum result  in  a  decrease  of 
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farnesylated proteins and to associated lysis of the parasites. Additionally, the completion of 
the  Plasmodium  falciparum genome  (www.plasmodb.org 2003)  revealed  no  existence  of 
geranylgeranyltransferase-1.  One  might  speculate  that  possessing  no  alternative  enzyme 
makes  inhibiting  ftase  in  malaria  is  lethal  compared  to  mammals.  Ftases  have  now been 
identified in other pathogens like Trypanosoma, Leishmania and Toxoplasma [Esteva, 2005]. 
Therefore inhibition of ftase has also been suggested as a treatment of parasitic infections 
[Cherkasov, 2006]. 
Different classes of protein ftase inhibitors are known so far. Some having their origins from 
the oncology efforts. Reviews to the current statement of ftase inhibitors in cancer treatment 
are  given  by  Mesa,  Haluska,  and Swanson  [Haluska,  2002],  [Mesa,  2006],  [Park,  1997]. 
Compounds derived from other drug design programs comprise favorable or even already 
optimized drug-like features. However, they target the human protein and differences with 
respect  to  the parasite  target  structures  might  provide the opportunity to  develop specific 
inhibitors to the latter diseases. Ftase inhibitors with respect to antimalarial treatment have 
been primarily investigated by two research groups, the teams around A. Hamilton and M. 
Schlitzer [Bohm, 2001], [Esteva, 2005], [Kettler,  2005], [Kettler,  2006], [Schlitzer,  1999], 
[Schlitzer, 2000], [Wiesner, 2003b], [Adnane, 2000], [Clark, 1997], [Glenn, 2005], [Lerner, 
1995], [Qian, 1994], [Qian, 1996], [Sebti, 1998], [Vasudevan, 1999].
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Examples for ftase inhibitors: 
Figure 4.3 Examples of ftase inhibitors. Figure is taken from Glenn  et al, [Glenn, 2006].  IC50 
values  represent  the  doses  that  inhibit  50%  of  the  ftase  enzyme  activity.  ED50 values 
represent the doses that inhibit 50% of P. falciparum growth.
As shown in Figure 4.3, most ligand classes comprise functional groups, known to be able 
to bind to zinc ions, e.g. sulfonamides or thiols.  Current ftase inhibitors are lacking the free 
thiol  incorporated  into  the  early  inhibitors  because  of  adverse drug effects  (skin,  nausea) 
associated with free thiols. Most of these so-called non-thiol ftase inhibitors have nitrogen-
containing heterocycles. Here, the ring nitrogen coordinates the enzyme-bound zinc similarly 
to the cysteine thiol group [Hunt, 1996]. However, nitrogen heterocycles can be replaced by 
aryl residues lacking the ability to coordinate metal atoms, without loosing too much of their 
ftase inhibitory activity [O'Connor, 1999]. Inhibitor series with a benzophenone (Figures 4.3 
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and 4.6) scaffold show an interesting example of high affinity ligands without targeting the 
zinc ion directly. 
Previous  work  on  benzophenone-based  ftase  inhibitors  showed  the  possibility  to  apply 
structure-based drug design approaches. Using ligand-based 3D QSAR methods, a model to 
explain and predict protein-ligand binding affinities could be established [Sakowski, 2001]. 
Applying flexible docking and GRID binding site analyses two regions in the ftase binding 
site could be identified [Bohm, 2001]. This way, benzophenone-based ftase inhibitors were 
optimized from IC50 of 2.7 μM to 200 nM. The present work shows further optimization of 
this compound series, specifically focusing on the (1) far aryl binding site, (2) the specificity 
pocket  and  (3)  the  tetrapeptide  region  in  the  ftase  binding  site  (see  Figure  4.4).  Now, 
benzophenone-based ftase inhibitors with IC50 up to 4 nM are available. 
Other docking studies have been performed on ftase: Cui et al., Henriksen et al. and Pedretti 
et  al.  investigated  possible  ftase  natural  ligands  and  calculated  possible  ternary  complex 
structures [Cui, 2005], [Henriksen, 2005], [Pedretti, 2002]. Guida et all compared docking 
generated geometries to crystal complex structures for two ligands, showing little side chain 
movements in the protein [Guida, 2005]. 
Methods
All  molecular  modeling  and  comparative  molecular  field  analyses  were  performed  using 
SYBYL 6.9 and DrugScore 1.2. The protein crystal structure used for all investigations in the 
present thesis was determined for the rat enzyme. The  Plasmodium falciparum ftase differs 
significantly  in  size  of  both  the  α– (472  vs  379  residues)  and  β- subunit  (621  vs  437). 
However these differences address mainly insertions in the protein sequence. The active site 
residues show a high degree of similarity  allowing the rat  protein structure to  serve as a 
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template.  The  slight  differences  in  eight  amino  acids  might  be  targeted  for  specificity 
purposes (Figure 4.4). 
Docking
Compatible to previously performed docking analyses,  ligands were initially docked using 
FlexX. Based on the coordinates of the published crystal  structure [Strickland, 1998] of a 
ternary complex of rat ftase with a farnesylpyrophosphate analogue and with N-acetyl-Cys-
Val-Ile-selenoMetOH  (pdb ID: 1QBQ).  For  initial  evaluation,  the  position  of  the 
benzophenone peptidomimetic  substructure,  calculated in a  previous study,  was used as a 
starting  fragment  for  the  docking  of  this  inhibitors  via  the  MAPREF command. Default 
parameters were employed except  the MAX_ENERGY value, that was set to 10 kJ mol-1. 
Subsequently, the remaining fragments of the inhibitors were placed into the active site using 
the incremental construction algorithm of FlexX. The docking runs provided sets of solutions 
which were inspected according to their calculated energy score. The resulting geometries 
were evaluated using the knowledge-based scoring function DrugScore. 
Due to misplacements of the initial base fragments, ligand construction of large molecules 
in  the binding site  could not  be finalized using FlexX.  Therefore,  subsequent  docking of 
inhibitors was performed with AutoDock3.0. Again, the protein structure was taken from pdb 
ID: 1QBQ.  Ligands  and  solvent  molecules  were  removed,  but  the  zinc  ion  and 
farnesyldiphosphate were included as part of the protein. For the use within AutoDock3.0 
[Goodsell,  1996],  [Morris,  1996],  [Morris,  1998]  polar  hydrogens  were  added  with  the 
PROTONATE utility from AMBER. AMBER united atom force field charges were assigned 
[Weiner,  1984],  and  solvation  parameters  were  added  using  the  ADDSOL  utility  from 
AutoDock3.0. Ligand structures were built in mol2-format, Gasteiger partial atomic charges 
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were assigned [Gasteiger,  1980] and all  bonds except for amides were kept rotatable.  For 
some  ligands,  in  contrast  to  the  biological  testing,  only  one  enantiomer  instead  of  the 
racemates were considered for molecular docking.  Docking runs were performed with the 
Lamarckian genetic algorithm included in AutoDock3.0, performing 50 independent runs per 
ligand, using an initial population of 50 randomly placed individuals, a maximum number of 
1.5 x 106 energy evaluations, a mutation rate of 0.02, a crossover rate of 0.80 and an elitism 
value of 1. Resulting ligand conformations that differ by less than 1 Å rmsd from each other 
were clustered together and represented by the result with the best docking energy. The results 
of the highest ranked clusters were chosen to compare structure-activity relationships. The 
relative  binding  affinity  was  predicted,  using  the  knowledge-based  scoring  function 
DrugScore. 
Results and Discussion
Rat ftase can be used as a reasonable homology model for the development of antimalarial 
ftase inhibitors because differences in the structure compared to Plasmodium falciparum do 
not majorly address the binding site. Only a Tyr166Phe and His201Asn mutation affect the 
peptide  and  farnesylpyrophosphate  binding  [Schlitzer,  2005].  The  binding  site  can  be 
subdivided in six different regions, near and far aryl binding site, farnesylpyrophosphate (fpp) 
and tetrapeptide binding site, specificity pocket and exit groove. 
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Figure 4.4 Left: Homology model of P. falciparum ftase (turquoise carbon atoms) in comparison 
to  rat/human ftase  (green carbon atoms).  Differences  in amino acids  which might  affect 
binding of inhibitor 7t (yellow carbons) are shown in stick mode. Right: Orientation of the 
six different binding site regions. 
QSAR in the far aryl binding sites
Several arylfurylacryl-substituted benzophenones targeting the far aryl binding site have been 
designed. In the study [Mitsch, 2004] extensive variation of the terminal aryl residue of the 
arylfuryl moiety are performed. Using flexible docking, two possible binding modes could be 
determined which enabled to establish structure-activity relationships for the series.
Table 4.1 Ftase inhibitory activity of 5-arylfuryl derivatives 7a-af.
 
N
H
N
H
O
O
O
O Ar
7
Far aryl
Near aryl
fpp
specificity
Exit grooveTetrapeptide 
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Compound R IC50 (nM) Compound R IC50 (nM)
7a 100 ± 32 7p
F
30 ± 5
7b 165 ± 22 7q
Cl
150 ± 28
7c 190 ± 16 7r
Br
925 ± 45
7d
CH3 4 ± 1 7s C
N
105 ± 65
7e
CF3 4 ±2 7t
NO2 35 ± 5
7f
CF3
220 10± 7u
NO2
710 ± 40
7g 90 ± 27 7v
NO2
925 ± 60
7h 130 ± 34 7w
O
225 ± 65
7i 115 ±45 7x
O
O
95 ± 10
7j S 170 ±65 7y SO O 30 ± 18
7k
S
CF3 140 ±22 7z S
O O
125 ± 6
7l
S
180 ±34 7aa
NH2 30 ±8
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Compound R IC50 (nM) Compound R IC50 (nM)
7m
O
510 ±76 7ab
NH2
O
330 ±62 
7n
O
CF3 225 ±48 7ac N
H
H
O 285 ± 38
7o
O
840 ±16 7ad N
H
O 545 ±107
7ae S
NH2
O O
40 ± 7
Experimental data is given in [Mitsch, 2004]. 
While  some  substitutions  show  affinity  differences  that  are  beyond  what  can  be 
distinguished via docking (comparing halogen substitutions 7p, 7q, 7r) some of the structure-
activity relationships described above may be explained. Figure 4.5 shows a binding mode of 
the para methyl substituted inhibitor  7d obtained by flexible docking. The methyl group is 
deeply buried in a hydrophobic area in the far aryl binding site. Any substituent larger than 
methyl  or trifluoromethyl  would prevent this favourable binding mode explaining the low 
activity  of  any  extended  alkyl  (other  than  methyl  or  trifluoromethyl),  alkylsulfanyl  or 
alkyloxy substituted derivative. However, considerable activity has also been obtained with 
substituents  larger  than  methyl  as  for  instance  with  nitro  or  methylsulfonyl.  For  these 
inhibitors docking indicates a different binding mode with the para substituent not that deeply 
buried  in  the  aryl  binding  site  (what  is  prevented  by  its  size)  but  directed  to  a  more 
hydrophilic area closer to the rim of the aryl binding site as shown for the nitro derivative 7t 
in Figure 4.5. 
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Figure 4.5 Views of a part of ftase’s active site and the far aryl binding site from slightly different 
angles. Lipophilic (brown) and hydrophilic (green to blue) properties are displayed on the 
Connolly surface. The structural zinc is shown as magenta sphere. Left: Methyl-substituted 
inhibitor 7d deeply buries its methyl group into a lipophilic area in the far aryl binding site. 
Right: Nitro-substituted inhibitor  7t directs its nitro group to a more hydrophilic area more 
towards the rim of the far aryl binding site.
Common feature of the nitro or sulfonyl substituents is a hydrogen bond acceptor property. 
At the rim of the aryl binding site are two lysine side chains (Lys294β and Lys353β) which 
might act as appropriate hydrogen-bond donors.  Inhibitors having residues too large to fit 
deeply into the binding site but lacking hydrogen bonding properties get penalized in terms of 
affinity. The presence of two amino acid side chains acting as hydrogen bond donors might 
also explain the relatively low activity of inhibitors 7w and 7x, since in contrast to the nitro or 
sulfonamide moieties their substituents are capable of forming only one but not two hydrogen 
bonds. As demonstrated by the amino substituted derivative 7aa also a hydrogen bond donor 
property seems to be favorable. Possible bonding partners for this moiety are provided by the 
side chains of Glu47β and Asp233β. 
QSAR in the specificity pocket
Two compounds with very promising activity in vitro turned out to be inactive in the malaria 
model, quite likely due to limited solubility. Introducing a methyl piperazinyl residue into the 
Optimizing ftase inhibitors 83
α-position of the phenyl acetyl moiety of the 2-amino group of the benzophenone scaffold. 
This modification resulted in a significantly improved water solubility (Table 4.2). 
N
H
N
H
O
O
R2
R1
O
O NO2
N N
N N
            R1            R2
1          H              H
2          H
3          Cl             H
4          Cl
Figure 4.6 Substitution on benzophenone-based ftase inhibitors addressing the specificity pocket 
(R1 substitution) and to the tetrapeptide region (R2 substitution). 
Table 4.2 In vitro and in vivo activity and solubility of compounds 1-4.
Comp. IC50
(nM)
ED50
(mg/kgBW)
ED90
(mg/kgBW)
Solubility [b]
(mM)
Solubility [c]
(mM)
1 270 ± 30 -- -- < 0.04 < 0.06
2 270 ± 35 30 40 0.35 > 3.33
3 64 ± 11 -- -- < 0.04 < 0.06
4 210 ± 21 21 [a] 25 [a] 0.25 1.25
[a] The experiment was repeated under comparable conditions with compound 4 resulting in an ED50 
value of 22 mg/kgBW and ED90 value of 28 mg/kgBW; [b] in phosphate buffer pH 7.2; [c] in water. 
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The introduction of the methyl piperazinyl residue had no influence on the in vitro activity 
in  case  of  compound  2  with  unsubstituted  phenyl  ring.  In  the  series  of  α-unsubstituted 
compounds  significantly  increased  activity  was  achieved  with  a  p-chloro-substituent. 
Although less pronounced, this effect was also observed with the α-piperazinyl derivatives 
(comparing compound 3 and 4). The docking results clearly show that both inhibitors adopt a 
similar  binding mode (Figure 4.7).  Yet,  the chlorine-substituted inhibitor  4  leads to better 
interactions with the protein, in particular it forms a N-H···Cl interaction with His149. As an 
additional piperazinyl-moiety would stericly hinder this interaction, less increase in activity is 
observed for piperazinyl derivatives compared to the unsubstituted inhibitors. 
Figure 4.7 Superposition of selected docking results of the inhibitors 2 (turquoise) and 4 (orange) 
in the binding pocket of the farnesyltransferase. Only the amino acids forming the pocket 
responsible for the difference in affinity are shown. The zinc ion is indicated by the blue 
ball. Both inhibitors possess a comparable binding mode. The slightly increased activity of 
compound 4 can be explained by an additional N-H···Cl interaction with His149 (in part 
hidden by the surface). 
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To overcome this effect and to obtain more active inhibitors, two approaches were envisioned. 
First, a methylene group was inserted between the α-position and the phenyl residue thereby 
obtaining  α-piperazinyl-β-phenylpropionic  acid  derivative  5.  In  docking  studies,  this 
compound behaved as planned with its piperazinyl moiety found in the same region as for the 
lead  4 and directing the terminal phenyl residue towards His149β but reaching closer to its 
imidazole because of the additional methylene group (Figure 4.8). 
Figure 4.8 Docking of both enantiomers of inhibitor 5 (orange and blue) into ftase in comparison 
to inhibitor 4 (yellow). The docking yielded a binding mode for both enantiomers in which 
the additional methylene group facilitates a better chlorine His149 interaction compared to 4.
However, in vitro activity of inhibitor 5 did not improve since it was virtually equipotent to 
inhibitor  4 against  blood  stages  of  P.  falciparum (Table 4.3).  Furthermore,  inhibitor  5 
displayed higher cytotoxicity than 4. Therefore, this approach was discontinued. 
86 Optimizing ftase inhibitors
Table 4.3 Activity of N-methylpiperacinyl-substituted compounds 2, 4 and 5. 
N
H
N
H
O
O
R
O
O
NO2
N
N
R IC50 (nM) 
FTase
IC50 (nM) 
P. falcip
ED50 
(mg/kg)
ED90 
(mg/kg)
CC50 (µM) 
HeLa cells
CC50 
/IC50
2 10 ± 3 270 30 40 37.0 137
4
Cl
4 ± 2 210 21 25 38.6 184
5
Cl
124 ± 15 210 nd nd 18.0 86
A second strategy envisioned to overcome the steric hinderance by the piperazinyl moiety 
was the replacement of the piperazinyl moiety by an open chain ethylene diamine hoping that 
the enhanced flexibility to this residue would allow for both, an optimal chlorine imidazol 
interaction as well as for an interaction of the terminal amine with the amino acids in the 
upper part  of the binding site.  Indeed, when assayed  in vitro against  P. falciparum  blood 
cultures the ethylene diamine derivatives 20 and 22 displayed considerably improved in vitro 
activity with IC50-values of 40 and 50 nM (Table 4.4). 
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Table 4.4 Activity of N,N’-trimethylethylenediamine-substituted compounds 20 and 22. 
N
H
N
H
O
O
O
O
NO2
N
N
R
R IC50 (nM) 
FTase
ED50 
(mg/kg)
ED90 
(mg/kg)
CC50 (µM) 
HeLa cells
20 H- 21 ± 3 16 20 14.4
22 Cl- 28 ± 3 26 30 6.6
An important feature can be delineated from these in vitro results. The cytotoxicity of the para 
chloro-substituted derivatives 22 is significantly higher than that of the phenyl-unsubstituted 
derivative 20, while anti-plasmodial activity of the phenyl-unsubstituted derivatives is higher. 
Although the absolute cytotoxicity of inhibitor  20 is higher than that of the lead  13 (CC50-
values 14.4 and 38.6 µM, respectively),  the toxicity/activity is  still  considerably improved 
because of the significantly improved antiplasmodial activity of inhibitor 20. More striking is 
the difference in the in vivo activity between these two compounds. The phenyl unsubstituted 
inhibitor  20 displays a significantly higher activity in the mouse model (ED50 = 16 mg/kg 
b.w.)  than the  para  chloro  substituted  derivative  22  (ED50 = 26 mg/kg b.w.).  Furthermore, 
inhibitor 20 is also more active than the piperazinyl derivatives 2 and 5. The binding modes 
suggested by AutoDock3.0 vary considerably from the originally planned mode (Figure 4.9). 
AutoDock3.0 proposes several solutions. In one mode the flexible ethylene diamine moiety is 
directed into the same region as the piperazinyl residue in 5 but the chlorophenyl residue is 
not  directed  towards  His149β.  Instead  it  is  oriented  more  steeply  downwards  towards 
Trp102β  resembling  a  binding  mode  which  we  obtained  earlier  for  simple  α-amino  acid 
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derivatives [Kettler,  2005]. For the corresponding epimer, the aryl  residue is now directed 
upwards  into  the  region  formerly  occupied  by  the  piperazinyl  moiety  and  the  ethylene 
diamine pointing towards His149β. 
Figure 4.9 Superimposition of docking results  of  the methylpiperazinyl-substituted inhibitor  5 
(yellow)  and  two  different  docking  solutions  of  inhibitor  20.  In  one  docking  solution 
(orange)  ethylene  diamine  residue  points  roughly  into  the  same  direction  as  the 
methylpiperazinyl  moiety  of  inhibitor  5,  while  the  phenyl  residue  is  markedly  shifted 
downwards forming a edge to face interaction with Trp102. In the second docking solution 
(blue) the phenyl and ethylene diamine moieties exchanged their positions.
Because energy values obtained for both solutions are virtually identical, no orientation can 
be  favored  at  this  time.  Regardless  which  binding  mode  is  realized  in  the  enzyme,  both 
binding modes  are considerably different  from the mode obtained for  inhibitors  2 and  5, 
explaining the different response as a result of the introduction of a para-chlorine atom at the 
terminal phenyl residue.
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Conclusions
At first, benzophenone-based ftase inhibitors with high in vitro antiplasmodial activity but no 
in vivo activity were discovered. Via the introduction of a methylpiperazinyl moiety into the 
α-position of the phenylacetic acid substructure, the first ftase inhibitors with  in vivo anti-
malarial activity have been obtained. Molecular docking studies supported some presumption 
about possible  binding modes but the results  also illustrate  the need for further structural 
analyses. Based on the docking results, in a second design cycle the piperazinyl moiety has 
been replaced by a N,N’-trimethylethylene diamine moiety. This resulted in an inhibitor with 
significantly improved  in vitro and  in vivo anti-malarial activity. Furthermore, this inhibitor 
displays notable selectivity towards malaria parasites in comparison to human cells. This is a 
particular  important  result  for  the  development  of  specific  anti-malarial  ftase  inhibitors. 
Whether  this  difference  is  due  to  binding  site  composition  is  not  yet  clear.  Homology 
modelling revealed slight differences between the active sites of rat/human and plasmodial 
ftases but without further experimental structural data an analysis of deviating binding modes 
would be too speculative. Still, the support via docking provided helpful guidance for further 
inhibitor design. In this example the lowest energy structure determined by DrugScore was 
chosen to select an appropriate binding mode for each ligand. The predicted binding mode 
was given attention while predicted affinities played only a minor role. In most cases, ranking 
inhibitors with respect to their protein-ligand affinity did not match the experimental data. 
However,  compared to their  overall  large  size the  compound's  structural  substitutions  are 
humble. Therefore trying to estimate affinity differences is beyond the level of accuracy. And 
the main objective of a knowledge-based scoring function is recognizing a possible binding 
mode from a set of multiple solutions for one ligand. In that case, DrugScore outperformed 
other applied scoring functions and showed to be a supportive tool for ligand optimization. 
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SUCCESSFUL LEAD IDENTIFICATION FOR 
METALLOPROTEINASES: A FRAGMENT-BASED 
APPROACH USING VIRTUAL SCREENING 
Introduction
Over the past decade, an enormous effort has been spent to enhance the success rate of the 
drug discovery process. One aspect has been the use of high-throughput technologies, applied 
to synthesis and screening. The conventional approach involves screening with respect to a 
disease, where a particular target protein is tested for inhibition against a large collection of 
drug-sized compounds. The collection typically consists of 200,000-2 millions compounds. 
The readout is typically a biochemical assay and compounds inhibiting the target with IC50s at 
or below 20  μM are usually regarded as  hits which get  developed into  leads and further 
optimized for potency and other drug-like properties. However, the success rate has not been 
as high as expected and one important aspect are inappropriate lead structures [Lahana, 1999], 
[Oprea, 2002]. Due to the diversity and huge size of chemical space one cannot expect to 
immediately detect a drug candidate in the primary screen. Therefore, a process of evolution 
by selection is inevitable, starting with a compound eligible for multiple substitutions [Leach, 
2006b]. Recently, several new technologies have emerged which screen small drug fragments 
(also  referred  to  as  needles,  shapes,  binding  elements  or  seeds)  and  thereby  open  the 
perspective towards a combinatorial approach to lead discovery.  The goal is to build drug 
leads  from  pieces,  by  identifying  small  molecular  fragments  and  then  either  linking  or 
expanding  them.  The  definition  of  a  'fragment'  varies,  but  usually  refers  to  molecules 
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weighing  less  than  200-300 Da,  with  fewer  than  15-20  heavy  atoms  [Erlanson,  2004a], 
[Erlanson, 2004b], [Rees, 2004], [Zartler, 2005]. 
Drug-like versus Lead-like
The definition of drug-likeness and lead-likeness serve their own ends: Drug-like molecules 
are suitable for drug development and clinical candidacy. Lead-like molecules instead bind in 
a non-covalent, reversible manner to their targets in a biochemically assay and show chemical 
stability  towards  proteins.  However,  they  should  not  be  a  “promiscuous  inhibitor” 
[McGovern,  2002], a “frequent hitter” [Roche, 2002] or a “warhead compound” [Rishton, 
2003].  The  latter  is  extremely  challenging  for  the  herein  applied  target  class  of 
metalloproteinases. 
Not  every  marketed  drug  is  derived  from  a  lead  structure.  Alternative  sources  for 
development are already existing drugs or more important, natural products (neuropeptide Y, 
taxol).  Contrarily,  there  are  also  lead-like  drugs  on  the  market,  e.g.  propranolol  or 
paracetamol. The key contribution to what defines a drug was an examination of clinically 
tested drug molecules in order to determine their shared properties [Lipinski, 1997], [Lipinski, 
2001]. The resulting “rule of five” tries to predict absorption problems due to poor solubility 
and/or poor permeability. Compounds that do NOT obey two of the four following parameters 
are likely to have poor absorption and/or distribution. 
1. Molecular weight ≥ 500 Da
2. log P > 5
3. More than five hydrogen bond donors (defined as the sum of OH and NH groups)
4. More than ten hydrogen bond acceptors (defined as the number of N and O atoms)
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Several other groups reported analyses of collections of drugs. The number of rotatable 
bonds [Veber, 2002] and polar surface area [Clark, 2000] have also contributed to predict 
drug-likeness of a molecule. Analyzing sets of corresponding lead and drug molecules Oprea 
et  al. and  Hann  et  al.  reported  statistics  over  the  increase  of  several  physicochemical 
properties in the lead optimization step [Hann, 2001], [Oprea, 2001], [Oprea, 2002]. 
Table 5.1 Changes in molecular properties from leads to drugs 
Property Average values 
for leads
Average values 
for drugs
Increment
Molecular weight (Da) 272.0 314.0 42
Hydrogen bond acceptors 2.2 2.5 0.3
Hydrogen bond donors 0.8 0.8 0
Number of heavy atoms 19.0 22.0 3.0
Clog P 1.9 2.4 0.5
Table is derived from [Hann, 2001]
This shows that physicochemical properties required for drug-like compounds are different 
from those required for lead-like compounds which are followed-up in early stages of drug 
discovery [Rishton, 2003]. Unlike the drug-like scores, the lead-like concept [Teague, 1999] 
is based on smaller data sets [Oprea, 2001], [Proudfoot, 2002]. Emerging from studying leads, 
the “rule of three” has been established [Congreve, 2003a]. Fragments that were positively 
tested against several target proteins seem to obey:
1. Molecular weight ≤ 300 Da
2. Number of hydrogen bond donors ≤ 3 
3. Number of hydrogen acceptors ≤ 3
4. ClogP is ≤ 3
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5. Number of rotatable bonds ≤ 3
6. Polar surface area ≤ 60 Å2 
These rules could be useful when constructing a fragment library. Another parameter often 
applied with respect to lead discovery is “ligand efficiency” [Hopkins, 2004]. Andrews et al. 
first introduced the concept of estimating potential activities as function of the presence of 
certain protein-ligand interacting groups [Andrews, 1984]. Considering the maximal affinity 
for  ligands  and  calculating  the  binding  affinity  per  atom  [Kuntz,  1999]  has  led  to  the 
following definition  for  ligand efficiency:  Converting Kd into free  energy of  binding and 
dividing by the number of heavy atoms. 
Free energy of binding: ΔG = -RT•lnKd 
ligand efficiency: Δg = ΔG/Nnon-hydrogen atoms
Considering an average mass of 13.29 Da for a non-hydrogen atom, a 500 Da compound with 
10 nM binding affinity possesses a ligand efficiency of 1.21 kJ/mol. Considering these figures 
it  should be mentioned that  fosmidomycin  from the previous AFMoC study has a ligand 
efficiency  of  3.68 J/mol  per  non-hydrogen  atom.  This  might  explain  the  difficulties  in 
optimizing  its  structure.  Taking  ligand  efficiency  one  step  further  is  reported  by  Abad-
Zapatero and Metz. They describe affinities as 'percentage of inhibition' measured in primary 
HTS and Ki, Kd or IC50 measured in secondary assays. Crucial physicochemical properties in 
the lead selection process are molecular weight and PSA. To provide a mathematical link they 
introduce a percentage efficiency index (%percent inhibition at a given [compound]/MW), a 
binding efficiency index (pKi, pKd or pIC50/MW) and a third surface-binding efficiency index 
(pKi, pKd or pIC50/PSA). Comparing these indexes to marketed drugs and molecules along the 
project  pipeline  shows how numerical  rules  can  work  as  guidance  in  the  drug  candidate 
decision process [Abad-Zapatero, 2005]. 
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Small is beautiful – the concept of Fragment-based ligand design
The concept that underlies the chemical fragments approach was first proposed by Jencks in 
1981 [Jencks, 1981]. Difficulties in identifying and linking fragments delayed its success but 
further  development  in  screening  for  low  affinity  compounds  led  to  the  first  practical 
demonstration in 1996 [Shuker, 1996]. Since then, the technology has become very popular 
and  numerous  fragment  discovery,  growing  and  linkage  strategies  have  been  published 
[Erlanson, 2006]. 
The basic approach of fragment-based ligand design is identifying small compounds that 
bind to a  target  protein  with low affinity.  They are subsequently  'grown'  or  decorated to 
generate  larger,  high-affinity  leads,  often  using  structure-guided  medicinal  chemistry. 
Fragment-based strategies  aim to  achieve  three  goals.  (1)  Reducing the  size  of  screening 
libraries, (2) chemical optimization can exploit the structural understanding of the protein-
ligand binding interactions and (3) starting with small fragments allows to further increase 
molecular weight during optimization without exceeding the desired limit for drug-likeness. A 
simple model  presented by Hann  et al. shows the relationship between the probability of 
finding a hit and the complexity of the molecule [Hann, 2001]. 
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Figure 5.1 Multiplying the probability of  a single  match with the probability of  detecting the 
binding event. The result is the “useful event” which passes through a maximum at rather 
low complexity. (data from [Hann, 2001])
The useful event is defined as determining unique molecular recognition in a biochemical 
assay.  This  depends  not  only  on  the  chance  of  measuring  binding  but  also  on  how  the 
complexity of the molecule effects its binding mode. The chance of determining the binding 
event increases with the complexity of the molecule. Contrary, the chance of finding a match 
between ligand and binding site properties is much higher for simpler molecules. Finding the 
useful event in HTS with a randomly assembled library of molecules with greater complexity 
is quite unlikely. For less complex molecules, multiple binding modes will dominate and thus 
confound  the  affinity  measurement.  The  aim  of  this  study  is  not  to  predict  the  optimal 
complexity for a library but to show that starting simple has still a reasonable chance for 
detection while offering chemical space for optimization. 
Applying  biophysical  methods  to  fragments  enables  better  correlation  of  structure  with 
affinity and establishes details about the interactions. To actually exhibit measurable activity a 
fragment has less possibilities to compensate entropy compared to a larger molecule. Binding 
to the protein requires a penalty in rigid-body translational and rotational entropy. This must 
be compensated by protein-ligand interaction energy. The entropic penalty is independent of 
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molecular weight [Finkelstein, 1989] and is estimated to be 15 to 20 kJ/mol [Murray, 2002]. 
The  fragment  requires  more  binding  energy  per  atom  to  display  comparable  affinity. 
Considering the affinity of the final drug-like molecule,  less additional interaction will  be 
required for growing from a small fragment  instead of substituting a drug-sized molecule 
[Verdonk, 2004]. 
The process of a fragment-based drug discovery project consists of three stages:
Figure  5.2 The  fragment-based  drug  discovery  process  involves  integration  and  parallel 
application of multiple technologies. 
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Library design
The low affinity of the fragment screening hit makes an optimization necessary. Independent 
of which optimization strategy is applied, it is difficult to modify molecules lacking suitable 
linker groups [Jacoby, 2003]. Avoiding functional groups which might react covalently with 
surface-exposed amino acids of the protein, fragments should be decorated with the groups 
that allow for subsequent chemical reaction. Typically these are carboxylic acids, amines and 
alcohols.  However,  in  some cases,  the  potential  linker  group participates  in  non-covalent 
protein  binding.  Selecting  fragments  for  specific  linker  reactions  (e.g.  self-assembly)  or 
having  multiple  possible  linker  groups  might  avoid  these  linkage  complication 
[Schuffenhauer, 2005]. Targeting a library with respect to a specific set of chemical reactions 
is  frequently  applied.  RECAP  (Retrosynthetic  Combinatorial  Analysis  Procedure)  is  an 
algorithm  which  enables  partitioning  of  molecules  in  fragments  corresponding  to  the 
following eleven chemical reactions. 
Figure 5.3 Eleven default bond cleavage types used in the RECAP algorithm [Lewell, 1998]. 
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While breaking the bonds, the size of the remaining fragments is assessed to create suitable 
starting materials [Lewell, 1998]. The retrosynthetic analyses of given data sets do not only 
enable library design for combinatorial synthesis. They also allow statistics about common 
functionalities especially when applied to a data set of drug molecules. One might speculate 
that fragments derived from approved drugs show desirable properties with respect to toxicity, 
common decoration groups to improve ADME properties and synthetic feasibility. Multiple 
studies about properties of known drugs have been reported. The work of Bemis and Murcko 
focuses  on  organizing  substructures  of  drug  molecules  into  the  categories  ring,  linker, 
framework and side chains and assigning shape descriptors. Subsequent cluster analyses show 
low  diversity  in  frameworks  based  on  two-dimensional  molecular  structure.  Contrarily, 
clustering based on atom types, bond types and hybridization reveals a large diversity [Bemis, 
1996]. In a sequel, a detailed study on the features and attributes of side chains to the drug 
molecule revealed an average number of four side chains per core and common classes of side 
chains  [Bemis,  1999].  Considering  molecular  structure  but  also  administration  and 
physicochemical  properties,  Vieth  et  al. describe  common  scaffolds  and  features  which 
distinguish orally administered drug form others routes [Vieth, 2004]. Studying properties of 
drugs provides guidance for future library design projects. Baurin et al. used a reference drug 
molecule  dataset,  crystallized  drug-sized molecules,  water  solubility  and several  synthesis 
guidelines to develop a fragment library for primary NMR screening [Baurin, 2004]. Kolb et  
al. used the decomposition program DAIM (Decomposition and Identification of Molecules) 
to compare commercially available fragments to fragments derived from drug molecules and 
thus, generated a screening library and successfully applied it to β-secretase [Kolb, 2006]. In 
another study, drug molecules of the National Cancer Institute dataset were analyzed for co-
occurence of fragments [Lameijer, 2006]. 
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Screening
There are various methods that can be used to detect the binding of a compound to a protein. 
However,  one  drawback  of  fragments  is  their  low expected  target  affinity,  making  their 
binding  not  always  compatible  with  classical  screening  strategies.  Higher  compound 
concentrations are required to detect low affinity binding than the usually applied micromolar 
cut-off. This can cause problems due to the incompatibility of most proteins to DMSO which 
is generally applied to dissolve the screening fragments [McGovern, 2003b]. 
X-ray  crystallography: Knowledge  of  the  binding  modes  assists  the  selection  which 
fragments  to  follow  up  (e.g.  whether  the  potential  linker  is  involved  in  interactions). 
Advances  in  parallel  cloning,  optimizing  expression,  nanolitre  crystallization,  automated 
phasing and model building and the increasing number of available protein structures opens 
the  perspective  to  use  protein  crystallography  as  screening  technology  [Blundell,  1996], 
[Jhoti,  2001].  Determining  the  structure  of  a  fragment-protein  complex  is  either  done  by 
soaking or by co-crystallization. Interpreting the difference electron density usually requires 
manual manipulation which can make this step time-consuming and is one bottleneck of using 
X-ray crystallography as a first screening approach. Recently, the algorithm AutoSolve has 
been shown to automatically refine a protein-ligand complex structure if the protein can be 
represented by molecular replacement [Mooij, 2006]. A disadvantage of the method is that it 
can only prove but never disprove binding, since unsuccessful soaking or co-crystallization 
with a  ligand can have various  reasons  apart  from lacking binding affinity.  Additionally, 
crystallization conditions and crystal packing can influence the complex structure. 
NMR: In  target-based  NMR  screening,  chemical  shift  changes  in  the  protein  spectrum, 
caused by the binding of a ligand, are measured. This allows not only to detect binding but 
given appropriate  isotope labeling and full  assignment of the spectra  the detection of  the 
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protein atoms involved in the interactions is possible. The pioneering approach using target-
based NMR is SAR by NMR [Shuker, 1996]. A disadvantage of this technique is the need of 
large amounts of labeled protein as well as time-consuming resonance assignments. Ligand-
based NMR screening detects changes in the ligand spectrum upon binding. It is independent 
of  any labeling  and is  particularly  suitable  for  detecting  weak binding.  Examples  are the 
SHAPES strategy and STD method [Fejzo,  1999],  [Meyer,  2003],  successfully applied to 
fragment-based screening approaches. 
Mass spectroscopy: Employing suitable ionization methods such as electrospray ionization, 
weakly binding of ligands can be detected by mass spectroscopy. Complexes will stay intact 
thus the observed mass indicates ligand binding and conclusions about stoichiometry can be 
drawn [Breuker,  2004],  [Moy,  2001].  The big advantage is  the low protein concentration 
needed and a well developed automation. However, compared to NMR or crystallography, no 
structural information is available and it is in question whether interactions detected in the gas 
phase are relevant for interactions in solution. 
Tethering: A special fragment screening approach developed by Sunesis Pharmaceuticals Inc 
combines  protein  engineering,  mass  spectroscopy  and  protein  crystallography  [Erlanson, 
2000],  [Erlanson,  2004c].  A  residue  close  to  the  active  site  is  mutated  to  cysteine  and 
fragments are covalently bound via disulfide bonds under reducing conditions. Facilitating 
subsequent mass spectroscopy or crystallography, the bound ligand can also be used to further 
explore the binding site. The approach has almost no false positives but it misses possible 
ligands due to steric coordination of the linker to the active site. 
SPR: Another label free binding assay is surface plasmon resonance. Immobilizing the target 
on an optical sensor surface, compound binding can be detected by measuring the change in 
mass concentration. Incoming light is partly reflected and partly refracted. Changes in mass, 
for example caused by ligand binding, cause a change in the refractive index and are thus 
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detected. The advantage is the low protein consumption and access to kinetic data such as 
association and dissociation rates [Neumann, 2005]. 
Linkage and growth
The strategies to transform a fragment to a lead range considerably, from small change to the 
fragment  itself  to  dramatic  substitutions  and  linkage  with  other  fragments.  Most  reports 
classify fragment progression in four classes (Figure 5.4), (I) fragment evolution (II) fragment 
linking (III) fragment self-assembly and (IV) fragment optimization [Rees, 2004]. However, 
these  distinctions  are  more  semantic  than determined  by rational  criteria.  The same final 
molecule  could  be  created  by linkage of  two fragments,  optimizing  a  single  fragment  or 
through some combination [Erlanson, 2004a]. 
(I) Fragment evolution: An initial fragment is optimized by adding functionality to bind 
to adjacent  region of  the binding site.  In  principle,  this  approach is  similar  to  the 
“common” drug discovery approach but starting with a smaller fragment. It is useful 
to get as much information as possible about the first fragment, thus direct binding 
techniques  are favorable.  The “needle  screen”  example  for  DNA gyrase  inhibitors 
followed  this  approach  [Boehm,  2000].  Assaying  the  ATP  binding  site,  a  first 
fragment  was  identified,  characterized  with  NMR  and  X-ray  crystallography  and 
further fragments were attached to get a > 10,000 fold more active inhibitor. More 
examples for fragment evolution are given below. 
(II) Fragment linking: Two fragments, binding to proximal parts of the binding site, are 
linked together. This is the classical approach to fragment-based strategies. The key 
issue for this approach is to find the appropriate linker. The availability of structural 
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information  is  almost  a  prerequisite,  otherwise  an  exhaustive  combinatorial  search 
following random conditions to find an effective linking scheme is required. The mass 
independent  loss  of  rigid-body  entropy  suggests  a  favorable  additivity  effect  for 
increasing affinity if a optimal linker is applied. An impressive example is the linkage 
of  two stromelysin  binding  fragments  via  NMR exploiting  structure-based  design. 
Starting with single affinities of 17 mM and 280 μM respectively for the fragments, 
the finally linked inhibitor showed 15 nM. Further examples are given in Table 5.2. 
(III) Fragment self- assembly: Fragments with matching functional groups are forced to 
react  with  each  other  in  the  presence  of  the  protein  target.  The  two  most  potent 
fragments are most likely to react enabling a selection of potent fragments out of a 
mixture. This approach can be seen as a specially designed way to form a fragment 
linking. The linkage reaction is predefined which determines the type of fragments 
suitable for this approach. Also referred to as dynamic combinatorial chemistry it has 
been successfully applied to proteins, exhibiting deep buried binding sites. Applying 
“click  chemistry”  fragment  self-assembly  led  to  tight  binding  inhibitors  of 
acetylcholine esterase and others (Table 5.2).
(IV) Fragment optimization: Fragment approaches are used to optimize or modify only 
parts  of  the  molecule,  enhancing  features  others  than  just  binding  affinity.  Again 
strategies  are  followed  that  do  not  differ  significantly  from  those  in  a  classical 
structure-based optimization process. An example is the development of an urokinase 
inhibitor with 100 fold improved affinity and additionally achieved oral bioavailablity 
of 38%. 
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Figure 5.4 Summary of fragment-based approaches. I Fragment evolution, II Fragment linking, III 
Fragment self-assembly and IV Fragment optimization
Computational support in fragment-based drug discovery
Computational  tools  have  been  developed  to  support  both,  fragment  identification  and 
fragment optimization.  Calculating probability  maps for the putative binding of particular 
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ligand  atoms  next  or  in  the  active  site  are  usually  summarized  as  so-called  'hot  spots'. 
Programs  to  perform  such  analyses  are  GRID  (energy  map  derived  from  force  field) 
[Goodford,  1985],  DrugScore  (mapping knowledge-based potentials)  [Gohlke,  2000b]  and 
SuperStar  (mapping  interaction  groups  based  on  crystallographic  data)  [Verdonk,  1999]. 
Their application helps building a targeted library and guiding the starting placement for the 
first  fragment.  Docking  in  fragment-based  drug  design  is  rarely  applied  for  the  initial 
fragment  screening.  The  available  scoring  functions  are  calibrated  towards  drug-sized 
molecules  and  perform  considerably  worse  on  small  compounds  [Mooij,  2005].  Mostly, 
virtual fragment libraries are docked to search for attachments to an previously determined 
ligand, either considering the fragment-grown ligand as a new completely flexible molecule 
or keeping the known binding part  as a rigid constraint.  In the case of a missing protein 
crystal structure, computational strategies for fragment-based approaches are ligand similarity 
searches and classification tools. They are reviewed by Oprea [Oprea, 2006]. Recently, the 
computational  strategy  BREED for  fragment  linking  was  reported.  So-called  “hybrid” 
compounds are generated by virtually combining previously known inhibitors [Pierce, 2004]. 
Well suited for later stage optimization, it is not faced with the problem of finding the correct 
linker fragment. Another attempt to address de novo design computationally via fragments is 
the program FlexNovo [Degen, 2006], a advancement to FlexX. Compared to the original 
program it consists of fragments derived from the World Drug Index and allows to define 
filters for property, pose geometry and diversity upon docking. 
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Table 5.2 Examples of applications of fragment-based drug design
Target Strategy Screening 
technique
Achievements Reference
DNA gyrase I VS, SBD Maximal non-effective con-
centration optimized to 30 ng/ml. 
[Böhm, 2000]
thymidylate 
synthase
I Tethering, 
SBD
Affinity to IC50 = 330 nM [Erlanson, 2000]
P38 kinase I NMR Affinity to Ki= 200 nM [Fejzo, 1999]
Anthrax 
lethal factor 
protease
I NMR Affinity to Ki = 320 nM [Forino, 2005]
Urokinase I, IV X-ray, 
bioassay, 
NMR
Affinity to Ki = 6.3 nM; affinity 
to Ki 370 nM, bioavailability
[Wendt, 2004]
Erm methyl 
transferase
I NMR Affinity to 7.5 μM [Hajduk, 1999]
Interleukin 2 II SPR, x-ray Affinity [Hyde, 2003]
FK506- 
binding 
protein 
II NMR Affinity to Kd = 49 nM [Shuker, 1996]
Avidin II Bioassay Affinity to Ki = 4 pM [Green, 1975]
Hepatitis C 
protease
II Bioassay, 
NMR
Affinity to Ki = 800 nM [Wyss, 2004]
Vancomycin II Bioassay Affinity to Ki = 1.1 nM [Rao, 1997], [Rao, 
2000]
Acetylcholin
e esterase
II Bioassay, 
SBD
Affinity to Ki = 0.4 nM [Pang, 1996]
C-SRC 
kinase
II Bioassay Affinity to IC50 = 64 nM [Maly, 2000]
Stromelysin II NMR, 
SBD
Affinity to Kd = 15 nM [Hajduk, 1997]
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Target Strategy Screening 
technique
Achievements Reference
Collagenase II HTS, NMR Selectivity towards MMP-1, 
MMP-9, TACE
[Chen, 2000]
Caspase II Tethering Affinity to Ki = 200 nM [Erlanson, 2003]
Protein 
tyrosine 
phosphatase
II NMR, 
SBD
Affinity to Kd = 22 nM, Kd = 
7 μM
[Liu, 2003], 
[Szczepankiewicz, 
2003]
Bacterial 23S 
rRNA
II MS, SAR 
by MS
Affinity to Kd = 6.5 μM [Swayze, 2002]
Carbonic 
anhydrase
III Virtual 
combinator
ial 
chemistry
Affinity [Huc, 1997]
Neuraminida
se
III Dynamic 
combinator
ial libraries
Affinity to Ki = 85 nM [Hochgurtel, 
2003]
CDK2 III X-ray Affinity to IC50 = 30 nM [Congreve, 2003b]
Acetylcholin
e esterase
III Click 
chemistry
Affinity to Kd = 77 fM [Lewis, 2002]
Factor Xa IV Bioassay, 
SBD
Bioavailability [Liebeschuetz, 
2002]
SH2 domain 
of pp60Src
IV X-ray, 
SPR, SBD
Affinity to IC50 = 3 nM, Plasma 
stability
[Lange, 2003], 
[Lesuisse, 2002]
Adenosine 
kinase
IV NMR Affinity to IC50 = 10 nM, 
enhanced in vivo data
[Hajduk, 2000]
Leukocyte 
Function 
-Associated 
Antigen 1
IV NMR, 
Bioassay
Affinity, Solubility, Oral 
Bioavailability
[Liu, 2001]
The  numbers  I,  II,  III,  IV represent  one  of  the  four  routes  to  fragment-based  lead 
discovery. X-ray stands for the detection of the initial fragment by protein-ligand complex 
crystal structure, MS for mass spectroscopy, VS for virtual screening, SBD for structure-
based design. 
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More  detailed  reviews  are  given  by  Rees,  Carr  and  Erlanson  [Carr,  2002],  [Erlanson, 
2004a],  [Erlanson,  2006],  [Rees,  2004].  Recently,  an  example  showing the  limitations  of 
fragment-based  drug  design  has  been  reported.  Deconstructing  an  AmpC  β-lactamase 
inhibitor revealed three possible fragments. The full ligand as well as the three fragments bind 
to the protein and all four corresponding protein-ligand complex structures were determined. 
They showed that fragments of a larger molecule did not recapitulate its binding [Babaoglu, 
2006]. Obviously, the recognition and binding properties of the fragments are strongly apart 
from  those  of  the  finally  composed  ligand.  This  example  points  to  some  deficiencies 
following a strategy starting with a set of individual fragments that are subsequently linked to 
a larger molecule. 
Target protein
Zn2+-containing  metalloproteinases  constitute  a  long  list  of  structurally  related  proteases 
which  are  widely  distributed in  nature.  They are  involved in  biochemical  events  of  high 
importance  such  as  digestion  (carboxypeptidase  A,  astacin),  tissue  remodeling  and 
extracellular  matrix  degradation  (matrix  metalloproteinases),  blood-pressure  regulation 
(neprilysin,  angiotensin  converting  enzyme),  formylation  and  deformylation  in  bacterial 
protein synthesis (peptide deformylase), etc. Thermolysin (TLN) is a heat-stable proteolytic 
enzyme isolated from Bacillus thermoproteolyticus and carries a catalytically essential zinc 
ion at the active site [Matthews, 1988]. Four additional calcium ions are required for stability. 
The enzyme is an extracellular endoproteinase, hydrolyzing the peptide bond on the imino 
side of the amino acid residue having a large hydrophobic side chain, such as Leu, Ile, and 
Phe. Thermolysin is bilobal and the active site is situated in a cleft between the two lobes. The 
zinc ion is tetrahedrally ligated in the apo structure, binding His142, His146, Glu166 and one 
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water  molecule.  Additionally,  there  is  a  Val-Lys  dipeptide  bound  to  the  active  site, 
presumably a product of self -proteolysis. It occupies the hydrophobic specificity pocket. 
Figure 5.5 Structure of thermolysin. Left: Overall structure, showing two domains (blue and as 
cartoon representation) and the binding cleft in the center. The zinc ion is shown as pink sphere 
and residues forming the binding site are shown in purple. Right: Binding site geometry of the 
catalytic zinc ion and observed in pdb ID: 2TLX. 
The enzyme has been extensively studied as a prototypical zinc enzyme and used as model 
target system for developing design strategies of enzyme inhibitors that can be transferred to 
other zinc proteinases of medicinal  interest such as the angiotensin converting enzyme or 
matrix  metalloproteinases.  Most  small  molecule  inhibitors  for  zinc  proteases  carry  a 
functional  group  that  coordinates  the  active  site  zinc  ion,  such  as  carboxylate,  thiol  or 
hydroxamate.  Of  these  zinc  ligating  groups,  hydroxamates  are  frequently  applied as  they 
show strong chelating properties towards zinc. The thermolysin and zinc metalloproteinase 
reaction mechanism is well studied [Bertini, 2006] and reversing its proteolytic activity TLN 
is also used for peptide synthesis or sugar-protein linkage. 
His 146
His 142
Glu166
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Figure 5.6 Detailed proteolysis mechanism of thermolysin.  Throughout Glu143, the O-H bond 
gets polarized. This enables a nucleophilic attack from the water oxygen atom to the carbon 
atom of the amide bond. The proton, previously temporally bound to Glu143 is transferred to 
the  amide  nitrogen  atom.  The  positive  charge  is  additionally  stabilized  by  Asn112  and 
Ala113.  Finally, the amide bond breaks and the upon product  dissociation,  a  new water 
molecule binds to the zinc ion. 
According  to  the  classification  from  Berger  and  Schlechter  [Schlechter,  1967],  protease 
binding sites can be subdivided. For thermolysin that involves most prominently:
● Zinc binding region, formed by His142, His146, Glu166 and a water molecule. The 
water molecule gets activated by Glu143. 
● S1´-pocket defining thermolysin specificity. It accommodates short lipophilic chains 
(up to four carbon) or a phenyl moiety. 
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● Huge, rather unspecific S1-pocket. Various fragments can bind here, often forming a 
hydrogen bond to the backbone nitrogen of Trp115. 
● Far  S2´-pocket.  Again  rather  unspecific  it  offers  the  possibility  for  a  lipophilic 
fragment and eventual hydrogen bonds to Asn111. 
Figure 5.7 Binding site  composition.  Left:  The binding  site  can be divided into  several  sub-
pockets.  Amino acids, strongly involved in substrate or inhibitor binding are highlighted. 
While the S1 and S2'-pocket can accommodate structurally diverse ligands, the S1'-pocket is 
specific for short hydrophobic side chains. Right: Protein-ligand geometries as observed in 
pdb ID: 1TMN. Tight binding ligands address all described sub-pockets. 
Multiple protein-ligand crystal structures have been solved for thermolysin. They indicate the 
importance  of  the different  sub-pockets  and they help to derive  a  pharmacophore  model. 
Binding to the zinc ion is either mono or bidentate. Bidentate ligands bind with a trigonal 
bipyramidal geometry representing transition state analogs. Possible coordination groups are 
hydroxamate, phosphate, carboxylate functions. The monodentate ligands bind in a tetragonal 
geometry representing substrate analogs. Examples are thiol, urea or carbonyl functions. 
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Figure 5.8 Example of ligand binding to thermolysin. Inhibitor ZGPLL binds with Ki = 9 nM in a 
competition  assay.  Left:  Schematic  overview  of  protein-ligand  interactions  including 
distances in Ǻ. Right: Protein-ligand geometry as observe in pdb ID: 5TMN [Holden, 1987]. 
Protein residues are shown with beige carbon atoms. Ligand carbon atoms are shown in 
green.  The pink sphere represents the zinc ion and dashed lines represent  protein-ligand 
interactions. 
Despite tight binding ligands, there are also several dipeptides known to inhibit thermolysin. 
The most  prominent  is  Val-Lys.  Feder  et  al. investigated  a  series  of  Phe,  Tyr,  Gly,  Leu 
combinations [Feder, 1974]. Most of these bind to the protein in the millimolar range and 
several  protein-dipeptide  complex  structures  could  be  solved  by  protein  crystallography. 
Strikingly, these ligands do not bind to the zinc ion, demonstrating that targeting one part of 
the binding site can be sufficient to provide a starting point for ligand design. 
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Figure 5.9 Small molecule inhibitors bound to thermolsyin. Left: Val-Lys dipeptide as observed in 
pdb ID:  2TLX [English,  1999].  It  occupies  the  S1' and  S2' pocket  whereas  the  zinc  ion 
remains uncomplexed.  Right:  Thermolysin structure crystallized in 100 % isopropanol as 
observed in pdb ID: 8TLI. The structure clearly shows favorable interactions sites in the 
binding pocket for possible hydrogen bonds. 
Thermolysin  is  a  thermostable  protein,  thus  comprising  a  core  built  extensively  by 
hydrophobic  amino acids compared to temperature  sensible  proteins.  This  higher  stability 
makes the protein structure and the assembled crystals  more resistant  to organic solvents. 
Thermolysin could be crystallized from 100% isopropanol [English, 1999] and in the presence 
of 70% acetone [English,  2001],  in  buffers  mixed with acetonitril,  thiocyanat  and phenol 
(supporting material). Even though these molecules possess only minor binding affinity they 
could be detected in the difference electron density. The possibility to grow protein-ligand 
complexes showing solvent  molecules  and other small  fragments in different  sub-pockets, 
renders thermolysin a promising target for fragment-based lead discovery. 
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Methods
Library composition
Different  data  sets  were  assembled  to  represent  molecular  properties  required  for  either 
thermolysin inhibition, or in agreement with criteria such as fragment likeness or accessibility 
as commercially available compounds. 
X-ray reference data set (XRAY): Ligands from thermolysin-ligand complex structures were 
extracted to represent a reference data set. Based on the ligand molecular size compounds 
were divided into 'ligands' and 'solvents'. To generate an additional reference fragment data 
set, the ligands were split in agreement with rules implemented into the RECAP algorithm. 
Drug fragments data set  (WDI):  To compile drug-like molecules the World Drug Index 
2001  (WDI)  (http://scientific.thomson.com/products/wdi/)  was  chosen  as  a  second  data 
source.  From this  set,  containing  approximately  70,000  biologically  active  molecules,  all 
diagnostics,  vitamins,  supplements  and  drugs  administered  differently  than  oral  were 
discarded.  A  further  selection  criterion  was  that  the  given  molecular  weight  should  be 
70 g/mol < x < 750 g/mol. Compounds in agreement with these conditions were split using 
the RECAP [Lewell, 1998] algorithm. For both kinds of RECAP sets, the XRAY and the 
WDI, two different labels were defined to the scissile atoms. They were either marked with an 
R group dummy atom (Rgroup) or saturated by a hydrogen atom (RsubH). The Rx label refers 
to the type of REACAP bond cleavage. To remove duplicates, all labels were later set to R1. 
The obtained chemical topologies were translated into 3D structures using CORINA. 
Commercially  available  compounds  data  set  (CAC):  The  2D connection  tables  of  the 
following  publicly  accessible  databases  have  been  converted  into  3D  structures  using 
CORINA: Asinex, IBS, Specs, Leadquest, Maybridge, and Sigma (addresses in supporting 
information).  Any  counter  ions  have  been  discarded.  For  virtual  screening  purposes 
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protonation states were used as defined by CORINA. For docking experiments a protonation 
state at pH=7.3 has been assumed. Hereby, phosphate, sulfonate and carboxylate functions are 
considered  deprotonated,  amines  protonated.  Corresponding  to  the  respective  vendor, 
molecules were either claimed HTS ligands or building blocks. 
Virtual Screening
Three hierarchical filter were applied to the data sets corresponding to library design rules 
either suggested by Baurin et al. [Baurin, 2004] or in agreement with (1) fragment likeness, 
(2) target specificity (3) unwanted functional groups. 
In a fast initial step, a filter based on definition of a fragment was applied using the Selector 
compound filtering utility of SYBYL. Molecular size and rotatable bonds were considered. 
The number of rotatable bonds criteria with respect to the published “rule of 3” for fragments 
was exceeded. In an intensive study, Hopkins et al. [Hopkins, 2003] correlated the ligand size 
to the corresponding target family. It turned out that proteinase inhibitors are distinctly larger 
compared to other enzyme family inhibitors. We did not include hydrogen bond acceptor or 
donor  functions  in  the  screen  due  to  limited  definitions  of  those  in  the  Selector  tool  of 
SYBYL  7.0.  To  avoid  solvents  or  ions  in  the  data  set,  the  minimum  number  of  atoms 
composing a considered candidate fragment was set to seven. Additional filter criteria were 
molecular  weight  70  ≤ x ≤ 250 g/mol and the number of rotatable  bonds:  ≤ 8.  A highly 
diverse fragment library increases the chance to find a hit during screening. This is important 
when only little is known about requirements for target inhibition. In case of prior knowledge 
about inhibitors a targeted fragment library may serve as a better approach [Zartler, 2005]. A 
protein targeted fragment library was successfully applied for factor Xa inhibitors [Fielding, 
2003].  To  generate  a  protein  targeted  library  for  thermolysin,  two  distinct  areas  in  the 
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thermolysin  binding  site  were  addressed,  the  zinc  binding  region  and  the  S1'-pocket.  To 
generate  appropriate  pharmacophores,  a  database  search  with  ReliBase+  [Bergner,  2001], 
[Cramer, 1989], [Gunther, 2003], [Hendlich, 2003] was performed. 
1. Zn-binder:  Defined  as  Zn-  nitrogen,  Zn-  oxygen,  or  Zn-  sulfur  contacts  with  a 
distance restraint  of 1.5Å < x < 2.0  Å. The zinc ion is defined as one ligand, the 
interacting molecule as a second. Both must be part of ligand entries (LIG) in the 
database. All functional groups capable of coordinating a zinc ion with tetra- or penta-
valent geometry were selected. 
2. S1'-pocket: Thermolysin and matrix metalloproteinase structures were analyzed for 
ligand moieties, addressing the S1'-pocket. Matrix metalloproteinases and thermolysin 
belong  to  the  same  superfamily  of  zinc  proteases,  the  zincis.  They  also  share a 
hydrophobic specificity pocket. Studying inhibitors and protein cavities, the maximal 
size and possible branching for the ligand was obtained. 
Molecules comprising the following functional groups were discarded: Either they contain an 
atom different from H, C, N, O, F, Cl, S, or sugars, anhydrides, aziridines, epoxides, ortho 
esters, nitroso compounds, isonitriles, acetals, thioacetals, N-C-O acetals, nitro compounds. 
All functional groups and pharmacophores were defined as 'Markush atom' and the program 
UNITY was used to perform a 2D connectivity screening. Passing compounds were sorted 
corresponding to the data bank/vendor they originated from and the matching pharmacophore. 
Docking
An appropriate strategy was chosen based on the docking of a benchmark data set. It consists 
of several drug-sized thermolysin inhibitors for which the protein-ligand complexes have been 
experimentally  determined.  The  protein  structure  was  retrieved  from  pdb ID: 1TMN 
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[Monzingo, 1984]. Water molecules assigned to the pdb complex structure were removed. 20 
ligands  were  tested  using  FlexX,  AutoDock  and  GOLD  using  the  scoring  functions 
implemented in FlexX, GOLD, AutoDock, along with Chemscore and DrugScore. Based on 
the achieved performance  in regenerating  the native the protein-ligand binding mode,  the 
most appropriate docking/scoring combination was selected for further analyses. Additionally, 
the fragment data set was docked as well as several solvent molecules for which the protein-
solvent structure was crystalographically determined. 
FlexX:  Standard settings were applied as suggested for FlexX 1.13. The binding site was 
defined by all residues coinciding within an 8Å distance around the bound ligand in pdb entry 
1TMN. This comprises S1, S1' and S2' pocket. The FlexX scoring function was used during the 
complex construction phase. No threshold for the number of accepted solutions was defined. 
The finally generated geometries were scored with both, the FlexX function and DrugScore. 
GOLD: Protein hydrogen atoms and lone pairs were added using GOLD 3.0. The binding site 
was chosen equivalent to that used in FlexX. Correct protonation states of histidine residues, 
especially at the zinc ion were manually adjusted. Allowed geometries to complex the zinc 
ion were tetrahedral and trigonal bipyramidal. Standard parameters for the genetic algorithm 
were applied and ligands were docked using the 'optimal accuracy' setting without any speed-
up. 10 docking runs were performed per ligand. Scoring was done with the GOLD function 
initially. Rescoring with Chemscore included a local optimization. Finally the GOLD scored 
geometries were rescored with DrugScore. 
AutoDock: Ligands were docked into the binding pocket using AutoDock 3.0. The binding 
site box was set to be similar to FlexX and GOLD. The partitioning of the total charge into 
individual  atomic  contributions  was  performed  using  the  Gasteiger-Marsili  charges 
[Gasteiger, 1980]. AutoDock 3.0 requires polar hydrogen atoms on the protein for docking. 
They were added with the PROTONATE utility in AMBER [Case, 2002] and the generated 
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hydrogen bonding network was visually inspected for internal consistency. AMBER united-
atom  charges  were  assigned  as  defined  in  the  AMBER  force  field  [Weiner,  1984],  and 
solvation parameters were added using the ADDSOL utility from AutoDock3.0. Docking runs 
were performed with the Lamarckian genetic  algorithm as implemented in AutoDock 3.0, 
using an initial population of 50 randomly placed individuals, a maximum number of 1.5 x 
106 energy evaluations (for fragments: 0.75 x 106), a mutation rate of 0.02, a crossover rate of 
0.80 and an elitism value of 1. Generated ligand docking solutions,  mutually differing by 
rmsd ≤ 1 Å were clustered together and the lowest docking energy found for one entry of a 
cluster  was  used  as  representative.  For  each  reference  ligand,  initially  50  solutions  were 
generated. For the reference fragment 20 solutions were generated and 10 in the subsequent 
screening. Docking results  were rescored using DrugScore.  All  applications of DrugScore 
included the solvent accessible surface term. 
Fragment Docking: The XRAY-fragment data set was docked and the obtained geometries 
were faced to the corresponding placement  of this fragment in the parent ligand complex 
structure. For an endoproteinase most likely the strongest interaction will occur in an area 
next to the scissile amide bond. Therefore, fragments addressing the S1 and S1' pocket were 
considered. Docking was done either with the Rgroup and the RsubH ligand setup. The WDI 
fragments and ligands from the CAC data set were docked using AutoDock3.0 as described 
with 20 docking solutions per ligand. The Rgroup was treated as dummy atom in GOLD and 
FlexX.  For  AutoDock  a  special  atom  type  R  was  introduced  to  prevent  Rgroup-protein 
interactions. Parameters were chosen similar to the non-aromatic carbon atom type and all 
attracting interaction points on the energy grid were set to 0. 
SFC  score: For  a  retrospective  analysis  of  the  generated  docking  solutions  a  recently 
developed scoring function was applied [Sotiffer, 2007]. Different to the establishment of the 
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original  function,  parameterized  on  the  base  of  large  overall  protein-ligand  complexes 
[Sotiffer,  2007],  only  complexes  with  fragment-like  ligands  were  considered.  Selection 
criteria were molecular weight < 300 g/mol and number of rotatable bonds ≤ 3. 
Post-filtering: Inherent to the docking smaller molecules is the increasing number of possible 
placements of the ligand into the pocket. This leads to multiple, structurally diverse docking 
modes for which approximately the same affinities are predicted. Therefore, the generated 
docking  geometries  were  examined  whether  they  agree  to  a  predefined  UNITY  3D 
pharmacophore.  During  this  post-docking  process,  ligands  were  kept  rigid  and  had  to 
penetrate either into a sphere around the zinc ion or to address the S1'-pocket. Mismatching 
docking modes were discarded. 
Crystallization
Using native thermolysin (purchased from Calbiochem) crystals suitable for X-ray diffraction 
were prepared as described by Holmes and Matthews [Holmes,  1982]  with the following 
slight  modifications.  TLN  was  dissolved  in  0.05 M  tris/HCl  buffer  (pH 7.3),  containing 
DMSO (50% (v/v)) and calcium acetate (0.05 M) and caesium chloride (2.5 M). The final 
protein concentration was 4.0-4.6 mM. The protein is predissolved in DMSO and then mixed 
with the buffer. Crystals were grown by the sitting-drop vapor diffusion method using water 
as reservoir solution. Crystals grew to their final size (0.4 mm) after 3 days. Protein-ligand 
complex crystals were obtained by soaking. Fully grown crystals were transferred to 0.01 M 
tris/acetate (pH 7.3) soaking buffer solution containing calcium acetate (0.01 M) and 5% (v/v) 
DMSO. Ligand concentrations were 10 mM for benzylsuccinat, 20-50 mM for the fragment 
soaking or saturated when low solubility was given and crystals were left at least two days in 
the soaking solution prior to freezing. 
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Data collection
Data  were  collected  at  temperature = 100K  using  a  cryo-protectant  solution  of  10 mM 
tris/acetate buffer containing 10 mM calcium acetate, 5% DMSO and 20% glycerol (pH 7.3). 
The  data  sets  were  collected  on  a  RIGAKU  RU-300  copper  rotating  anode  (Molecular 
Structure Cooperation) at 50kV, wavelength = 1.5418 Å, 90mA using a R-AXIS IV++ image 
plate system. For each frame the exposure time and oscillation rate were set to 7 minutes and 
Δφ = 0.5°, respectively. The crystal to detector distance was 120 mm. Data processing and 
scaling was performed using the HKL2000 package [Otwinowski, 1997]. The 3-methylaspirin 
complex structure was additionally determined at the synchrotron BESSYII in Berlin on PSF 
beam line  II  equipped  with  a  MAR-CCD detector.  In  total,  120  frames  with  Δφ = 0.5°, 
wavelength = 0.91841 Å at a crystal to detector distance of 175 mm were collected at −170°C. 
Exposure  time  was  8  seconds.  Data  processing  and  scaling  were  performed  using  the 
HKL2000 package [Otwinowski, 1997]. 
Structure determination
The coordinates of thermolysin in complex with Val-Lys (pdb ID: 2TLX) were used after 
removal of ligand, metal ions and water molecules for initial rigid-body refinement of the 
protein  atoms  followed  by  repeated  cycles  of  conjugate  gradient  energy  minimization, 
simulated  annealing  and  B-factor  refinement  using  the  CNS  program package  [Brunger, 
1998].  Refinement  at  later  stages  was  performed with  the  program SHELXL [Sheldrick, 
1997].  Here,  at  least  20  cycles  of  conjugate  gradient  minimization  were  performed  with 
default restraints on bonding geometry and B-values. Five percent of all data were used for 
Rfree calculation. Amino acid side-chains were fitted into sigmaA-weighted 2Fo-Fc and Fo-Fc 
electron  density  maps  using  O  and  Coot  [Jones,  1991],  [Emsley,  2004]  .  After  the  first 
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refinement cycle, water molecules and subsequently the zinc atom and ligand were located in 
the electron density and added to the model. Restraints were applied to bond lengths and 
angles, chiral volume, planarity of aromatic rings and van der Waals contacts. Multiple side-
chain conformations  were built  in  case an appropriate  electron density was observed and 
maintained during the refinement, and if the minor populated side-chain showed at least 10% 
occupancy. During the last refinement cycles, riding H atoms were introduced without using 
additional  parameters.  The  final  models  were  validated  using  PROCHECK  [Laskowski, 
1993]. Data collection, unit cell parameters and refinement statistics are given in Table s.11. 
Binding Assay
Determining enzyme and inhibitor  kinetics  was performed as described by Morgan  et  al. 
[Morgan, 1978] with slight modifications. 
Kinetic Parameters for thermolysin hydrolysis: To a thermolysin solution (13 nM) FAGLA 
was added from 0.1 to 8.0 mM. For higher concentrations, 5 mM and 2 mM path length cells 
were used to keep the absorbance of the solution below 2.5. At each concentration, the initial 
velocity was determined by measuring the molar extinction coefficient at ε=345 nm. 
Determination of inhibition constant Ki: Kinetics were followed with protein concentration of 
13 nM and two substrate concentration of 2 mM and 4 mM. The number of applied inhibitor 
concentrations ([I]) varied, depending on solubility and availability of the compounds. The Ki 
values were determined from ν0/νi versus [I] plots with concentrations over a range of at least 
0.5 (Ki) – 10 (Ki). Depending on solubility, inhibitors were dissolved in standard buffer, 50% 
or 100% DMSO. 
General procedure: Phosphoramidon and thermolysin were purchased from Calbiochem and 
FAGLA (3-2-furylacryloyl)-L-glycyl-L-leucine-aminde)  from Bachem.  All  stock  solutions 
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were prepared with doubled distilled water and filtered through 0.45 μM pore size Millipore 
filter. The buffer for FAGLA and thermolysin was 0.1 M 3-(N-morpholino)propanesulfonic 
acid (MOPS), 2.5 M NaBr and 10 mM CaCl2. FAGLA was pre-dissolved in DMF to yield a 
final DMF concentration of 2.5% (v/v) at pH 7.0. Assays were performed at 25°C, monitored 
by absorbance change at 345 nm and followed for five minutes. At least double measurements 
were applied to each substrate and inhibitor concentration. 
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Figure 5.10 Hydrolysis reaction for thermolysin inhibition assay. 
In an extensive study analyzing thermolysin sensitivity to organic solvents, DMSO showed 
the  least  effect  on  the  residual  activity  and  protein  structure.  However,  the  influence  of 
organic solvents on the inhibitor kinetics were determined for phosphoramidon. Ki values for 
phosphoramidon with 5% and 10% DMSO were determined. 10% corresponds to dissolving 
the ligand in pure DMSO. The determined affinities of Ki(5%) = 226  μM and Ki(10%) = 
558 μM demonstrate the strong solvent influence on protein inhibition. Assuming competitive 
inhibition kinetics the following mechanism and equations were applied to calculate inhibition 
constant Ki. 
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Figure 5.11 Scheme for competitive enzyme  inhibition assuming that  only either  substrate  or 
inhibitor can bind to the enzyme.  ν is velocity measured per substrate  [A] and inhibition 
concentration  [I].  V  is  the  maximal  enzyme  velocity  and  Km is  the  Michaelis-Menten 
constant. 
V is not changed in this inhibition mechanism, as FAGLA present in large extent displaces the 
inhibitor  (on  the  opposite  large  quantities  of  inhibitor  displace  FAGLA).  This  feature  is 
indicative for this type of inhibition and in the Dixon plot [Dixon, 1953], [Dixon, 1972] the 
straight lines meet in a joint intercept in the second quadrant with –Ki as x-coordinates. 
Results and Discussion
The  present  study  describes  a  fragment-based  virtual  screening  and  the  experimental 
confirmation of the detected hits. To generate the appropriate ligand and fragment libraries we 
divided already known ligands stored in the WDI. Obtained fragments were requested to be 
commercially available. The XRAY data set comprised 58 thermolysin complexes deposited 
in the protein data bank (http://www.rcsb.org). NMR structures, apo structures, non-Zn metal 
structures were removed, yielding 49 protein-ligand and 6 protein-solvent complex structures. 
Superimposition  of  all  complex  structures  showed  rigidity  in  the  binding  site,  proving 
thermolysin  to  be  a  auspicious  target  for  molecular  docking.  However,  there  are  three 
macrocyclic  inhibitors  (pdb ID's  1PE5,  1PE7,  1PE8 [Hansen,  2003]) forcing Asn112 to a 
Fragment-based virtual screening 123
slight adjustment in the χ2 angle. Analyzing the superimposed ligands, all inhibitors address 
the S1'-binding site and most are involved in zinc ion coordination. While the narrow S1' site 
only  allows  limited  access,  ligands  addressing  the  S1 site  show  a  broad  variety  in 
functionalities and conformations. 
Figure 5.12 Superimposition of 49 protein-ligand complex structures. Left: Superimposition of 
protein chains only,  showing some but only minor  flexibility in the binding sites.  Right: 
Superimposition of 49 different ligands into the binding site of pdb ID: 1TMN. While ligand 
moieties for the S1' are limited in size and orientation, the S2 and S1 pocket get addressed by a 
variety of functional groups and sizes. 
In case of a ligand not binding to the Zn2+ ion, two water molecules are found to occupy the 
remaining  two  positions  to  form  a  bidentate  coordination  (for  example,  pdb ID  series 
(1-8)TLI). However, these two water molecules are at a very close mutual distance of on 
average  2.32 Å.  Superimposing  these  structures  with  the  difference  density  from  our 
thermolysin  Val-Lys  complex  structures,  we  observed  these  two  oxygen  positions  to 
superimpose very well with two density peaks in our Fo−Fc density. However, we believe that 
instead of two water molecules in very close proximity, these oxygen atoms rather belong to 
the same molecule, which is likely to be a picked-up acetate from the crystallization or cryo 
buffer (Figure 5.13). 
Asn112
Arg203
Glu143
Tyr157
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Figure 5.13 Coordination next to the Zn2+ ion in thermolysin. Left: pdb ID: 1TLI [English, 1999] 
shows two water  molecules,  binding  to  the  Zn2+ ion  with  a  mutual  distance  of  2.35  Å. 
Center:  Fo−Fc density  at  2.0  σ found  in  a  thermolysin  crystal  structure  measured  in  the 
context of this study. An acetate ion has been assigned to the zinc ion for one refinement 
cycle. Shown is 2Fo−Fc density at 1.5 σ. 
Library design and Virtual Screening
Fragmenting the 21 XRAY data set ligands into small building blocks yielded 46 fragments. 
Unfortunately, non of the resulting fragments coordinating zinc or occupying in the complete 
parent ligand the S1'-pocket were commercially available. Solvents and cosolvents determined 
to  bind  to  the  thermolysin  binding  site  by  X-ray  crystallography  are  DMSO,  acetonitril, 
acetone, isopropanol and phenol. Applying the filter criteria described above to the World 
Drug Index yielded 4086 unique fragments of which 3976 remained after setting the Rgroup 
in all  scissile bonds to R1 to remove duplicates.  Figure 5.14 shows examples of size and 
functionalities. 
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Figure 5.14 Example fragments from the data set derived from the World Drug Index. Molecules 
were divided using the RECAP algorithm. To avoid duplicates, all cuts were subsequently 
set to R1. 
Assembling data from six commercial  suppliers revealed ca 800,000 available compounds 
and 100,000 building blocks. Virtual screening was performed in a stepwise fashion using 
Selector and Unity with hierarchical filters of increasing complexity. 
Table 5.3 Summary of screening results after Selector filter
Data set Number of passing compounds  (%)
XRAY 46 100
WDI 3,090 77
Building blocks 10,034 10
HTS compounds 53,825 6.7
While molecules of the XRAY and WDI set were already fragment biased, maximal 10% of 
the ligands originating from the database of commercially available compounds passed the 
filter. These compounds represent a non target biased fragment set. However, as only 10% 
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passed the predefined fragment criteria, the low success rate indicates the tendency towards 
inadequate entries not only for the library of 'complete'  ligands used for HTS but also for 
building block libraries. It also suggests that a well designed fragment library requires novel 
synthesis.  Compared to the estimated number of 1060  possible drug-like molecules [Villar, 
2000] the here considered randomly assembled 65,000 compounds cover only a small part of 
chemical space. 
The target-based pharmacophores have been applied as a second filter step in the screening 
scenario, using the 2D search tool in UNITY. The applied pharmacophore hypothesis was 
based on current knowledge about established and crystallographically studied compounds 
binding to thermolysin and matrix metalloproteinases. The resulting Zn contact groups reflect 
the current  knowledge of experimentally determined functional  groups,  that  complex Zn2+ 
ions in proteinases. 
Table 5.4 Functional groups found to complex Zn2+ ions in metalloproteinses
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Zn-binding fragments are drawn as they are translated into SYBYL markush atoms. 
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Additionally  to  the  zinc  binding  fragments,  a  second  pharmacophore  for  ligand  moieties 
addressing the S1' specificity pockets was generated. In summary, they show limited space 
and the bias for hydrophobicity for this area. Branching seems almost impossible. 
Table 5.5 Pharmacophores representing ligands found to address the S1'-pockets. 
Core 
structures
R2
R1
R1
R1
R1
R1
ANY
ANY
Substitutions R1 = H, F, Cl, Br, IR2 = all but N Incl. N,O planar
All pharmacophores were translated to UNITY markush atoms. 
Table 5.6 Results from applying the second filter criteria for virtual screening.
Data sets Zn- 
binder
(%) S1'-
binding site 
(%)
XRAY 37 80 28 63
WDI 958 24 577 14
Building blocks 2,900 2.9 1,473 1.47
HTS 
compounds
21,404 2.7 10,004 1.25
The high amount of WDI Zn-binder fragments passing this filter can be explained by the fact 
that many metalloproteinases have already been studies as potential drug targets and thus, 
such  examples  should  pass  this  filter.  Compared  to  the  Zn-binder,  the  amount  of  WDI 
fragments passing the S1'-pocket filter is lower. However, the pharmacophores are retrieved 
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from molecules  which are inhibitors  for their  targets  but  not  necessarily drugs.  Marketed 
drugs are optimized not only for affinity but for pharmacokinetic parameters as well. In order 
to achieve better ADME properties, the hydrophobic moieties are often further substituted. 
The  amount  of  commercially  available  compounds  passing  the  pharmacophore  filter  is 
surprisingly  high  indicating  that  a  broad  variety  of  ligands  is  in  agreement  with  the 
pharmacophore  hypothesis.  The  final  2D filter  step  was  introduced  to  discard  molecules 
comprising functional groups not likely to be favorable in drugs. 
Table 5.7 Functional groups applied in the unwanted functionalities filter in virtual screening. 
N O N O N S
O
N
OH
O O
O
S S O
O OH OH
OH
This last filer was not applied to the XRAY data set, because it served as a reference data 
set only. Table 2.8 shows the final hit lists derived from virtual screening. 
Table 5.8: Final compound data sets after virtual screening
Data base Zn-Binder S1'-pocket Intersection(Zn/S1')
Intersection
(Zn/S1')
XRAY 37 28
WDI 958 577
HTS/BBlocks 13 990 7 952
112 / 75
0 / 1
We were especially interested in fragments found as intersection between the CAC and 
WDI data set.  Even though a relatively small number of 200 entries remained for virtual 
130 Fragment-based virtual screening
screening it is still a reasonable number to perform docking experiments. Docking fragment-
sized molecules has been described as difficult and correctly predicting binding affinities is 
hardly  possible  [Mooij,  2005].  We focused  on  the  XRAY/CAC intersection  data  set  for 
further docking studies. Comparing the lists of intersections for the XRAY data set shows 
disappointingly  no  intersection  for  the  Zn-binder  and  only  benzylic  alcohol  is  found  in 
common for the S1'-pocket. 
Docking
To select the most appropriate docking tool, we performed docking for the XRAY ligands 
first using three different docking programs in combination with several scoring functions. 
XRAY data  set  duplicate  ligands  were  removed  yielding  20  ligands.  Splitting  those  into 
fragments resulted in 47 fragments. 
Table 5.9 Docking comparison of 20 Xray data set ligands 
AutoDock GOLD GOLD-
Chemscore
FlexX FlexX
DrugScore
Number of best solutions 
with RMSD < 2Å
20 9 14 16 16
Ø RMSD of rank 1 solution 2.2 4.9 2.9 5.6 5.1
Number of rank 1 solution 
with RMSD < 2Å
12 7 12 4 5
Rescoring results are only given if better results were obtained. 
The docking results  clearly show the superior performance of AutoDock.  It  was not only 
capable  of  producing  at  least  one  good  solution  per  ligands,  but  the  AutoDock  scoring 
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function was best capable to identify a placement of the fragments that best approximated its 
orientation as found for the unfragmented parent ligand (Table 5.9 row 2). Rescoring with 
other scoring functions did not improve the performance generally. This might be due to the 
final minimization step. Docking modes are minimized into the respective function. Using 
these  modes  without  adjusted  minimization  for  other  scoring  functions  complicates  their 
scoring. In the case of GOLD-docking/Chemscore-scoring a post-docking minimization with 
respect  to  the  new  potentials  is  performed.  This  minimization  contributes  to  the  better 
rescoring performance of Chemscore compared to DrugScore. 
Quality assessment of generated docking solutions was based on calculated RMSD between 
docking mode and crystal structure geometry. However, relying on calculated RMSD values 
might  not  be  sufficient  as  a  criteria  for  correct  docking.  Val-Lys dipeptide  docking with 
AutoDock serves as a good example. While the best RMSD might show the atoms close to 
their respective position in the crystal  structure,  clearly the solution given on the right of 
Figure 5.15 identifies best the correct binding mode. 
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RMSD 2.73 1.01 3.25
Rank 1 47 33
Cluster size 2 1 12
Figure 5.15 Docking solution of Val-Lys. Ligand conformation as experimentally derived from 
pdb ID: 2TLX is given with yellow carbon atoms. The docking solution are given with pink 
carbon atoms. Left:  Docking solution selected  for  rank1 by AutoDock.  Center:  Docking 
solution with the best RMSD. Right: Docking solution which identifies the protein-ligand 
interactions the best. Far away from the binding site, the Lys side chains not not match. 
As  expected  the  ligand  conformation  shown  on  the  left  receives  the  highest  score.  The 
docking  mode  has  a  strong  interaction  with  the  zinc  ion  and  if  in  fact  so,  this  should 
contribute significantly to the interaction energy. One possible explanation might be that in 
the crystal structure, two water molecules or an acetate ion are complexed to the zinc ion and 
block a direct access, whereas in docking such interaction partners are not regarded and the 
docking program seeks to find a coordination to the metal ion. The docking solution on the 
right recognizes all necessary protein-ligand interactions. However, the overall RMSD results 
in a fairly large value. The terminal lysine side chain which mainly interacts with solvent 
water  molecules  is  not  correctly  placed.  It  should  be  noted  that  this  solution  was  found 
multiple times, in fact for AutoDock this geometry represents the largest cluster of solutions. 
While  not  available  in  the  lab,  the  application  of  the  IBAC (interactions-based  accuracy 
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classification)  scoring  system  might  serve  as  a  further  addition  or  alternative  [Kroemer, 
2004].  For  IBAC,  a  two  step  scoring  is  applied.  First,  the  ligand  position  is  compared 
regarding the atom-by-atom match  to  the crystal  structure.  In  a  second step,  the  docking 
solution is checked for the presence of key interactions with the protein. Docking poses are 
thus  classified  as  correct  (all  interactions  present),  nearly  correct  (up  to  a  quarter  of  the 
relevant interactions are not present) or incorrect. As an advantage, docking poses which are 
close by RMSD but inadequate by means of protein-ligand recognition are discarded. In the 
given Val-Lys example, IBAC would recognize the solution on the right as the best one. Due 
to these findings, all docking solutions were visually inspected for identified interactions to 
the zinc ion and possible hydrogen bonds to Arg203. 
Pushing  the  fragment  approach  to  its  limit  we  tried  docking  six  solvent  and  cosolvent 
molecules, for which complex crystal structures are available. One apparent problem to those 
very small ligands is the energetic differentiation between multiply generated binding modes. 
However, already the generation of docking solutions turned out to be difficult. 
 
Figure 5.16 Docking the cosolvent to thermolysin is difficult. Two docking solutions (pink carbon 
atoms) for phenole are compared to the corresponding experimental structure (yellow carbon 
atoms). Left: AutoDock docking solution with the highest score. Right: Docking solution 
with the best RMSD. 
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As shown in Figure 5.16, there was no better solution generated than the one shown in the 
right  figure.  However,  the  docking  mode  shown  on  the  left  achieved  higher  scores.  A 
hydrogen bond is formed which yields more interaction energy than burying the hydrophobic 
part into the S1'-pocket. Analyzing the thermolysin solvent complex structures shows that the 
solvent  molecules  are  embedded  into  a  network  of  water  molecules  that  also  solvate  the 
binding pocket.  While this might be true to some degree for all  ligands in general,  those 
interaction strongly influence the placement of the organic solvent binding to the protein. 
Figure 5.17 Water network around a ligand. Shown is pdb ID: 1FJQ, which is thermolysin soaked 
in  70% acetone.  While  there  are  some protein  acetone  interactions,  more  are  generated 
between acetone and the adjacent water molecules. 
Despite  the  described  shortcomings,  docking  of  complete  drug-sized  thermolysin  ligands 
worked  very  well.  Most  docking  algorithms  managed  to  generate  suitable  ligand 
conformations. However, the selection of “the best” conformation from multiple geometries 
for  one  ligand  did  not  work  sufficiently.  Further  improvement  in  scoring  and ranking is 
required to enhance the chance of ranking the biologically relevant conformation on rank 1. 
For a fragment docking reference, the XRAY data set ligands were split into fragments based 
on  the  RECAP  algorithm  and  docked  to  thermolysin.  This  approach  is  based  on  the 
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assumption  that  the  assembly  of  drug-size  molecules  from  fragments  can  be  reversed. 
Babaoglu and Shoichet have demonstrated in an insightful example for β-lactamase, that this 
assumption does not hold in general. However, while we were not able to obtain complex 
crystal  structures  with any of the fragments  disassembled from the XRAY references  we 
consulted protein-ligand complex structures binding fragments, which are structurally close to 
fragments  obtained  from  our  RECAP  splitting  of  the  known  inhibitors  [Senda, to be 
published]. Quite convincing results are found for these cases. If a fragment-protein complex 
structure can be determined the found fragment geometry provides a reasonable estimate of 
the conformation of this fragment when it is integrated into a larger and more complex ligand. 
Same functional groups, even in smaller ligands or different ligands, address the same binding 
site in similar fashion. 
Figure 5.18 Same ligand moieties address binding sites in similar fashion. Left: Superimposition 
of ligands derived from pdb IDs 3TMN (green carbon atoms) and 5TMN (orange carbon 
atoms). Val and Leu address S1'-pocket similar. The same applies for the peptide backbone. 
Right: Superimposition of ligand moieties from pdb ID 1ZDP (yellow carbon atoms) and 
1KJP (light blue carbon atoms). The strong hydrogen bond between the backbone nitrogen 
and the ester  oxygen  forces the ligand to adopt  a different  binding mode.  However,  the 
aromatic ring to address the S1'-pocket aligns convincingly. 
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In a first attempt the docking of the XRAY fragments was performed using three docking 
programs in combination with several  scoring functions.  The RsubH (scissile  atom set  to 
hydrogen) data set was used. All XRAY fragments were docked into the whole and empty 
binding site and wrong placements were observed for fragments which bind to the rim of the 
pocket (S1- and S2'-pocket) in the parent structure. The strong binding capabilities of the zinc 
ion  and  the  S1'  pocket  guide  this  misplacement  into  the  center  of  the  pocket.  As  a 
consequence, all but the ZN-binder and the S1'-binder were discarded. In total 32 fragments 
remained to be considered for docking. A detailed list is given in the supporting information. 
Table 5.10 Docking comparison of the 32 X-ray data set fragments 
Auto
Dock
AutoDock
DrugScore (CSD)
GOLD GOLD-
Chemscore
FlexX FlexX
DrugScore
Number  of  best 
solutions  with 
RMSD < 2Å
23 23 (23) 9 15 16 16
Ø RMSD  of 
rank 1 solution
3.28 2.83 (3.49) 6.0 5.6 7.8 7.4
Number of rank 
1  solutions  with 
RMSD < 2Å
12 14 (9) 6 7 3 4
Rescoring results are only given if better results were obtained. Values in parantheses 
represent  DrugScore  when  taking  the  CSD  instead  of  the  PDB  as  crystal  structure 
database. 
Again the docking performance of AutoDock is superior to the other programs. However, 
compared to the docking of the entire ligands, the detection of the right binding mode is less 
successful. But one has to keep in mind that the geometry in the present case is built on a 
hypothesis and not on an experimental confirmed structure. Still, as the fragments clearly can 
adopt  those  conformations,  their  crystal  structure  geometry  is  one possibility.  Again,  the 
analysis of docking results was not only based on RMSD values but also a visual inspection 
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has been accomplished. DrugScore performed best in recognizing the binding modes. As we 
have  specific  interest  in  the  performance  of  the  scoring  functions  DrugScore  and 
DrugScoreCSD, we analyzed their performance in depth. Two major problems were observed:
1. The fragments form interactions to the protein via the atoms at the RECAP splitting 
site. This way, fragment growth at this location would be impossible. 
2. Fragments, supposed to bind to the S1'-pocket are falsely dragged towards the zinc ion. 
Especially oxygen atoms placed close to the zinc ion achieve significant scoring and 
result in false ranking. 
In order to avoid potential interaction of RECAP splitting sites with protein residues a new 
atom  type  R  was  introduced.  An  additional  AutoDock  energy  grid  was  derived  with 
parameters similar to non aromatic carbon atoms and all attractive interactions set to 0. This 
way,  the  RECAP splitting  sites  of  the  fragments  were  considered in  a  way to  use  them 
subsequently for further exploration of the binding site. 
 
Figure 5.19 Fragment docking performance. The ligand (pdb ID: 4TMN) is cleaved to represent 
the part addressing the S1 site. The crystal structure is given in yellow and the white atom 
indicates the R group. Left: Docking using RsubH (gray) allows the prospective growing site 
to adopt a geometry which hampers  the possibility to grow the fragment  (arrow). Right: 
Docking with repulsive R atom type prevents (orange) interaction at the growing site. 
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Table 5.11 Docking / Scoring results for XRAY fragments with either hydrogen or R-groups 
AutoDock AutoDock
DrugScore
AutoDock
DrugScoreCSD
AutoDock AutoDock
DrugScore
AutoDock
DrugScoreCSD
RECAP sites substituted to H RECAP site with atom type R
Zn-binder (13)
Number of best 
solutions with 
RMSD < 2Å
6 6 6 8 8 8
Ø RMSD of rank 
1 solution
3.58 3.37 3.28 3.56 3.60 3.31
Number of rank 1 
solution with 
RMSD < 2Å
2 2 2 0 0 1
S1'-pocket (11)
Number of best 
solutions with
 RMSD < 2Å
10 10 10 7 7 7
Ø RMSD of rank 
1 solution
3.2 2.92 4.51 3.32 4.13 4.7
Number of rank 1 
solution with 
RMSD < 2Å
6 7 4 6 1 1
both (8)
Number of best 
solutions with 
RMSD < 2Å
7 7 7 7 7 7
Ø RMSD of rank 
1 solution
3.06 2.19 2.67 1.57 1.60 2.66
Number of rank 1 
solution with 
RMSD < 2Å
4 5 3 6 7 5
A  detailed  list  of  all  scores  per  fragment  and  scoring  function  are  given  in  the 
supporting information. 
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Introduction  of  the  R-group  increased  the  docking  performance  for  Zn-binder  and 
fragments, addressing both, the zinc ion and the S1'-pocket. It reduced placements of ligands 
addressing  the  S1'-pocket  only.  Unfortunately,  even  if  better  solutions  are  generated,  the 
scoring  function  cannot  pick  them  and  rank  them  correctly.  There  is  only  a  slight 
improvement in ranking for the fragments addressing Zn2+ and S1'. Subsequently docking has 
been performed with both systems. 
In order to avoid artificially performed contacts between the zinc ion and oxygen atoms of a 
fragment, the charge at the zinc ions was removed. Secondly, the coordination site at the zinc 
ion  was  blocked  by  a  water  molecule.  Following  this  strategy  better  placement  of  some 
fragments was obtained assessed by the achieved RMSD values. However, visually inspecting 
the generated  binding modes  and found protein-ligand interactions it  did not  result  in  an 
overall improved performance. 
Table 5.12 S1'-pocket fragments docked with zinc ion uncharged 
AutoDock AutoDock
DrugScore
AutoDock
DrugScore
CSD
AutoDock AutoDock
DrugScore
AutoDock
DrugScore
CSD
RECAP sites substituted to H RECAP site with atom type R
Number of best 
solutions with 
RMSD < 2Å
11 11 11 9 9 9
Ø RMSD of 
rank 1 solution
3.52 4.36 4.51 3.9 4.47 6.3
Number of 
rank 1 sol. with 
RMSD < 2Å
4 4 3 3 4 3
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The introduction of the R-atom type did not results in more reasonable docking modes of the 
S1'-pocket  fragments  either  for  the  straight-forward  docking or  using  the  model  with  the 
uncharged zinc ion. 
Table 5.13 S1'-pocket fragments docked with permanent water at the zinc ion 
AutoDock AutoDock
DrugScore
AutoDock
DrugScoreCSD
RECAP sites substituted to H
Number of best 
solutions with 
RMSD < 2Å
10 10 10
Ø RMSD of rank 1 
solution
2.8 2.57 2.57
Number of rank 1 
solution with 
RMSD < 2Å
9 10 10
Figure 5.20 Docking of the S1'-pocket fragment extracted from the ligand in the pdb structure 
1TMN. Upon calculating the AutoDock energy grids, a water molecule occupying the fourth 
coordination site at the zinc ion was considered. Therefore, the docking geometries did not 
form undesired zinc contacts. Crystal structure geometry is given by yellow carbon atoms. 
Left:  Rank 1 docking solution  (AutoDock)  with  Zn2+ without  bias  (pink carbon atoms). 
Right: Rank 1 docking solution when docked with permanent water molecules complexing 
the zinc ion (green carbon atoms). 
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During  the  resting  state  of  the  protein  a  water  molecule  is  coordinated  to  the  zinc  ion. 
Considering  this  water  molecule  upon docking facilitates  the  placement  of  the  S1'-pocket 
fragments. However, it restricts the binding site size dramatically and the remaining space is 
so small that all but one fragment had at least one docking solution with RMSD < 2Å. 
The  different  binding  site  modification  provided  some  insightful  knowledge  about  the 
docking algorithm and enhanced the docking results by means of RMSD matches slightly. 
However, either restricting accessibility to the only relevant sub-pocket by placing a water 
molecule or discarding metal interactions are huge and artifical modification. Therefore, they 
were both not considered for the further screening of the CAC/WDI interaction. One could 
think of applying these binding site representations as a post docking filter when docking 
larger data sets of molecules. 
An  alternative  is  to  filter  the  generated  docking  modes  according  to  a  pharmacophore 
hypothesis.  This post  docking filter  was performed with the rigid 3D search algorithm as 
implemented in Unity. The zinc binding area is represented as a sphere of 3Å around the zinc 
ion.  The  part  of  the  fragment  which  satisfied  the  Zn-binder  pharmacophore  in  virtual 
screening must address this sphere with at least one atom to pass the filter. Representing the 
required depth in the S1'-pocket is a γ-carbon atom of the Leucine residue (pdb ID: 1TMN) 
experimentally determined to address the pocket. The docking mode passes the filter if at least 
one atom of the S1'-binder region penetrates into a sphere with 2Å radius around this atom. 
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Table 5.14 Results for passing docking modes through a post dock pharmacophore filter 
AutoDock DrugScore DrugScoreCSD AutoDock DrugScore DrugScoreCSD
Before pharmacophore After pharmacophore
Zn-
binder
Ø of best 
RMSD 
overall
1.8 1.8 1.8 1.52 1.52 1.52
Ø rank 
of best 
RMSD
9.6 7.8 9.3 7.6 5.5 5.0
Ø RMSD 
of rank1 
3.31 2.84 4.29 2.57 2.46 2.67
S1'-
binder
Ø of best 
RMSD 
overall
1.1 1.1 1.1 1.0 1.0 1.0
Ø rank 
of best 
RMSD
14.27 7.0 7.18 7.9 3.9 1.4
Ø RMSD 
of rank1 
4.13 4.36 4.51 1.1 1.0 0.9
There is no pharmacophore post filter for the fragments which bind to both, the zinc ion and 
the  S1'-pocket,  because  docking them works  very well  without  any further  adjustment  or 
filtering. For seven out of eight structures, a solution with RMSD <2 Å was generated and for 
five even better than RMSD = 1 Å. Probably, these fragments comprise the minimal size and 
interaction capabilities to enable docking analyses. 
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Figure 5.21 Docking solutions for fragments, binding to both the zinc ion and S1'-pocket. Docking 
runs  included  the  R-group at  the  RECAP splitting  site.  Crystal  structure  geometries  are 
shown with orange carbon atoms, docking modes with green carbon atoms. Left: Fragment 
1QF2_f1:  best  docking  solution  has  RMSD  =  0.76Å.  Right:  Fragment  1TLP_f2:  best 
docking solution has RMSD = 0.96Å. 
After benchmarking this fragment reference data set, the 187 intersection ligands between the 
WDI and CAC data set were docked with AutoDock and scored with AutoDock, DrugScore 
and  DrugScoreCSD.  The  RECAP  splitting  site  was  capped  by  the  R-group.  Ideally,  the 
selection  of  virtual  screening  hits  should  be  solely  based  on  the  ranking  of  the  scoring 
function  used  to  examine  the  interactions  geometry.  Facing  the  shortcomings  of  current 
scoring  functions  and  particularly  their  minor  performance  with  respect  to  fragments 
stimulated us to consider a consensus scoring by applying several functions in parallel [Wang, 
2003]. We selected the 10% highest scored docking solutions from each scoring function. 
They  were  post-filtered  as  described  above.  The  obtained  hits  were  visually  inspected, 
especially regarding the following characteristics: 
● reliability of the ligand conformation, 
● formed protein-ligand interactions to Arg203 and Asn112, 
● geometry of the generated metal-ligand interaction, 
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● penetration into the the S1' pocket of buried fragments and 
● in  case  of  AutoDock,  the  amount  of  docking  modes  found  in  each  cluster  of 
solutions. 
Applying these criteria, finally 14 compounds were selected for experimental validation. They 
comprise  a  variety  of  functional  groups (Table  5.15).  Validation  of  virtual  screening hits 
usually starts with the determination of the binding affinity of the hit list compounds. In a 
second step soaking and co-crystallization experiments  are  done with candidates showing 
relevant binding affinities. In the case of fragment-like molecules one expects affinities in the 
millimolar to micromolar range which require special assay conditions to detect low affinity 
binders. As mentioned NMR or SPR could serve this purpose. As there was no access to 
neither  of  these  methods,  we  decided  to  test  the  hit  list  compounds  directly  by 
crystallography. Protein complex crystal structures for low binding fragments can be obtained 
if soaking is performed at high ligand concentrations.
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Table 5.15 Compounds, selected for experimental binding studies using crystallography 
1
N
N N
NH
8
NH2
O
O
2 O
OH
9
OHO
O
O
3
OH
OH
O
10
OH S
NH2
O
O
NH2
4
N
N N
NH2
11
N
H
NH2
O
5
OHO
O
O
12 OH
O
N
H
N
H
O
6 NH2 S NH
O
O
O
13
O O
NH2
7 NH N S
O
O
NH2 14
NH2 S
O
N
H
O NH2
O
146 Fragment-based virtual screening
Crystallization
Thermolysin crystals were generated as described above and soaking was started with crystals 
at least five days old. Thermolysin crystallizes in different shapes but only hexagonal crystals 
were selected for the soaking experiments. 
Figure 5.22 Thermolysin crystals after 5 days growing. Left: Thermolysin crystallizes is different 
sizes and shapes. Right: Hexagonal crystals chosen for soaking experiments. 
An alternative method to obtain protein-ligand complexes would be co-crystallization. For 
thermolysin,  this  method  is  not  applicable:  Thermolysin  is  soluble  in  DMSO.  The 
crystallization  drop  initially  contains  50%  DMSO.  Due  to  pronounced  osmotic  pressure 
present in the buffer with high salt concentration, water will diffuse from the mother liquor 
into the drop. Upon decreasing DMSO concentrations, thermolysin crystallizes and after five 
days the initial  1 μl drop increases to 300 μl. The resulting ligand concentration would be 
significantly reduced and especially for fragments with low affinity, detection in the electron 
density would be difficult. Adding the ligand constantly over five days would be an option but 
would most likely interfere with crystal growth. According to these concerns, we focused on 
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soaking and started with ligand concentration of 50 mM if possible or with a saturated ligand 
solutions. As a decrease in ligand affinity is experienced in DMSO solution, organic solvent 
concentrations  were  kept  as  low  as  possible.  To  validate  our  soaking  protocol,  we  re-
determined the complex structure of the fragment-like thermolysin inhibitor benzylsuccinic 
acid. 
Figure  5.23 Confirmation  of  soaking  conditions  by  determining  complex  structure  for 
benzylsuccinic  acid.  Left:  Complex as determined from pdb ID: 1HYT [Hausrath, 1994]. 
Center: AutoDock Rank1 docking solution for benzylsuccinic acid. Right: 2Fo-Fc density at 
σ-level 2.5. 
Table 5.16 Refinement parameter for thermolysin-benzylsuccinic acid complex.
Resolution (Å) 1.9 <B>Protein (Å2) 14.4
Rsym (%) 10.0 <B>Ligand (Å2) 20.1
Rwork (%) 17.2
Rfree (%) 24.2
The benzylsuccinic acid example shows that applying the herein described experimental 
conditions, similar complex structures compared to previously reported ones can be obtained. 
It also shows correct prediction of the binding mode using AutoDock. 
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Most of the purchased compounds were not soluble at  50 mM and therefore soaking was 
performed in saturated ligand solutions. Compounds 3, 11 and 13 were completely insoluble 
in  the  buffer.  The  at  ambient  temperature  liquid  compound  2 was  not  miscible  with  the 
soaking  buffer.  Thermolysin  crystals  were  transferred  directly  into  the  liquid  where  they 
immediately dissolved. For compound 8, the crystals dissolved in the soaking solution. After 
soaking compounds  1 and  11, the exposed crystals did not diffract anymore. Upon soaking 
compound 14, the soaking drop turned yellow. The crystals still diffracted but after the first 
refinement, Fo−Fc density clearly indicated that the Val-Lys dipeptide was still bound to the 
protein. Furthermore, the Val-Lys dipeptide could also be detected after soaking compounds 6 
and 12. 
Figure  5.24 Detecting  Val-Lys dipeptide  in  Fo−Fc density.  Left:  Fo−Fc density  at  σ =  2.0  as 
determined after initial refinement of a potential thermolysin-ligand complex. Only protein 
atoms are considered in the calculated model. Right: Fitting Val-Lys into the density clearly 
indicates that the tested ligand could not replace the dipeptide from the binding site. 
For  compound  4,  5,  7 and  10,  some  electron  density  was  observed  which  could  not be 
explained by the presence of the Val-Lys dipeptide. Obviously, the affinity of the screening 
hits  was  strong enough to displace  the  dipeptide.  However,  the  affinity  was  too weak to 
achieve sufficient occupation to determine their complex structure. Additionally to a lack of 
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affinity, poor solubility might be the reason for only partially successful soaking. Compound 
9 (3-methylaspirin) was soaked at 100 mM. A clearly visible difference electron density of the 
bound fragment could be determined. 
Figure 5.25 3-Methylaspirin binds to thermolysin. Left: 3-methylaspirin addresses both, the zinc 
ion  and  the  S1'-pocket.  Right:  Additionally  to  the  zinc  complex,  the  ligand  performs  a 
hydrogen bond to Arg203. 
Table 5.17: Refinement parameter for thermolysin-3-methylaspirin complex.
Resolution (Å) 1.95 (1.75) <B>Protein (Å2) 16.3 (13.6)
Rsym (%) 11.6 (8.8) <B>Ligand (Å2) 26.9 (18.4)
Rwork (%) 16.1 (15.7)
Rfree (%) 24.7 (21.7)
Additional crystal structure parameters are given in the supporting information. Values 
in parentheses represent a second structure determination at  ligand concentration = 50 
mM and data collection performed at the synchrotron radiation facility BESSY in Berlin.
Asn112
Arg203
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Docking and Scoring 3-Methylaspirin 
Validation of the binding of 3-methylaspirin to thermolysin stimulated us to check how well 
docking had been capable to generate the correct binding mode. Furthermore, the ranking of 
docking  modes  approximating  most  closely  the  subsequently  determined  structure  was 
performed to assess the prediction power of the applied scoring functions. Considering the 
formerly applied binding site of pdb ID 1TMN, 20 docking solutions for 3-methylaspirin were 
generated by AutoDock. All address the zinc ion with the carboxylic acid moiety; 16 docking 
solutions address the S1-pocket and only four the S1'-pocket. 
Figure  5.26 Docking  solutions  for  3-methylaspirin.  Left:  20  docking  solutions  generated  by 
AutoDock superimposed into the protein structure of pdb ID: 1TMN. Right: Comparison of 
all docking geometries and experimentally determined binding mode (white carbon atoms). 
As  structural  reference  and  to  assess  the  quality  of  this  docking  experiment,  the 
3-methylaspirin  complex  structure  was  superimposed  onto  the  protein  chain  from 
pdb ID: 1TMN. The superimposition shows the ligand clashing into the side chain of Asn112 
in the binding site used for docking. This demonstrates that without considering side chain 
flexibility,  3-methylaspirin  cannot  be  correctly  docked.  The  docking  mode  closest  to  the 
obtained crystal structure has an RMSD of 1.89Å. 
Fragment-based virtual screening 151
Figure  5.27 Thermolysin  slightly  adapts  upon  ligand  binding.  Left:  Protein  structure  as 
determined  with  3-methylaspirin  (blue  carbon  atoms)  superimposed  to  1TMN  (beige) 
Center: Blow-up of the superimposition of Asn112 highlighting the side chain movement. 
Right: Fo−Fc density for 3-methylaspirin (no model refinement for the ligand) superimposed 
with the 1TMN protein structure. It  demonstrates that ligand and protein clash into each 
other at Asn112 if it would adopt the conformation present in the structure used as reference 
in docking. 
The side chain adaption (Figure 5.28 Center) is analog to the one observed upon binding of 
benzyloxycarbonyl  D-aspartic/glutamic  inhibitors  in  1KR6,  1KS7.  This  demonstrated  the 
need for the consideration of side chain flexibility upon docking even for binding sites which 
have been described as 'rigid'. Although some initial success has been reported, consideration 
of target flexibility remains a challenging obstacle in protein-ligand docking. We therefore 
analyzed the performance of the herein applied docking and scoring methods while docking 
3-methylaspirin to the rigid 1TMN binding pocket. 
DrugScore and DrugScoreCSD ranked one of the 16 S1-pocket geometries best (Figure 5.28). 
Even though not approximating the orientation found in the crystal  structure, this selected 
binding  mode  does  not  appear  unreasonable.  There  are  examples  in  the  XRAY  ligand 
reference data set, addressing the S1-pocket with an aromatic moiety. Additionally, the acetate 
carbonyl  oxygen  atom  is  placed  to  interact  with  the  backbone  nitrogen  of  Trp116 
(distance = 3.13Å), a position usually occupied by a water oxygen atom. 
Asn 112
Asn 112
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Figure 5.28 Scoring 3-methylaspirin with DrugScore. Left: Docking solution ranked highest by 
both, DrugScore and DrugScoreCSD. Right: Superimposition of DrugScore predicted binding 
mode  (green  carbon  atoms)  with  S1-pocket  fragment  of  pdb ID: 1QF0  [Gaucher,  1999] 
(yellow carbon atoms, R-group white). 
AutoDock and SFC-Score both recognize docking solution as best which address the zinc ion 
and the S1'-pocket. In case of AutoDock, a hydrogen bond between Arg203 and the acetate 
carbonyl oxygen determines the geometry. It forces the methyl substituent to orient towards 
the solvent which would require a desolvation penalty. However, the generated docking mode 
is not unreasonable as the oxygen position of the acetate to Arg203 contact is highly favorable 
for an hydrogen bonding acceptor. In the crystal structure a water molecule occupies exactly 
this position (Figure 5.29 and 5.30). 
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Figure  5.29 Docking  solutions  for  3-methylaspirin  in  the  protein  structure  derived  from 
pdb ID 1TMN (beige protein carbon atoms). Upper row: Left:  AutoDock rank 1 docking 
mode  (light  green),  forming  a hydrogen  bond to  Arg203;  Right:  Superimposition  of  the 
ligand crystal structure geometry (blue) and the AutoDock rank 1 solution. Lower row: Left: 
The docking solution selected on rank 1 with the SFC-Score scoring function (dark green) 
recognizes all interactions; Right: Superimposition of experimental ligand crystal structure 
geometry (blue) and SFC-Score rank 1. The only difference is a shift in the z-axis towards 
the Asn112 side chain. Superimpositions are calculated based on the protein backbone atoms 
of the experimentally observed complex structure and the 1TMN protein structure used for 
docking. 
Applying the fragment specific SFC-Score to rank the AutoDock docking solutions, another 
conformation addressing the zinc ion and the S1'-pocket is selected on rank 1 (Figure 5.29, 
lower  row).  In  this  conformation  the  acetate  residue  is  placed  in  a  way  that  enables  a 
hydrogen  bond  to  Arg203  as  well  as  buries  the  methyl  moiety  of  the  acetate  into  the 
S1'-pocket. Additionally, the 3-methyl substituent points favorable into a hydrophobic area. 
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This binding is more favorable and the closest to the experimental binding mode. All scoring 
function results with deviations from the experimentally observed binding mode are given in 
the table below. 
 
Figure 5.30 Sensitivity of  docking solution to protein crystal  structure.  Left:  Rank 1 docking 
solution  from  AutoDock  (light  green)  into  the  protein  structure  from  pdb ID 1TMN. 
Superimposed (based on protein backbone) is the experimentally determined 3-methylaspirin 
complex crystal structure (blue carbon atoms, blue spheres represent water molecules). The 
docked ligand conformation enables a hydrogen bond to Arg203; the acetate oxygen of the 
AutoDock solution and the crystal structure water directly superimpose. Right: 20 AutoDock 
runs  for  3-methylaspirin  back  into  its  parent protein  crystal  structure.  All  solutions 
recognize correct binding mode. 
In  a  subsequent  attempt,  3-methylaspirin  is  redocked  in  the  newly  determined  protein 
structure. The Asn112 side chain conformation allows to allocate more space in the binding 
site. 20 out of 20 docking runs adopt a good geometry (Figure 5.30). They all cluster within 
an  RMSD  of  1Å.  This  demonstrates  that  given  the  right  conditions,  the  computational 
prediction  is  highly  accurate.  However,  the  'right  condition'  is  hard  to  predict.  Potential 
solutions to accommodate the protein structure is the application of soft docking approaches 
[Ferrari, 2004] or including a certain degree of protein flexibility explicitly (see chapter 3) 
into the docking process. 
Asn112
Asn112
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Table 5.18: Docking/Scoring results for 3-methylaspirin 
DrugScore DrugScoreCSD AutoDock SFC-Score
C-Func
SFC-Score 
CAS I
SFC Score
CAS II
RMSD
first rank
6.00 6.12 3.48 1.89 1.89 1.89
pKi 
predicted
5.88 6.94 6.11 5.4
The first crystal structure of the 3-methylaspirin-thermolysin complex was obtained on the in-
house device.  Curious about  the contribution  of the methyl  group to thermolysin  binding 
additional soakings with aspirin and 3-methylaspirin were performed now at 50 mM. Crystal 
structures  were  determined  with  synchrotron  radiation  this  time.  Again,  3-methylaspirin 
binding could be detected whereas no binding of aspirin could be observed. However, unlike 
the  previous  structure,  ligand  occupancy  was  only  ~80%.  Compared  to  the  previous 
experiment  only  half  the  ligand  concentration  has  been applied  for  soaking.  This  clearly 
demonstrates  the  need  for  highly  soluble  ligands  considering  X-ray  crystallography  as  a 
screening  method.  In  order  to  study  the  influence  of  a  meta  substituents  on  binding, 
3-chloroaspirin was synthesized which turned out to  be less soluble than 3-methylaspirin. 
Therefore,  soaking was  performed in  a  saturated  ligand  solution.  The Fo−Fc density  map 
showed no indication for a bound ligand. To determine binding capabilities we tested the two 
aspirin derivatives and aspirin itself in an photometric affinity assay. 
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Determining the inhibition constant 
Kinetic measurements  have been performed using a  photometric  affinity  assay with 3-(2-
furylacryloyl)-L-glycyl-L-leucine-amide  (Fagla)  as  substrate.  Due  to  the  sensitivity  of  the 
protein activity to the presence of DMSO, ligands were dissolved in TRIS-buffer solution. 
Protein activity was monitored at λ=345nm. 
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Figure 5.31 Detection wavelength for thermolysin kinetics. Left: Difference spectrum from pure 
Fagla  2 mM and a mixture  of  Fagla  2 mM and TLN 13 nM after  10 minutes.  Right:  A 
mixture of Fagla 2 mM and TLN 13 nM followed over 10 minutes. Highlighted is the time 
frame for determining the initial velocity. 
To  validate  the  applied  protocol  the  inhibition  constant  of  phosphoramidon  was  re-
determined. Phospharmidon acts as a competitive inhibitor and has been published with an 
inhibitions constant Ki=28 nM [Tronrud, 1986]. 
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Figure 5.32 Validation of the inhibition constant  for phosphoramidon. As competitive binding 
kinetics apply, the inhibition constant is graphically determined via the Dixon plot [Dixon, 
1953], [Dixon, 1972]. Shown data points are averages from double measurements. 
Using the Dixon plot and the above described assay setup, the Ki for phosphoramidon was 
determined  as  27 nM.  Subsequently,  inhibition  constants  were  determined  for  aspirin,  3-
methylaspirin and 3-chloroaspirin. 
Table 5.19: Assay results and physicochemical properties for aspirin derivatives 
Ligand Inhibition 
constant (Ki)
Molecular 
weight (Da)
pKa
Aspirin 2.42 mM ± 0.23 180.04 3.491
3-methylaspirin 1.73 mM ± 0.2 194.06 3.481
3-chloroaspirin 522 μM ± 0.06 214 3.051
1Pka  values  were  estimated  using  the  prediction  model  as  provided  online  via 
http://www.chemaxon.com
As expected, the binding affinity of the methyl derivative is slightly better than that of aspirin 
itself.  One  possible  explanation  would  be  that  the  3-methyl  group  fixes  a  favorable 
conformation. The rotation about the phenyl carbon - ester oxygen bond in 3-methylaspirin is 
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restricted compared to unsubstituted aspirin (Figure 5.33, left). However, a conformational 
search showed that the preferred angle for the acetate moiety- aromatic ring angle is 90° even 
if the ring is unsubstituted (see supporting information).  Thus, both compounds adopt this 
preferred conformation independent of protein binding. As a result, the ligand conformation 
prior to binding cannot serve as cause for the different affinities. Another explanation could 
be the modified acidity.  Again,  hardly any difference can be expected following the pKa 
estimations.  Therefore,  the  difference  likely  arises  from  the  meta  substituent  and  its 
interactions with the protein. The methyl group binds in the proximity of the hydrophobic 
residues Leu133, Val192, Val139 and Leu202. It does not penetrate deeply into the pocket. 
Considering a similar binding mode for aspirin, this position would possibly be occupied by a 
water molecule. The only substrate free crystal structure of thermolysin (pdb ID 1L3F) shows 
a water molecule at the corresponding position (see supporting information). Water buried in 
a hydrophobic area is unfavorable and its replacement explains enhanced affinity. However, 
for  a  water  replacement,  the  affinity  difference  is  too  subtle.  Also  in  the  substrate-free 
structure, the relative orientation of the two domains that define the active-site cleft differ by a 
five  degrees  rotation  relative  to  their  positions  in  the  previously  studied  ligand-bound 
structures. This rotation makes a direct comparison of water positions difficult. Most likely, 
the shape of 3-methylaspirin provides the better counterpart to fit opposite the shape of the 
brink of the hydrophobic pocket (Figure 5.33, right). 
3-chloroaspirin  binds  three  times  better  than  3-methylaspirin.  Possibly  the  decreased 
solubility  prevents  soaking  at  sufficiently  high  concentration  to  successfully  populate  the 
fragment in crystals. Assuming a similar binding mode, the chlorine atom would address the 
hydrophobic pocket. Additionally,  the meta-chloro substitution increases the acidity of the 
molecule. Thus, the capability of the carboxylic acid to coordinate the zinc ion is improved 
which possibly allows for tighter binding. 
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Figure 5.33 Analyzing the screening results. Upper Row: Left: Rotatable bond in salicylic acid. 
Preferred conformation of aspirin as obtained by analyzing the energy in steps of 30°.This 
rotation is not restricted in aspirin. Right: Conformation of 3-methylaspirin. Rotation around 
the  phenol  oxygen  bond  is  stericly  hindered. Lower  Row:  Left:  Superimposition  of  3-
methylaspirin  complex  crystal  structure  (blue  carbon atoms)  and pdb ID 1L3F.  Right:  A 
suggested  salicylic  acid  derivative  expected  to  exhibit  enhanced  affinity  towards 
thermolysin. 
Based on the newly discovered lead structure, further inhibitors can be designed. In the 3-
methylaspirin  complex  the  methyl  substituent  points  towards  the  S1'-pocket.  Larger 
substitutions could better accommodate the remaining space. This could be achieved by larger 
ester  side  chains  that  could  accommodate  more  efficiently  the  S1'-pocket.  Docking  the 
benzylic acid ester reveals (Figure 5.33, right) a promising binding mode. 
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Conclusions
A strategy for fragment-based screening for metalloproteinase inhibitors is presented which 
led to the discovery of a new lead structure for optimization. We focused on virtual screening 
and  docking  to  select  a  limited  number  of  compounds  for  further  validation  using 
crystallography.  Applying  filter  criteria  with  respect  to  chemical  properties  of  fragments, 
metalloproteinase  inhibition  and  undesired  reactivity,  data  sets  of  commercially  available 
compounds and fragments derived from the World Drug index were compared. Subsequent 
docking experiments and geometry assessment with several scoring functions resulted in 14 
compounds selected for crystallographic screening. 
Based  on  the  determined  protein-fragment  structure  and  a  subsequent  affinity  assay  we 
discovered  aspirin  derivatives  as  novel  thermolysin  inhibitors.  They  inhibit  in  the  low 
millimolar  range.  No  ligand density  could  be  found  for  unsubsituted  aspirin.  The  crystal 
structure additionally revealed an unexpected protein flexibility induced by the discovered 
inhibitors. The side chain of Asn112 has to move out of space to accommodate the ligand in 
the binding site. 
Interested in the contribution of the meta-substituent to binding capabilities of aspirin, the 3-
chloroaspririn analog was synthesized. It inhibits thermolysin with a Ki=522 M. Consideringμ  
the  small  size  of  the  investigated  inhibitors,  their  affinity  and  the  crystal  structure  are  a 
starting  point  to  assess  whether  aspirin  derivatives  could  be  promising  leads  for  the 
development of novel metalloproteinase inhibitors. To improve affinity a possible structural 
modification would be the synthesis of esters with larger side chains. 
Considering  the  limited  number  of  compounds  actually  tested  experimentally,  the  herein 
applied  strategy  demonstrates  the  power  of  computational  lead  discovery.  Docking 
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thermolysin ligands illustrates that experimentally observed binding modes can be predicted 
and  scoring  functions  are  capable  to  recognize  important  protein-ligand  interactions. 
However, predicting interactions for ligands which only address a small part of a much larger 
binding site has been proven difficult. In these cases, water interactions and the amount of 
buried ligand surface is of increasing importance. The growing number of crystallographically 
studied protein-ligand complexes covering a larger range of functionalities and properties will 
certainly support our understanding of the physical nature of ligand binding. 
This study focused on commercially available fragments which have also been described in 
drug molecules. Future applications using the developed screening protocol can be based on 
larger data sets of fragments, exploring better and more exhaustively chemical space of small 
organic molecules. This way, new surprising lead structures can be identified. 
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Supporting information for fragment-based virtual screening
XRAY Fragment data set
Table s.1: Fragments, binding to both the zinc ion and the S1’-pocket. 
Zinc and S1'-pocket binder
Code Structure Code Structure 
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Table s.2: Fragments, binding to the zinc ion only but not to the S1’-pocket.  In most  cases, these 
fragments address the S1-pocket. 
Zinc-binder
Code Structure Code Structure 
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Table s.3: Fragments, binding to the S1’-pocket only 
S1'-pocket binder
Code Structure Code Structure 
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R
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Table s.4: Results for docking fragments with RECAP site set to hydrogen 
fragment AutoDock DrugScore DrugScoreCSD
Best 
overall
Run
RMSD 
(Å) Run
RMSD 
(Å) Run
RMSD 
(Å)
RMSD 
(Å)
Zn2+ and 
S1’ 1HYT 14 0.73 8 0.93 12 5.97 0.69
1NO0_f2 1 2.26 16 2.95 12 4.24 2.26
1QF2_f1 7 9.87 1 2.15 1 2.15 1.84
1TLP_f2 4 4.67 7 0.99 7 0.99 0.99
2TMN 12 1.35 20 6.74 17 2.36 0.99
4TLN 16 3.07 12 1.33 7 2.83 1.33
5TLN_f1 8 1.32 16 1.23 6 1.64 1.19
7TLN 14 1.21 14 1.21 14 1.21 1.21
average 3.06 2.19 2.67 1.31
number of solutions 
with rank1 <2 Å 4 5 3 7
Zn-
binder 1KRO_f1 16 1.87 5 0.97 10 1.01 0.94
1KTO_f1 6 1.86 7 1.73 7 1.73 1.68
1PE5_f1 7 2.47 18 3.86 16 2.67 2.47
1PE7_f1 18 2.27 10 2.97 10 2.97 1.57
1PE8_f2 4 3.1 10 2.54 1 2.64 2.54
1QF0_f2 2 5.34 7 5.35 7 5.35 2.84
1QF1_f1 10 2.98 18 3.57 14 3 2.95
1TLP_f1 7 5.2 11 2.73 19 5.62 2.73
1TMN_f1 9 6.81 3 6.21 10 3.46 2.91
4TMN_f2 14 3.44 14 3.44 7 3.39 1.31
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fragment AutoDock DrugScore DrugScoreCSD
Best 
overall
Run
RMSD 
(Å) Run
RMSD 
(Å) Run
RMSD 
(Å)
RMSD 
(Å)
4TMN_f5 4 5.89 3 5.22 3 5.22 1.4
5TMN_f3 9 2.99 9 2.99 9 2.99 1.79
6TMN_f2 3 2.32 15 2.16 12 2.55 2.1
average 3.58 3.36 3.28 2.09
number of solutions 
with rank1 <2 Å 2 2 2 6
S1'-binder 1PE5_f2 16 4.69 15 1.43 10 1.37 1.33
1QF0_f1 14 7.85 10 1.98 19 11.11 1.05
1QF1_f2 10 5 17 2.63 17 2.63 0.99
1TM_f2 17 1.89 10 1.7 12 9.56 1.1
2TLX_f2 16 1.98 12 1.49 6 2.01 0.93
3TMN_f1 1 0.93 8 0.92 4 0.9 0.9
4TMN_f1 5 3.45 20 8.47 20 8.47 2.93
4TMN_f3 10 1.14 18 0.97 18 0.97 0.97
4TMN_f4 19 1.61 12 4.33 12 4.33 1.54
5TMN_f2 13 4.84 9 1.62 20 1.7 0.9
6TMN_f1 3 1.75 17 6.59 17 6.59 1.23
average 3.2 2.92 4.51 1.26
number of solutions 
with rank1 <2 Å 6 7 4 10
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Table s.5: Results for docking fragments with RECAP site set to R-group 
fragment AutoDock DrugScore DrugScoreCSD
best 
overall
Run
RMSD 
(Å) Run
RMSD 
(Å) Run
RMSD 
(Å)
RMSD 
(Å)
Zn2+ and 
S1’ 1HYT 14 0.73 4 0.87 16 0.77 0.67
1NO0_f2 11 4.5 11 4.5 11 4.5 2.18
1QF2_f1 15 0.91 3 0.76 2 1.51 0.76
1TLP_f2 14 1.06 10 1 10 1 0.96
2TMN 20 0.96 9 1 11 0.91 0.86
4TLN 9 2.11 7 1.85 7 1.85 1.45
5TLN_f1 9 1.28 7 1.57 5 7.04 0.72
7TLN_ 9 1.04 5 1.26 3 3.72 1.04
average 1.57 1.60 2.66 1.08
number of solutions 
with rank1 <2 Å 6 7 5 7
Zn-binder 1KRO_f1 15 3.09 10 2.54 9 3.01 2.38
1KTO_f1 11 3.86 19 2.26 19 2.26 2.26
1PE5_f1 17 2.49 18 3.16 13 2.34 1.04
1PE7_f1 5 2.91 9 3.06 13 2.82 1.66
1PE8_f2 2 2.97 15 3.09 3 2.87 1.39
1QF0_f2 19 6.19 8 6.34 20 0.95 0.94
1QF1_f1 14 4.1 10 4.26 14 4.1 2.9
1TLP_f1 11 6.14 16 3.73 15 6.04 3.72
1TMN_f1 12 5.03 9 5.98 9 5.98 0.64
4TMN_f2 10 0.78 3 4.47 3 4.47 0.69
4TMN_f5 8 3.43 19 3.56 19 3.56 0.73
5TMN_f3 6 2.59 18 2.14 18 2.14 1.83
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fragment AutoDock DrugScore DrugScoreCSD
best 
overall
Run
RMSD 
(Å) Run
RMSD 
(Å) Run
RMSD 
(Å)
RMSD 
(Å)
6TMN_f2 3 2.7 8 2.3 8 2.3 2.3
average 3.56 3.60 3.30 1.73
number of solutions 
with rank1 <2 Å 0 0 1 8
S1’-binder 1PE5_f2 9 5.41 13 5.24 14 3.75 2.31
1QF0_f1 3 10.17 12 2.79 18 10.49 2.25
1QF1_f2 11 0.86 8 2.59 8 2.59 0.86
1TMN_f2 13 1.56 8 2.45 8 2.45 1.55
2TLX_f2 10 3.54 14 1.34 14 1.34 1.34
3TMN_f1 3 0.93 20 3.48 20 3.48 0.89
4TMN_f1 19 3.58 20 3.71 20 3.71 3.4
4TMN_f3 12 5.56 8 4.97 6 3.87 2.34
4TMN_f4 1 1.64 13 7.99 13 7.99 1.53
5TMN_f2 12 1.79 10 2.81 1 3.92 1.72
6TMN_f1 16 1.51 3 8.06 3 8.06 1.48
average 3.32 4.13 4.70 1.79
number of solutions 
with rank1 <2 Å 6 1 1 7
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Table s.6: Results for docking S1’-pocket fragments with RECAP site set to R-group and zinc ion 
uncharged 
fragment AutoDock DrugScore DrugScoreCSD
Best 
overall
Run
RMSD 
(Å) Run
RMSD 
(Å) Run
RMSD 
(Å)
RMSD 
(Å)
S1’-
binder 1PE5_f2 7 2.61 18 7.86 18 7.86 2.54
1QF0_f1 20 10.15 8 1.54 18 10.28 1.49
1QF1_f2 9 0.85 9 0.85 1 9.99 0.85
1TMN_f2 11 1.59 4 2.42 19 1.63 1.52
2TLX_f2 17 4.93 15 0.71 15 0.71 0.71
3TMN_f1 5 2.31 11 0.6 11 0.6 0.59
4TMN_f1 12 9.77 2 5.28 4 9.58 1.52
4TMN_f3 6 2.66 17 8.25 7 8.5 2.41
4TMN_f4 13 3.72 15 5.57 10 3.71 1.43
5TMN_f2 11 2.72 2 8.25 6 8.33 1.78
6TMN_f1 10 1.61 17 7.89 20 8.05 1.46
average 3.908 4.50 6.30 1.48
number of solutions 
with rank1 <2 Å 3 4 3 9
Fragment-based virtual screening 171
Table s.7: Results for docking S1’-pocket fragments with RECAP site set to hydrogen and zinc ion 
uncharged 
fragment AutoDock DrugScore DrugScoreCSD
Best 
overall
Run
RMSD 
(Å) Run
RMSD 
(Å) Run
RMSD 
(Å)
RMSD 
(Å)
S1’-
binder 1PE5_f2 4 1.19 5 9.54 5 9.54 1.02
1QF0_f1 13 5.31 6 1.16 2 10.87 1.01
1QF1_f2 5 5.01 15 1.02 15 1.02 1.02
1TMN_f2 14 1.47 9 3.05 9 3.05 1.11
2TLX_f2 15 3.9 13 0.62 12 0.62 0.62
3TMN_f1 1 2.32 18 2.42 18 2.42 0.74
4TMN_f1 11 3.38 2 10.79 18 5.73 1.83
4TMN_f3 6 1.14 1 0.99 17 0.97 0.97
4TMN_f4 16 3.31 12 5.18 9 3.25 1.48
5TMN_f2 15 1.3 20 2.72 20 2.72 1.2
6TMN_f1 1 10.43 1 10.43 19 9.47 1.03
average 3.52 4.35 4.51 1.10
number of solutions 
with rank1 <2 Å 4 4 3
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Dixon plots for aspirin derivatives
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SFC Scoring function docking scores 
Table s.8: Statistics for the derived SFC-Score fragment-based functions 
Function CAS I Function CAS II 
N_hb +0.426 N_hb +0.484
RMSScore +0.793 TotBurSurf +0.013
TotBurSurf +0.0114
HydBurSurf +0.00297
Statistics
n 130 n 137
r 0.81 r 0.745
s 0.973 s 1.142
Fa) 59.762 F 55.267
q2b) 0.627 q2 0.525
S-PRESSc,d) 1.015 S-PRESS 1.180
n= number of data points, r= correlation coefficient; s= standard deviation a) Fisher’s F-
value.  b)  q2 = 1-PRESS/SSD as  obtained  by  “leave-one-out”  cross-validation.  PRESS 
equals  to  the  sum  of  squared  differences  between  predicted  and  experimentally 
determined  binding  affinities,  SSD is  the  sum  of  the  squared  differences  between 
experimentally  determined binding affinities  and the  mean of  the training set  binding 
affinities. c) In logarithmic units. d) )1( −−= hnPRESSsPRESS  as obtained by “leave-
one-out” cross-validation. h is the number of components. For detailed information of the 
descriptors see in Sotriffer et al. 
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Table s.9: SFC-function scores for 3-methylaspirin to thermolysin 
C-Function CAS I Function CAS II Function 
Docking Score
RMS to 
xray
RMS 
to run3 Score
RMS 
to xray
RMS 
to run3 Score
RMS 
to xray
RMS 
to 
run3
Run 1 6.69 3.43 3.33 5.69 3.43 3.33 5.03 3.43 3.33
Run 2 6.7 3.42 3.33 5.68 3.42 3.33 5.00 3.42 3.33
Run 3 6.94 1.78 0.00 6.11 1.78 0.00 5.40 1.78 0.00
Run 4 6.62 6.24 7.05 4.57 6.24 7.05 3.86 6.24 7.05
Run 5 6.92 5.61 6.38 4.72 5.61 6.38 4.09 5.61 6.38
Run 6 6.7 6.15 6.96 4.62 6.15 6.96 3.96 6.15 6.96
Run 7 6.53 6.22 7.03 4.31 6.22 7.03 3.57 6.22 7.03
Run 8 6.6 6.25 7.07 4.53 6.25 7.07 3.83 6.25 7.07
Run 9 6.00 7.85 8.75 3.84 7.85 8.75 3.16 7.85 8.75
Run 10 6.35 6.18 6.97 4.18 6.18 6.97 3.54 6.18 6.97
Run 11 6.48 5.93 6.76 4.49 5.93 6.76 3.87 5.93 6.76
Run 12 6.94 1.78 0.14 5.86 1.78 0.14 5.12 1.78 0.14
Run 13 6.5 6.33 7.14 4.55 6.33 7.14 3.90 6.33 7.14
Run 14 6.55 6.22 7.04 4.3 6.22 7.04 3.62 6.22 7.04
Run 15 6.63 3.36 3.30 5.55 3.36 3.3 4.88 3.36 3.3
Run 16 6.47 6.17 6.98 4.52 6.17 6.98 3.91 6.17 6.98
Run 17 6.55 6.16 6.97 4.85 6.16 6.97 4.24 6.16 6.97
Run 18 6.35 6.15 6.95 4.22 6.15 6.95 3.57 6.15 6.95
Run 19 6.64 6.27 7.07 4.57 6.27 7.07 3.88 6.27 7.07
Run 20 6.52 6.22 7.00 4.64 6.22 7.00 3.98 6.22 7.00
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Databases and Programs used throughout this work 
Asinex: http://www.asinex.com/libraries.html
IBS: InterBioScreen  http://cds.dl.ac.uk/cds/datasets/orgchem/isis/ibscreen.html
Specs: http://www.specs.net/
Leadquest: http://www.leadquest.com/
Maybridge http://www.maybridge.com/default.aspx
Sigma: http://www.sigmaaldrich.com/
World Drug Index http://scientific.thomson.com/products/wdi/ 
Unity http://www.tripos.com (Version 4.0) 
Sybyl http://www.tripos.com (Version 7.0) 
ReliBase+ http://www.ccdc.cam.ac.uk/products/life_sciences/relibase/ (Version 2.0)
Pymol http://pymol.sourceforge.net/ (Version 0.98) 
FlexX http://www.biosolveit.de/FlexX/ (Version 1.13)
AutoDock http://autodock.scripps.edu/ (Version 3.0)
GOLD http://www.ccdc.cam.ac.uk/products/life_sciences/gold/ (Version 3.0)
SFC-Score http://www.agklebe.de (Version 1.0)
CORINA http://www.molecular-networks.com/software/corina/index.html (Version 2.6)
DrugScore http://www.agklebe.de (Version 1.2)
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PDB entries
Table s.10: Protein data bank entries for thermolysin used in this work. 
pdb 
ID Description
Reso-
lution Authors
1FJ3 thermolysin (50% acetone soaked) 2.0 English, A.C., Groom, C.R., 
Hubbard, R.E.
1FJO thermolysin (60% acetone soaked) 2.00 English, A.C., Groom, C.R., 
Hubbard, R.E.
1FJQ thermolysin (70% acetone soaked) 1.70 English, A.C., Groom, C.R., 
Hubbard, R.E.
1FJT thermolysin (50% acetonitrile soaked) 2.20 English, A.C., Groom, C.R., 
Hubbard, R.E.
1FJU thermolysin (80% acetonitrile soaked) 2.00 English, A.C., Groom, C.R., 
Hubbard, R.E.
1FJV thermolysin (60% acetonitrile soaked) 2.00 English, A.C., Groom, C.R., 
Hubbard, R.E.
1FJW thermolysin (50 mM phenol soaked) 1.90 English, A.C., Groom, C.R., 
Hubbard, R.E.
1GX
W
thermolysin in presence of potassium 
thiocyanate
2.18 Gaucher, J.F., Selkti, M., 
Prange, T., Tomas, A.
1HYT benzylsuccinis acid with thermolysin 1.70 Hausrath, A.C., Matthews, B.W.
1KEI thermolysin (substrate-free) 1.60 Senda, M., Senda, T., Kidokoro, 
S.
1KJO thermolysin complexed with Z-L-
threonine (benzyloxycarbonyl-L-
threonine)
1.60 Senda, M., Senda, T., Kidokoro, 
S.
1KJP thermolysin with Z-L-Glutamic acid 
(benzyloxycarbonyl-L-glutamic acid)
1.60 Senda, M., Senda, T., Kidokoro, 
S.
1KKK thermolysin Z-L-aspartic acid 
(benzyloxycarbonyl-L-aspartic acid)
1.60 Senda, M., Senda, T., Kidokoro, 
S.
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pdb 
ID Description
Reso-
lution Authors
1KL6 thermolysin with Z-L-alanine 
(benzyloxycarbonyl-L-alanine)
1.80 Senda, M., Senda, T., Kidokoro, 
1KR6 thermolysin with Z-D-glutamic acid 
(benzyloxycarbonyl-D-glutamic acid)
1.80 Senda, M., Senda, T., Kidokoro, 
S.
1KRO thermolysin with Z-D-threonine 
(benzyloxycarbonyl-D-threonine)
1.70 Senda, M., Senda, T., Kidokoro, 
S.
1KS7 thermolysin with Z-D-aspartic acid 
(benzyloxycarbonyl-D-aspartic acid)
1.70 Senda, M., Senda, T., Kidokoro, 
S.
1KTO thermolysin with Z-D-alanine 
(benzyloxycarbonyl-D-alanine)
1.90 Senda, M., Senda, T., Kidokoro, 
S.
1L3F thermolysin substrate has an Open 
Conformation
2.30 Hausrath, A.C., Matthews, B.W.
1LNA different metals in thermolysin 1.90 Holland, D.R., Hausrath, A.C., 
Juers, D., Matthews, B.W.
1LNB different metals in thermolysin 1.80 Holland, D.R., Hausrath, A.C., 
Juers, D., Matthews, B.W.
1LNC different metals in thermolysin 1.80 Holland, D.R., Hausrath, A.C., 
Juers, D., Matthews, B.W.
1LND different metals in thermolysin 1.70 Holland, D.R., Hausrath, A.C., 
Juers, D., Matthews, B.W.
1LNE different metals in thermolysin 1.70 Holland, D.R., Hausrath, A.C., 
Juers, D., Matthews, B.W.
1LNF different metals in thermolysin 1.70 Holland, D.R., Matthews, B.W.
1OS0 thermolysin with alpha-amino 
phosphinic inhibitop
2.10 Selkti, M., Tomas, A., Prange, 
T.
1PE5 thermolysin with tricyclic inhibitor 1.70 Juers, D., Holland, D., Morgan, 
B.P., Bartlett, P.A., Matthews, 
B.W.
1PE7 thermolysin with bicyclic inhibitor 1.82 Juers, D., Yusuff, N., Bartlett, 
P.A., Matthews, B.W.
1PE8 thermolysin with monocyclic inhibitor 1.80 Juers, D., Pyun, H.-J., Bartlett, 
P.A., Matthews, B.W.
178 Fragment-based virtual screening
pdb 
ID Description
Reso-
lution Authors
1QF0 thermolysin with (2-sulphanyl-3-
phenylpropanoyl)-phe-tyr. Parameters 
for Zn-bidentation
2.20 Gaucher, J.-F., Selkti, M., 
Tiraboschi, G., Prange, T., 
Roques, B.P., Tomas, A., 
Fournie-Zaluski, M.C.
1QF1 thermolysin thermolysin with (2
-sulphanylheptanoyl)-phe-ala 
parameters for Zn-bidentation
2.00 Gaucher, J.-F., Selkti, M., 
Tiraboschi, G., Prange, T., 
Roques, B.P., Tomas, A., 
Fournie-Zaluski, M.C.
1QF2 thermolysin with (2-sulphanyl-3-
phenylpropanoyl)-gly-(5-
phenylproline). Parameters for Zn-
monodentation
2.06 Gaucher, J.-F., Selkti, M., 
Tiraboschi, G., Prange, T., 
Roques, B.P., Tomas, A., 
Fournie-Zaluski, M.C.
1THL Thermolysin complexed with a novel 
glutaramide derivative, n-(1-(2(r,s)-
carboxy-4-phenylbutyl) 
cyclopentylcarbonyl)-(s)-tryptophan
1.70 Holland, D.R., Matthews, B.W.
1TLI thermolysin (2% isopropanol soaked 
crystals)
2.05 English, A.C., Done, S.H., 
Groom, C.R., Hubbard, R.E.
1TLP phosphoramidates as inhibitors and 
transition-state analogs of thermolysin
2.30 Tronrud, D.E., Monzingo, A.F., 
Matthews, B.W.
1TLX thermolysin (native) 2.10 English, A.C., Done, S.H., 
Groom, C.R., Hubbard, R.E.
1TMN N-carboxymathyl dipeptide inhibitors 
of thermolysin
1.90 Monzingo, A.F., Matthews, 
B.W.
1Y3G sructure of a slanediol potease 
inhibitor bound to thermolysin
2.10 Juers, D.H., Kim, J., Matthews, 
B.W., Sieburth, S.M.
1Z9G structure analysis of thermolysin with 
the inhibitor (R)-retro-thiorphan
1.70 Roderick, S.L., Fournie-Zaluski, 
M.C., Roques, B.P., Matthews, 
B.W.
1ZDP structure of thermolysin with the 
inhibitor (S)-thiorphan
1.70 Roderick, S.L., Fournie-Zaluski, 
M.C., Roques, B.P., Matthews, 
B.W.
2TLI thermolysin (5% isopropanol soaked) 1.95 English, A.C., Done, S.H., 
Groom, C.R., Hubbard, R.E.
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pdb 
ID Description
Reso-
lution Authors
2TLX thermolysin (native) 1.65 English, A.C., Done, S.H., 
Groom, C.R., Hubbard, R.E.
2TMN Phosphoramidates as inhibitors and 
transitionstate analogs of thermolysin
1.60 Tronrud, D.E., Monzingo, A.F., 
Matthews, B.W.
3TLI thermolysin (10% isopropanol soaked) 1.95 English, A.C., Done, S.H., 
Groom, C.R., Hubbard, R.E.
3TMN Binding of L-valyl-L-tryptophan to 
thermolysin: the mode of interaction 
of a product of peptide hydrolysis
1.70 Holden, H.M., Matthews, B.W.
4TLI thermolysin (25% isopropanol soaked) 1.95 English, A.C., Done, S.H., 
Groom, C.R., Hubbard, R.E.
4TLN Hydroxamic acid inhibitors of 
thermolysin suggest a 
pentacoordinated Zn intermediate in 
catalysis
2.30 Matthews, B.W., Holmes, M.A.
4TMN Slow and fast binding inhibitors of 
thermolysin display different modes of 
binding
1.70 Holden, H.M., Tronrud, D.E., 
Monzingo, A.F., Weaver, L.H., 
Matthews, B.W.
5TLI thermolysin (60%isopropanol soaked) 2.10 English, A.C., Done, S.H., 
Groom, C.R., Hubbard, R.E.
5TLN Hydroxamic acid inhibitors of 
thermolysin suggest a 
pentacoordinated Zn intermediate in 
catalysis
2.30 Matthews, B.W., Holmes, M.A.
5TMN Slow and fast binding inhibitors of 
thermolysin display different modes of 
binding
1.60 Holden, H.M., Tronrud, D.E., 
Monzingo, A.F., Weaver, L.H., 
Matthews, B.W.
6TLI thermolysin (60% isopropanol soaked) 2.10 English, A.C., Done, S.H., 
Groom, C.R., Hubbard, R.E.
6TMN Structures of thermolysin-inhibitors 
complexes that differ by a single 
hydrogen bond
1.6 Tronrud, D.E., Holden, H.M., 
Matthews, B.W.
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pdb 
ID Description
Reso-
lution Authors
7TLI thermolysin (90% isopropanol soaked) 1.95 English, A.C., Done, S.H., 
Groom, C.R., Hubbard, R.E.
7TLN Inhibition of thermolysin by an active 
site directed irreversible inhibitor
2.3 Matthews, B.W., Holmes, M.A., 
Tronrud, D.E.
8TLI thermolysin (100% isopropanol 
soaked)
2.2 English, A.C., Done, S.H., 
Groom, C.R., Hubbard, R.E.
8TLN Comparison suggests that thermolysin 
and related neutral proteases undergo 
hinge-binding motion during catalysis
1.60 Tronrud, D., Matthews, B.W.
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Conformation search for aspirin
The phenyl carbon-phenol oxygen bond was turned in steps of 30°. Energy was determined 
using Gaussian. 
Figure s.1 Energy evaluation of different aspirin conformers
-90° +90°0.0°
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Substrate free protein structure
The herein determined protein-3methylaspirin complex structure is  superimposed onto the 
substrate free thermolysin protein structure (pdb ID 1L3F). The 3-methyl substituent occupies 
an  area  close  to  a  structural  water  molecule  position  in  1L3F  (distance  =1.2Å).  Direct 
comparison is  hindered because in the case of a substrate free structure,  the two proteins 
domains show a 5 degree rotation and a second zinc ion is bound into the active site. 
Figure  s.2 Superimposition  of  3-methylaspirin  complex  structure  (blue:  carbon  atoms  –  blue 
spheres:  water  molecules) and  pdb ID 1L3F(pink:  carbon  atoms  –  red  spheres:  water 
molecules). The relevant  zinc ion is represented as a big purple sphere. The additionally 
bound zinc ion of the substrate free structure is shown as a little purple sphere. 
1.2Å
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Refinement data
Table s.11: refinement data for two 3-methylaspirin complex structures
Complex structure at
1.95 Å resolution
Complex structure at
1.75 Å resolution
Data collection and Processing
   No. of crystals used
   Wavelength [Å]
   Space group
   Unit cell parameters
     a, b, c [Å]
     β [°]
 Matthews coefficient [Å³/Da]
 Solvent content
Diffraction data*
   Resolution range [Å]
  Unique reflections
   R(I)sym [%]
   Completeness [%]
   Redundancy
   I/σ(I)
Refinement
   Resolution range [Å]
   Reflections used in refinement 
 (work/free)
   Final R values for all reflections
   (work/free) [%]
1
1.5418
P6122
92.8, 92.8, 130.2
90, 90, 120
2.3
46.8
50.0 – 1.95 
(1.98-1.95)
24 548 (1 178)
11.6 (50.7)
98.8 (97.8)
5.0 (5.0)
14.6 (3.2)
30.0 - 1.95
22 493 / 1150
16.1 / 24.7
14.5 / 23.1
1
0.91841
P6122
92.7, 92.7, 130.0
90, 90, 120
2.3
46.6
50.0 – 1.75
(1.78 – 1.75)
33 957 (1 669)
8.8 (49.5)
100 (100)
6.7 (7.1)
21.0 (3.9)
30.0 - 1.75
30957 / 1625
15.7 / 21.7
14.5 / 19.9
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Complex structure at
1.95 Å resolution
Complex structure at
1.75 Å resolution
   Final R values for reflections with F > 4 σ
   (work/free) [%]
   Protein residues
   Metal ions
   Inhibitor
   Water molecules
RMSDs
   Bonds [Å]
   Angles [°]
Ramachandran plot
   Residues in most favored regions [%]
   Residues in additional allowed regions [%]
   Residues in generously allowed regions [%]
   Residues in disallowed regions [%]
Mean B factor [Å2]
   Protein
   Metal ions
    Inhibitor
  Water molecules
316
1 Zn2+, 4 Ca2+
1
308
0.006
1.7
87.0
12.6
0.0
0.4 (Thr 26)
16.3
15.4
26.9
29.6
316
1 Zn2+, 4 Ca2+
1
328
0.007
1.9
88.5
10.0
1.1
0.4 (Thr 26)
13.6
11.4
18.4
26.9
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SUMMARY & OUTLOOK
The present thesis demonstrates several examples of how to support a drug discovery project 
by computational methods. If some information about ligand and their binding properties is 
already  available  quantitative  structure-activity  relationships  can  be  established  to  assist 
future ligand design. 
In an example for antimalarial drugs, targeting the enzyme DOXP-reductoisomerase, three 
different  3D QSAR methods,  CoMFA,  CoMSIA and  AFMoC have  been  compared.  The 
training data set comprised 27 ligands and allowed to generate QSAR models based on leave-
one-out analysis for all three methods. When applied to predict affinities for ligands, not used 
to  calculate  the  model,  AFMoC clearly  outperformed the  other  two  considered  methods. 
CoMFA and CoMSIA models are solely based on ligand structures and thus more sensitive to 
size and composition of the training set data. AFMoC is a method which can be considered as 
either a target-tailored scoring function or a 3D-QSAR method which considers protein-ligand 
interactions. Using information from both, ligands and protein, it is less dependent on training 
data.  Docking has been difficult  because the protein comprises large flexible loops which 
interact  with  the  potential  ligands.  Using  all  information  available,  a  predictive  AFMoC 
model could be established which can now be used to predict binding affinities of newly 
suggested inhibitors. However, as shown by synthesizing multiple derivatives, it has to be 
concluded that it is very difficult to optimize fosmidomycin. It is a very small ligand which 
mimics the natural substrate almost perfect while forming strong interactions. Further studies 
might include inhibitor design for DXR not only targeting malaria. DXR has been discovered 
in  Mycobacterium  tuberculosis as  well  as  in  Pseudomonas  aeruginosa.  The  developed 
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AFMoC  model  could  be  applied  not  only  to  rationalize  affinity  but  also  to  determine 
selectivity between targets.
A  second  example  for  lead  optimization  has  been  shown  on  benzophenone-based 
farnesyltransferase inhibitors. In previous studies the binding site of farnesyltransferase has 
been explored in a  stepwise fashion.  To further  optimize affinity  the so-called specificity 
pocket has been explored and additional derivatives have been prioritized using computational 
method. The newly synthesized inhibitors showed improved binding not only in vitro but in 
vivo as well. 
Farnesyltransferase is a target not only for malaria but most prominent in the oncology field. 
While possible  cell  toxicity  should be a  concern,  in  general  the double targeting of anti-
infectives and cancer drugs is not a contradiction. Both are administered for short time and 
few dosages only, therefore another level of toxicity compared to e.g. cardiovascular drugs 
can be tolerated. Additionally, the binding site of P. falciparum and human ftase show some 
differences. This requires a high specificity in the ligands. The compounds investigated here 
are of a large size. A study made by Hann et al. [Hann, 2001] demonstrates the relationship 
between complexity of a ligand and its specificity towards a certain target.  Therefore, the 
benzophenone-based inhibitors  provide  very promising ligand  series  to  study affinity  and 
selectivity for multiple farnesyltransferase targets. 
Additionally to the computer-assisted lead optimization efforts, we applied a virtual screening 
protocol and docking for a fragment-based lead discovery project. Fragment-based screening 
has  been  applied  recently  successfully  and  has  gained  importance  as  an  alternative  to 
conventional HTS. However, most fragment-based approaches do not include computational 
support and if applied, mostly at the library design level or to predict substitutions for lead 
optimization. In contrast to those studies we applied virtual screening and docking as main 
screening tool. The decomposition of the substrate recognition site in proteases into multiple 
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sub-pockets  makes  the  target  enzyme  thermolysin  ideal  for  fragment-based  screening. 
Furthermore, thermolysin is robust and allows access to crystallization and prior knowledge 
about fragment binding is available. Starting with 800,000 compounds several filter criteria 
led  to  14  fragments  purchased  for  experimental  validation.  3-Methylaspirin  could  be 
determined  as  a  thermolysin  inhibitor  and  its  binding  geometry  was  identified 
crystallographically.  In  a subsequent  study we analyzed  binding affinities  not  only for 3-
methylaspirin  but  aspirin  and 3-chloroaspirin.  The latter  ligand was  determined to  inhibit 
thermolysin with 522 μM. 
Having  successfully  applied  virtual  screening  to  fragments  several  shortcomings  became 
obvious.  The  small  intersection  between  fragments  of  the  World  Drug  Index  and  the 
commercial available molecules demonstrates the need for synthesis support already at the 
library design level. It additionally serves as evidence for fragment-based approaches which 
provide an easier coverage of chemical space. Compared to larger molecules fragments hardly 
address  the  binding  site  completely.  The  remaining  area  is  filled  with  solvent  and  the 
fragment does interact not only with the protein but also with the residual water molecules 
occupying the partially filled binding pocket. While this might be true for any ligand, the 
reduced  number  of  possible  protein-fragment  interactions  enhances  the  importance  of 
interactions to the water network as shown by several  thermolysin-organic solvent crystal 
structures.  Recently,  some  attempts  have  been  made  to  include  water  in  protein-ligand 
docking.  However,  to  successfully  apply  automated  docking  to  fragments  a  better 
consideration of the contribution of water in the protein-ligand interface is required. 
In summary, several promising results have been obtained which demonstrate the capabilities 
of computational methods in the drug discovery process. They reduce time, cost and effort 
and provide guidance not only in the optimization but also in the discovery stage of lead 
compounds and series. 
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Abbreviations
ADME administration, distribution, metabolism, excretion
BW body weight 
CAC commercially available compounds data set
COX cyclooxygenase
CSD Cambridge structural database
DMF dimethylformamide
DMSO dimethylsulfoxide
DXR DOXP-Reductoisomerase 
ED50/90 effective dose, that produces a response in 50/90% of the test species
EMEA European Agency for the Evaluations of Medicinal Products 
Fagla 3-(2-furyl)acryloyl-glycyl-leucinamide
FBS fragment-based screening
FDA food and drug administration
FTASE farnesyltransferase
HIV human immunodeficiency virus
HTS high throughput screening
Ki Inhibition constant
Km michaelis-menten constant
MMP matrix-metallo-proteinase 
MOPS 3-(N-morpholino)propansulfonic acid
MW molecular weight
NME new molecular entity
NMR nuclear magnetic resonance
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P. falc. Plasmodiun falciparum
PDB protein data bank
PDE phosphodiesterase
PLS Partial least-square 
RECAP retrosynthetic combinatorial analysis procedure
RMSD (root mean square deviation)
SAS Solvent Accessible Surface
SFC Scoring function consortium
SPR surface plasmon resonance
TLN Thermolysin
TRIS 2-amino-2-hydroxymethyl-1,3-propanediol 
WDI World Drug Index resp. Drug fragments data set
XRAY X-ray reference data set
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Overview over described scoring function:
Boehm function as defined in FlexX:
rotrot NGG ×∆+∆= 0ΔG
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Here,  f(ΔR,  Δα) penalizes deviations from the ideal geometry.  ΔG Coefficients are derived 
from regression analysis of a training set.
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Interactions ΔWi,j between atoms of type i and j, located at a distance r, can be obtained from 
the normalized radial pair distribution function gi,j(r). The binding score between protein and 
ligand by DrugScore as the sum of all occurring atom-atom interactions. The second part is 
the solvent accessible surface term, for which a specific description can be found in Gohlke et  
al. (JMB 2000). DrugScore can be used with the PDB or the CSD as data base. The main 
difference are better statistics in the CSD for several atom types which are rarely found in the 
PDB (F, S, Cl, Br,)
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AutoDock
ΔG=ΔGvdw+ ΔGhbond+ΔGelec+ΔGconform+ΔGtor+ΔGsol
The  first  four  terms represent  dispersion,  repulsion,  hydrogen  bonding,  electrostatics  and 
deviations from ideal geometry, “tor” considers restriction of internal rotors “sol” desolvation. 
GOLD 
GOLDscore function is a molecular mechanics-like function with four terms: 
GOLD Fitness = Shb_ext + Svdw_ext + Shb_int + Svdw_int
Shb_ext is the protein-ligand hydrogen-bond score,  Svdw_ext is the protein-ligand van der Waals 
score.  Shb_int  is the contribution due to intramolecular hydrogen bonds in the ligand.  Svdw_int is 
the contribution due to intramolecular strain in the ligand
Chemscore
The Chemscore function estimates free energy of binding of a ligand to a protein as follows: 
rotrotlipolipometalmetalhbondhbondbinding HGSGSGSGG ∆+∆+∆+∆+∆= 0ΔG
where  Shbond,  Smetal,  and  Slipo are scores for hydrogen-binding, acceptor-metal,  and lipophilic 
interactions,  respectively.  Hrot is  a  score  to  compensate  for  conformational  entropy  loss. 
Coefficients are derived from regression analysis of a training set. 
SFC-Score
Regression functions have the general form:
.constdesccpK
k
kki +


×= ∑
where k is the number of descriptor variables and ck is the coefficient of the descriptor desck 
in the regression equation. 
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Virtual Screening examples 
Table a.1: Reported virtual screening examples (derived from Coupez, 2006 and extended): 
Target Procedure and methods Results
T4-lysozyme and 
W66F/L44A double 
mutant
[Machicado, 2005]
a) Physical-chemical filtering 
the ligand database.
b) ligand flexible and fast 
docking (LigandFit) procedure 
+ consensus scoring
c) fine docking (Affinity) + 
free energy calculation
3 step Protocol set-up and 
validation of the protocol with 
known T4-lysozyme binder. 
Identification of binders on the 
W66F/L44A double mutant.
Cannabinoid CB2 
receptor (GPCR)
[Salo, 2005]
a) Ligand-based screening with 
pharmacophoric and surface 
volume constrains
b) flexible ligand docking 
(GOLD) on the homology 
model of the receptor + 
consensus scoring
Protocol combining ligand-
based approach to filter the 
database and docking on a 
homology model of the 
receptor. 1 hit found in G-
protein activation assays
P. falciparum kinase 
(Pfmrk)
[Peng, 2005]
a) homology model based on 
the hCDK7 X-ray structure 
refined by QM, energy 
minimization and molecular 
dynamics
b) docking of oxindole-based 
Pfmrk inhibitors (GOLD) + 
scoring (GOLD score) to 
validate the model.
A 3D structural model of Pfmrk 
was constructed and refined 
using homology modeling, ab 
initio quantum mechanical 
calculations, and EM and MD 
simulations. The refined 
structural model was further 
evaluated by the molecular 
docking of a series of known 
Pfmrk inhibitors. Identification 
of new in vitro inhibitor hits 
against Pfmrk.
CDK2
[Cotesta, 2005]
a) Docking (Gold or QXP)
b) Scoring functions (PLP, 
Ligscore, Ludi, Jain, 
ChemScore, PMF) and four 
composite scoring models
Using the QXP and GOLD 
programs, Comparaison of the 
ability of six single scoring 
functions and four composite 
scoring models to separate 
compounds that are active 
against CDK2 from inactives.
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Target Procedure and methods Results
Estrogen receptor, 
thymidine kinase, 
coagulation factor 
VIIa, and 
neuraminidase
[Miteva, 2005]
a) Physical-chemical filtering 
of the ligand database 
b) Rigid body docking fitting 
(Fred)
c) flexible ligand docking 
(Surflex or Dock)
Multistep VLS protocol set-up 
based on sequential 
docking/scoring steps using a 
consensus docking / scoring 
approach. Tuning 
docking/scoring parameters 
according to the pocket 
properties improved the 
performance of both docking 
methods.
Bacterial hyaluronan 
lyase
[Botzki, 2005]
a) Homology model based on 
two streptococcal hyalronan 
lyases X-ray structures
b) Docking and scoring (Ludi)
c) Physical-chemical filtering 
of the docked ligand
Identification of Hits
type 4 
phosphodiesterase 
(PDE4B)
[Mpamhanga, 2005]
a) Docking (Ligandfit)
b) Scoring functions (PMF, 
JAIN, PLP2, LigScore2, and 
DockScore)
Comparison and testing the 
combination of various scoring 
functions
Plasmodium 
falciparum Ca2+-
ATPase (PfATP6) 
[Jung, 2005]
a) Homology model of PfATP6
b) Docking (Ligandfit)
c) Scoring (LUDI)
Validation of a model of 
PfATP6 by docking known 
artemisinin derivatives
Erythropoietin-
producing 
hepatocellular B2 
(EphB2) kinase
[Toledo-Sherman, 
2005]
a) ligand-based pharmacophore 
search
b) Docking (GOLD) + 
consensus scoring (C-score)
Ligand-based and docking 
approaches combined with a 
mass spectrometry screening 
approach enable the 
identification of hits as 
inhibitors for EphB2
cytochrome P450 
[Kirton, 2005]
a) Docking (GOLD)
b) Scoring (Goldscore, 
Chemscore, modified
Goldscore, modified 
Chemscore)
Improvement of the scoring 
functions by providing a better 
treatment of the environment 
around the heme, which leads 
to higher success rates.
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Target Procedure and methods Results
Alpha1A Receptor 
GPCR 
[Evers, 2005]
a) Homology model based on 
the bovine rhodopsin
X-ray structure
b) 2D and three dimensional 
pharmacophore
filtering of the ligand database
c) Docking (GOLD)
d) Scoring (PMF)
The generation and validation 
of a homology model for the 
alpha1A receptor is described. 
The generated model was used 
to discover alpha1A antagonists 
hits which were validated in an 
experimental assay.
Cyclooxygenase-2
[Mozziconacci, 2005]
a) docking (DOCK)
b) Consensus scoring (C-
score+SCORE)
c) geometric criteria filtering
Optimization of the DOCK 
parameters and validation study 
of this protocol shows that the 
SCORE and DOCK scoring 
functions are the best for this 
target. Screening retreived a set 
of compounds bearing a sulfonyl 
group and compounds, that are 
fairly similar to known potent 
inhibitors. One-third of the 
dozen tested compounds ended 
up inhibiting the COX-2 
enzyme.
alpha-beta barrel 
enzymes
[Kalyanaraman, 2005]
a) Docking : Glide
b) Rescoring: OPLS-AA + a 
generalized Born
implicit solvent model
Presentation of physics-based 
method for rescoring
protein-ligand complexes 
generated by a docking program
in the case of a highly charged 
active site.
HIV-1 Integrase (IN) 
[Dayam, 2005]
a) 3D pharmacophore guided 
database search
b) Docking + Scoring (GOLD)
c) Selection based on structural 
novelty, ability to chelate Mg2+ 
ion in the active site of IN, and 
satisfying Lipinski's rule-of-five
Discovery of a new class of 
HIV-1 Integrase inhibitor, by 
applying ligand-based screening 
methods, followed by docking.
Metallo-b-lactamases 
[Olsen, 2004]
a)Docking + scoring 
(AutoDock, Gold, FlexX)
b) rescoring (GRID)
Evaluation the AutoDock, 
GOLD and FlexX docking 
programs for docking of 
dicarboxylic acid inhibitors into 
metallo-ß-lactamases (MBLs). 
GOLD provides the best 
performance.
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SARS coronavirus 
3C-like proteinase
[Liu, 2005]
a) model for the receptor built 
by homology
modeling and multicanonical 
MD method
b) Docking and scoring 
(DOCK)
c) Pharmocophore model, 
consensus scoring, and
"drug-like" filters
Discovery of hits that inhibiting 
the SARS coronavirus 3Clike 
proteinase, by using a 
homology model for docking 
and by applying 
Pharmocophore model, 
consensus scoring, and "drug-
like" filters
Cytochrome P450 
2D6
[Kemp, 2004]
a) Docking
b) scoring (ChemScore)
Validation of Model of 
Cytochrome P450 2D6 by 
docking.
Aspartic proteinase 
renin
[Krovat, 2004]
a) Docking (Ligandfit)
b) Scoring functions 
(LigScore1, LigScore2, PLP1,
PLP2, JAIN, PMF, LUDI)
Comparison and testing the 
combination of various scoring 
functions
Chk-1 kinase
[Lyne, 2004]
a) Physical-chemical filtering 
of the ligand database
b) 3-D pharmacophore filtering 
for compounds with kinase 
binding motifs
c) docking (FlexX-Pharm)
d) consensus scoring (C-Score)
Protocol based on knowledge-
based strategy using 
ligandbased and docking 
approaches. 36 of 103 selected 
compounds for testing 
(corresponding to four 
chemical classes) were found to 
inhibit the enzyme. 
Estrogen 
receptor α
[Virag, 2005]
a) Docking (FlexX-Pharm, 
FleX)
b) Scoring functions (PMF, 
Chem, Dock, GOLD,FLexX)
The combination of FlexX-
Pharm and ChemScore gave 
the best performance. Increased 
performance of FlexXPharm 
over FlexX was also 
demonstrated on the estrogen 
receptor.
Carbonic anhydrase II
[Gruneberg, 2002]
a) pharmacophore search Unity
b) ligand superimposition 
FlexS
c) docking FlexX, DrugScore
Inhibitors with nanomolar 
sffinity ( sulfonamides) 
including structural validadtion
tRNA-guanine 
transglycosylase
[Brenk, 2003], 
a) Hot sport analyses with 
SuperStar and DrugScore
b) Pharmacophore 3D search 
Unity
c)Docking FlexX, Scoring with 
FleX and DrugScore
Suibmicromolar inhibitors with 
different cheemptypes. 
Extensive affinity and structual 
validation (multiple X-ray 
crystal structures)
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tailor-made scoring functions
Submitted
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Manuscript n preparation
Kettler K, Wiesner J, Sakowski J, Silber K, Haebel P, Klebe G, Schlitzer M, et al.
Development of Farnesyltransferase Inhibitors as novel Anti-Malarials
J. Med Chem, submitted
Silber K, Heidler P, Kurz T, Klebe G
AFMoC enhances predictivity of 3D QSAR: A Case Study with DOXP-reductoisomerase 
J. Med Chem, 2005 May 19;48(10):3547-63
Kettler K, Wiesner J, Silber K, Haebel P, Ortmann R, Sattler I, Dahse HM, Jomaa H, Klebe 
G, Schlitzer M. 
Non-thiol  farnesyltransferase  inhibitors:  N-(4-aminoacylamino-3-benzoylphenyl)-3-[5-(4-
nitrophenyl)-2 furyl]acrylic acid amides and their antimalarial activity.
Eur J Med Chem. 2005 Jan;40(1):93-101
Mitsch A, Wissner P, Bohm M, Silber K, Klebe G, Sattler I, Schlitzer M. 
Non-thiol  farnesyltransferase  inhibitors:  utilization  of  the  far  aryl  binding  site  by  5-
cinnamoylaminobenzophenones.
Arch Pharm (Weinheim). 2004 Sep;337(9):493-501
236 Appendix
Mitsch A, Wissner P, Silber K, Haebel P, Sattler I, Klebe G, Schlitzer M. 
Non-thiol  farnesyltransferase  inhibitors:  N-(4-tolylacetylamino-3-benzoylphenyl)-3-
arylfurylacrylic acid amides.
Bioorg Med Chem. 2004 Sep 1;12(17):4585-600.
Wiesner J, Kettler K, Sakowski J, Ortmann R, Katzin AM, Kimura EA, Silber K, Klebe G, 
Jomaa H, Schlitzer M. 
Farnesyltransferase inhibitors inhibit the growth of malaria parasites in vitro and in vivo. 
Angew Chem Int Ed Engl. 2004 Jan;43(2):251-4 
Kettler K, Sakowski J, Silber K, Sattler I, Klebe G, Schlitzer M. 
Non-thiol  farnesyltransferase  inhibitors  N-(4-acylamino-3-benzoylphenyl)-3-[5-(4-
nitrophenyl)-2-furyl]acrylic acid amides. Bioorg Med Chem. 2003 Apr 3;11(7):1521-30.
Oral communications
Silber, K., Klebe, G.
Inhibitors of DOXP-Reductoisomerase - Strucutre-based drug design using AFMoC
DPhG Doktorandentagung, Freudenstadt-Lauterbad, Germany, 2004 
Silber, K,. Klebe, G.
AFMoC: Combining Receptor- and Ligand-based Strategies for lead optimization Frontiers in 
Medicinal Chemistry, Fulda, Gemany, 2003 
Silber, K., Klebe, G.
Combining Receptor-based and Ligand-based Searching Strategies for Virtual Screening.
16th Molecular Modeling Workshop, Darmstadt, Germany, 2002 
Appendix 237
Poster presentations 
Silber K., Steuber H., Klebe, G.:
Scoring Fragments for Metalloproteinase Inhibitors, 
European Union- Asia link Sommer School of Medicinal Chemistry, Shanghai, China, 2005
Silber K., Steuber H., Reinscheid U., Klebe, G.:
A Fragment-based Screening Approach for Metalloproteinase Inhibitors, 
Gordon Research Conference on Computer Aided Drug Design, Tilton, NH, USA, 2005
Silber K., Gohlke H., Wiesner J., Heidler P., Kurz T., Jomaa H., Klebe G.:
Rationalizing Inhibitor Potency for New Antimalarials: 3D QSAR, Docking, and AFMoC for  
DOXP-Reductoisomerase Inhibitors 
15th European Symposium on Quantitative  Structure-Activity  Relationships  and Molecular 
Modelling in Istanbul, Turkey, 2004 
(awarded best poster)
Silber K., Wiesner J., Jomaa H., Klebe, G.
Rationalizing Inhibitor Potency using AFMoC
Gordon Research Conference on Computer Aided Drug Design, Tilton, NH, USA, 2003
Silber K., Wiesner J., Jomaa H., Klebe G.: AFMoC, a Ligand- and Receptor-based 3D-QSAR 
Approach tested on Inhibitor for DOXP-Reudctoisomerase
Frontiers in Medicinal Chemistry, Fulda; Germany, 2003 
(awarded best poster)
Silber K., Wiesner J., Jomaa H. und Klebe G.:
Inhibiting DOXP-Reductoisomerase: A new Approach to Combat Malaria
17. Darmstädter "Molecular Modelling Workshop", Erlangen, Germany, 2003 
(awarded best poster)
238 Acknowledgments
Acknowledgments 
Numerous people have contributed to this work and I am grateful to all of them. Especially, 
I would like to thank the following people:
• Prof. Dr. Gerhard Klebe for the opportunity to do my PhD thesis under his supervision. 
He provided not  only guidance but also allowed space for own creative ideas.  He 
encouraged, supported and enabled my attendance to international conferences and I 
am very grateful for all his advice throughout my entire education in Marburg. 
• Prof. Christoph Sotriffer for his support throughout the thesis and the great supervision 
and cooperation of the first semester lab. He is remarkably knowledgeable and patient 
and was very creative in lighting up meetings with English poems. 
• Dr. Nils Rackelmann for  listening  whenever  needed,  spontaneous  traveling,  his 
permanent motivation and his efforts in getting me finalizing this thesis. 
• My parents, Lydia and Prof. Dieter Silber for their never ending support, for convincing 
me that University is a special place and for being exceptional role models.
• The A203 gang, Dr. Andreas Evers and Dr. Peter Haebel for a great time, discussion on- 
and off-work and countless pizza ceremonies. Dr. Matthias Zentgraf for supporting my 
work, for pizza, movie and game nights, the autumn day photo sessions and most of all 
for being a great friend.
• Nils Weskamp for the great neighborhood relationship, Stella and more. 
• Holger Steuber and Dr. Andreas Heine for the collaboration on crystal structures. 
• Drs. Matthias Zentgraf, Nils Weskamp. Peter Block, Christoph Sotriffer and Hans Velec for 
dedicating a lot of time in keeping the Klebe-lab computer facilities running, 
• Prof. Holger Gohlke for his support and the introduction into molecular modeling. 
• The Erstsemester-Assistenten for their commitment to teaching and supervision. 
Acknowledgments 239
• Christian Sohn for incredibly precise work on the fragment assay and for keeping the 
X-ray facilities running. 
• Drs. Clayton Springer, Donovan Chin, William Egan and Nils Rackelmann for proofreading 
and fruitful discussions on fragments, QSAR, docking and statistics. 
• Angela Scholz for support for meetings, orders, offices, application forms, etc...
• The whole  AG Klebe group for the nice and stimulating working atmosphere. The 
large diversity of topics and people, the group meetings, coffee room discussions and 
meeting organization provided an exceptional experience for the future. 
• The  AG Schlitzer group for the nice collaboration on the Ftase project.  It  opened 
unexpected doors and taught me a lot. 
• The Graduiertenkolleg  'Proteinfunktion auf atomarer Ebene' for funding parts of  this 
work and for some nice seminar trips to Hirschegg.
Curriculum vitae 240
Curriculum vitae
Full name: Katrin Edith Elisabeth Silber
Date of birth: August, 11 1976
Place of birth: Frankfurt, Germany
2006- 2007 Research associate at the Novartis Institutes for Biomedical 
Research in Collaboration with Prof. Mike Yaffe, MIT
⇒ Druggability assessment and computational  
characterization of protein-protein interfaces
2001-2006 PhD student at the Institute of Pharmaceutical Chemistry, 
Philipps-University, Marburg, in the group of Prof. G. Klebe 
⇒ Fragment-, ligand- and receptor-based virtual screening 
strategies for new enzyme inhibitors
2002 Additional certificate as “Diplom-Pharmazeut”
2003- 2005 Fellow of the Marburg Graduiertenkolleg “Protein function at 
the atomic level” 
2001 Third state examination and licensure as pharmacist
2000- 2001 Obligatory practical training student in pharmacy (research and 
trade)
First half (research): Virtual screening approaches for new 
inhibitors of metalloproteinases (modelling and biochemical 
validation), G. Klebe, Philipps-University, Marburg
Second half (public pharmacy): Obligatory practical training in 
public pharmacies in Munich
1999- 2000 Studies of pharmacy at the University Paris sud (XI) as 
participant of an Erasmus/Sokrates student exchange program
1996- 2000 Studies of pharmacy at Philipps-University, Marburg 
1996 Abitur (majors: chemistry and maths)
1987- 1996 Marienschule der Ursulinen, Offenbach, 
1983- 1987 Friedrich- Fröbel Schule, Obertshausen
241 Erklärung
Erklärung
Ich versichere, dass ich meine Dissertation
LEAD OPTIMIZATION FOR NEW ANTIMALARIALS 
AND
SUCCESSFUL LEAD IDENTIFICATION FOR METALLOPROTEINASES: 
A FRAGMENT-BASED APPROACH USING VIRTUAL SCREENING 
selbständig ohne unerlaubte Hilfe angefertigt und mich dabei keiner anderen als der von
mir ausdrücklich bezeichneten Quellen bedient habe.
Die Dissertation wurde in der jetzigen oder einer ähnlich Form noch bei keiner anderen
Hochschule eingereicht und hat noch keinen sonstigen Prüfungszwecken gedient.
Marburg an der Lahn, den 08. August 2007
